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ABSTRACT 
In this dissertation, there are developed different analytical strategies to discover 
and characterize mammalian brain peptides using small amount of tissues. The 
magnocellular neurons of rat supraoptic nucleus in tissue and cell culture served as the 
main model to study neuropeptides, in addition to hippocampal neurons and mouse 
embryonic pituitaries. The neuropeptidomcis studies dcscribed here usc differcnt 
extraction methods on tissue or cell culture combined with mass spectrometry (MS) 
techniques, matrix-assisted laser desorptionlionization (MALDI) and eleetrospray 
ionization (ESl). Thesc strategies lead to the identification of multiple peptides from the 
rat/mouse brain in tissue and cell cultures, including novel compounds 
One of the goals in this dissertation was to optimize sample preparations on 
samples isolated from well-defined brain regions for mass spectromctric analysis. Here, 
the neuropeptidomics study of the SON resulted in the identification of 85 peptides, 
including 20 unique peptides from known prohOlmones. This study includes mass 
spectrometric analysis even from individually isolated magnocellular neuroendocrine 
cells, where vasopressin and several other peptides are detected. At the same time, it was 
shown that the same approach could be applied to analyze peptides isolated from a 
similar hypothalamic region, the suprachiasmatic nucleus (SCN). Although therc were 
some overlaps regarding the detection of the peptides in the two brain nuclei, different 
peptides were detected specific to each nucleus. Among other peptides, provasopressin 
fragments were specifically detected in the SON while angiotensin 1, somatostatin-14, 
neurokinin B, galanin, and vasoactive-intestinal peptide (VIP) were detected in the SCN 
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only. Lists of peptides were generated from both brain regions for comparison of the 
peptidome of SON and SCN nuclei. 
Moving from analysis of magnocellular neurons in tissue to cell culture, the direct 
peptidomics of the maguocellular and hippocampal neurons led to the detection of 10 
peaks that were assigned to previously characterized peptides and 17 peaks that remain 
unassigned. Peptides from the vasopressin prohormone and secretogranin-2 arc attributed 
to magnocellular neurons, whereas neurokinin A, peptide J, and neurokinin Bare 
attributed to cultured hippocampal neurons. This approach enabled the elucidation of 
cell-specific prohormone processing and the discovery of cell-cell signaling peptidcs. 
The peptides with roles in the development of the pituitary were analyzed using 
transgenic mice. Hesl KO is a genetically modified mouse that lives only e18.5 
(embryonic days). Anterior pituitaries of Hesl null mice exhibit hypoplasia due to 
increased cell death and reduced proliferation and in the intennediate lobe, the cells 
differentiate abnormally into somatotropes instead of melanotropes. These previous 
findings demonstrate that Hesl has multiple roles in pituitary development, cell 
differentiation, and cell fate. A VP was detected in all samples. Interestingly, somatostatin 
[92-100] and provasopressin [151-168] were detected in the mutant but not in the wild 
type or heterozygous pituitaries while somatostatin-14 was detected only in the 
heterozygous pituitary. In addition, the putative peptide corresponding to mlz 1330.2 and 
POMC [205-222] are detected in the mutant and heterozygous pituitaries, but not in the 
wild type. These results indicate that Hesl influences the processing of different 
prohormones having possible roles during development and opens new directions for 
further developmental studies. 
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This research demonstratcs thc robust capabilities of MS, which ensurcs the 
unbiased direct analysis of peptides extracted from complex biological systems and 
allows addressing imp011ant questions to understand cell-cell signaling in the brain. 
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CHAPTERl 
INTRODUCTION AND RESEARCH SUMMARY 
1.1 Introduction and Background Information 
The brain is the most complex structure known. The cerebral c0l1ex of the human 
brain contains roughly 20-30 billion neurons, linked with up to 10,000 synaptic 
connections each.l A volume equivalent to a cubic millimeter of cerebral cortex contains 
roughly one billion synapses 2 These neurons communicate with one another through 
electrical or chemical messages by means of long processes, the axons, projecting from 
one neuron to another in different parts of the brain or distant parts of the body with 
specific cells as targets. Exploring and understanding aspects of cellular cOlmnunication 
in thc brain have been major goals of neuroscience in past decadcs and many 
accomplishments have been achieved using different animal models and advanced 
technologies. 
In recent years, a large number of peptides have emerged as central players in the 
regulation of neurochemical commwlication which represents the fOWl dation of cognition 
and behavior. Some of thesc pcptides were prcviously characterizcd in nonneural tissue 
found in the gastrointestinal, respiratory, or genital tracts -including vasoactive intestinal 
peptide (VIP), pituitary adenylate cyclase activating peptide (PACAP), cholecystokinin 
(CCK), galanin, substance P, somatostatin, neuropeptide Y, bombesin, and insulin, etc. 3·g 
These endogenous peptides are widely distributed and synthesized within the central 
nervous system (CNS) as well as the peripheral nervous system (PNS) in a time and/or 
I 
tissue dependent manner7 Peptides derive from post-translational proteolytic cleavages 
of larger precursor molecules. Cleavages in the peptide backbone usually occur at pairs of 
basic amino acids within the trans-Golgi network where different enzymes become active 
and post-translational modifications (PTMs) such as amidation, acetylation, disulfide 
bonds, sulfation, glyeosylation, or phosphorylation take place. Some of these 
modifications occur in the secretory vesicles before release into the extracellular space. 
The role of PTMs is to create thc pcptide product that is recognized by the G-protcin-
coupled receptors, to regulate the peptide binding affinity to its receptor, and to increase 
the resistance to enzymatic degradation. 9-11 Once the pep tides are released by nerve cells 
at synapses, somata or axons whether via autocrine, paracrine or endocrine mechanisms, 
they interact with their receptors and are either degraded or taken up by cells. 12 Others are 
modified after release to interact with different receptors such as angiotensinogen13-16 
The presence ofpeptidcs, and their multitude, diversity, localization, synthesis, and 
release within CNS have raised many questions regarding their source, mechanism of 
action, and function. 
In all areas of the brain there are subsets of neurons that express particular 
peptides. The bioactive peptides are the most diverse and numerous group of cell to cell 
signaling molecules and can function as neurotransmitters, ncuromodulators, 
h k· d h" 7 10 12 17-19 Th' . ,. . h b neuro ormones, cyto mes an even growt I actors. . . , IS mlormatlOn as een 
gained using immunocytochemical and radioimmunoassay techniques, bioassay, and 
physicochemical characterization.4• 5. 7. 13. 15. 16.20 Othcr types of approaches were 
assessed to study aspects regarding functions of peptides within the CNS. One research 
direction has moved toward behavioral investigations during administration of a specific 
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peptide intraventricularly or intracerebrally. 21-23 Other studies have been perfonned for 
noticing the behavioral effects after increasing or decreasing the action of the endogenous 
·d b "_.. . f· . . 7 24-27A h f pepli es y awmmstratlOn 0 Its antagomsts or agomst. . not er set 0 
investigations studied peptide concentrations within the CNS in a diseased state or during 
a circadian period?8-32 This has been done either on postmortem tissues samples or using 
cerebral spinal fluid (CSF).23. 33. 34 For many brain signaling peptides, their major 
functional role in the CNS is still unknown regardless of whether we know the alterations 
in peptide concentrations during certain diseased state or behavioral observations during 
increased or decreased peptide activity. Despite rapid scientific progress, there is more to 
be clarified regarding the roles of brain peptides especially when it is known that a given 
behavior is governed by multiple pep tides, which interact. 
Discovery, characterization and measurement of endogenous signaling peptides in 
the CNS including chemical information, spatial distribution, and temporal dynamics 
have been essential steps in neurobiology. Signaling peptides typically arc effective at the 
nanomolar to picomolar concentration range, they are present in multiple isofonns, often 
contain multiple PTMs, and they frequently exhibit a variety of actions. To characterize 
peptides, it is necessary to usc reliable techniques with high sensitivity and 
reproducibility. Over the years, mass spectrometry (MS) techniques increased the 
discovery of novel neuropeptides and considerably decreased the required sample size. In 
the Sweedler group, characterization of peptides using MS has had great success in 
elucidating the chemical and functional complexity within highly peptidergic, 
biochemically interconnected systems. MS is therefore suited to characterizing peptides 
in the CNS in different animal models in combination with advanced analytical tools. 35-40 
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In our group, particularly successful are direct tissue and single neuron analyses by 
matrix-assisted laser desorption/ionization (MALDT) MS and examination of neuronal 
homogenates by clcctrospray ionization (ESI) techniques which have been used to 
identify the structure of hundreds ofneuropeptides39-44 In addition, MS methods allow 
the Sweedler group to detect and discover novel neuropeptides in large-scale peptidomics 
studies. 39,40,44 
1.2 Mass Spectrometric Techniqnes 
In this dissertation, there are described two types of MS, MALDI and ESI, which 
are used to study endogenous peptides that are either isolated from mammalian brain 
tissue, or studied in primary neuronal eell cultures. With MS, multiple compounds can be 
rapidly detected and analyzed simultaneously using a few microliter sample volumes, and 
small amounts of sample, all derived from a few milligrams or less of tissue. Although 
EST and MALDT MS are similar techniques, more peptides and their PTMs are detected 
when using both methods due to different fragmentation pattems obtained using each 
technique. This leads to an increase in the peptidome coverage and makes the 
combination ofMALDI and EST MS a key method to study peptides. 
1.2.1 MALDI TOF MS 
In 1988, Tananka et al. obtained mass spectra of large molecules by using metal 
nanoparticles-assisted laser desorption45 At the same time, Hillenkamp and co-workers 
developed MALDI MS.46 In the case of MALDI MS, the sample solution is mixed I: I 
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with a UV absorbent organic matrix on a platc to dry. During drying, the matrix 
incorporates the biomolecules into matrix crystals. Then, the sample plate is placed in the 
mass spectrometer for analysis. The matrix will absorb the UV laser beam, which causes 
a rapid local heating vaporization and ionization of analytes (Fig. 1.2 A). Subscqucntly, 
the charged ions are accelerated and separated using the time-of-flight (TOF) mass 
analyzer, and reach the detector where ion intensities are measured according to their 
time of flight. 
The organic matrix can be sinapinic acid (SA) for larger molecules, a-cyano-4-
hydroxy cinnamic acid (CHCA) for smaller analytes, and in other cases 2,5 
dihydroxybenzoic acid (DHB). The major advantages ofMALDI-TOF MS are: 1) fast 
speed of analysis: it takes less than a few minutes to analyze a spot; 2) low detection 
limits: it can detect peptides found in the range oHew attomoles; 3) simple mass spectra: 
most ions arc singly charged; 4) adjustable laser bcam (100-10 ~l1n) to focus to a small 
spot: successful for MS tissue imaging; 5) unlimited mass range: it can reach the range of 
megaDa; 6) a low volume of sample is needed: 1 [!L or less; 7) salt tolerant: suitable for 
biomolecules kept in different buffers or even physiology salin. There are also limitations 
such as: I) low reproducibility: due to uneven crystallization and therefore uncontrollable 
ion production; 2) inappropriate for detection of small molccules: at low mass range thc 
matrix interferes with analyte molecules; 3) ditliculty in obtaining MSn fragmentation: 
due to the low (single) charge state of the molecules. However, MALDI-TOF MS is a 
primary tool for qualitative analysis of peptidcs47 
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1.2.2 ESI MS 
At about the same time as MALDI, Fenn and co-workers developed ESI. Similar 
to MALDI, ESI is a soft ionization tcchnique suitable for biomoleculcs analysis, and 
therefore broadly used in proteomics and applications that require mass measurement of 
analytes. The sample molecules need to be found in an aqueous liquid solution such as 
volatile acids, bases or butlers. A volume of I 0 ~lL or less is taken into a metal or metal-
coated glass capillary (a needle) and pushed out of the needle by the influence of a high 
voltage electric field, fonning droplets of charged particles/ions (Fig. 1.2 B). A noble gas 
or nitrogen is used to nebulize the liquid producing the solvent droplets. The solvent 
evaporates and the charged molecules are guided into mass spectrometer, often an ion 
trap (IT) or quadrupole time-of-flight (qTOF) analyzer. ESI produces multiply charged 
ions trom a single molecule, created by protonation or deprotonation of the parent ion. 
The pattern of the multiple peaks of different charge helps to get high mass accuracy for 
the analyte but it adds complexity to the mass spectrum. Therefore, ESI is often coupled 
to a separation method such as liquid chromatography (LC) that lowers the sample 
complexity by separating the sample mixture into simplified fractions before MS 
analysis. Similar to MALDI, ESI is a soft ionization method, which produces little or no 
tragmentation during ionization and therefore is suitable for peptides analysis. 
Advantages of ESI: 1) high reproducibility: no crystallization of the analyte in a matrix is 
required, and for the same reason it is 2) semi-quantifiable: due to uniform ionization of 
the analytes and no matrix crystal "hot spots", which can alter the intensity signal. 
Disadvantages of ESI: 1) complex spectra: due to peak intensities of multiple charges; 2) 
it needs larger sample volumes compared with MALDI 47• 48 Recently, the nanospray has 
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been introduced, which uses only nanoliters of sample volume, thus this last disadvantage 
is overcome. 3) it is a less suitable technique for imaging experiments: an EST interfacing 
sample preparation method for imaging has not yet been developed. Desorption ESI 
(DESI) is available for imaging but spatial resolution is poor47 However, ESI and 
MALDT have been well used in the past decades for biomoleeules detection, 
'd 'fi' d 47-S1 1 ent! leatlOn, an measurement. -
1.3 Separation Method: Liquid Chromatography 
In the current work, as in many other studies, sample fractionation is useful prior 
to MS analysis due to biological sample complexity and wide dynamic range of the 
peptides in the sample tissue extracts. Reversed-phased (RP) liquid chromatography (LC) 
is most commonly used for separation of endogenous peptidcs. 52-54 
The principle of chromatographic separation of a mixture of analytes, including 
peptides, is based on the differential interaction of the solutes with the solid phase 
(stationary phase) and the mobile phase. The separation in RP is based on the 
hydrophobic interaction between the peptides and the packing material, which is 
represented by silica particles packed into a cohnnn55 In addition, this serves as a 
desalting step as well. The elution is done as the most hydrophobic pcptides elute later 
than the least hydrophobic. RP has high resolving power and it is compatible with most 
solvents52• 53. 55 Resolution improves considerably when the solute, the mobile, and the 
stationary phase work at optimum parameters. Peptide composition, solubility, and 
chemical properties together with column selection, solid phase, and mobile phase 
properties highly influence the peptides separation, selectivity and detection. 
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The separation methods can be coupled on-line or off-line with different 
ionization techniques EST (on-line) or MALDT (usually off-line), and different mass 
spectrometers. The ionization, separation, and MS setup improved considerably over the 
past years, greatly increasing the detcction and analysis of pcptides; with every 
experiment the peptidome coverage of many species is becoming more complete. 
1.4 Dissertation Overview 
The goal of this dissertation is to characterize and identify part of the most 
complex set of peptides, the brain peptides, using MS analysis. Prior to MS analysis, the 
sample is isolatcd from well-defined structures such as pituitary, or the hypothalamus or 
even cell cultures, and suffers many manipulation steps during preparation. Sample 
preparation is one of the most important aspects for MS analysis. During preparation, the 
main goals are the recovery of a large number of bioactive peptides in the tissue, a lower 
interference of protein products, and matching the most compatible separation method 
with mass analyzer specifications for the analyte of interest. The strategies of sample 
preparation described in this dissertation arc focuscd on post-mortem tissue dissection 
and manipulation, analyte extraction while keeping the peptides as close as possible to 
their endogenous chemistry, and the imp011ance of using of complementary analytical 
techniques in the characterization and analysis of pcptides. 
Chapter 2 represents a complete up-to-date review of the neuropeptidomics field. 
The goal is to describe relevant sample handling methodologies for peptidomics studies 
that allow for the assay of an array of chemical analytes found in diversc brain tissues 
from large structures or small nuclei, or from cells grown in culture or manually and 
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individually isolated from CNS. Direct tissue profiling, extraction-based and release 
collection methods in addition to different analytical methods for qualitative and 
quantitative analysis of endogenous peptides in the CNS are reviewed in this chapter. 
Chapter 3 describes a comparative neuropeptidome analysis of the SON and SCN 
using mass spectrometric approaches. The CNS uses a surprisingly complex suite of 
neuropeptidcs that are involved in cell-cell commLmication. Thc hypothalamus contains 
multiple nuclei that contain neurosecretory cells producing and releasing cell-cell 
signaling peptides with the hypothalamic SON and suprachiasmatic nuclei (SCN). These 
are cxamplcs of nuclci involved in endocrine signaling. Both SON and SCN cell-to-cell 
signaling molecules have regulatory effects in the CNS, as well as in the PNS. The 
neuropeptide measurements have been optimized using extraction-based methods that 
allow for identifying multiple endogcnous peptides at different abundance lev cis. Post-
mortem degradation was minimized by deactivating proteases via rapid heat denaturation 
before acidic extraction. Microwave irradiation and boiling buffer extraction followed by 
acidified acetone or acid acetic extraction has been used to achieve complemctary effects 
and lower sample complexity. In addition, MALDl-TOF MS and ESI-MS are both used 
to increase the number ofneuropeptides to be characterized. We have identified diverse 
peptides including their PTMs from different precursor prohorrnoncs, including 
provasopressin [24-32], protachykinin 1[58-68], proenkephalin A [219-229], 
proopiomelanocortin (POMC) [205-235], proSAAS [42-59], prochromatogranin [443-
459], [554-572], prosomatostatin [103-116], and sevcral unidcntified peptides. 
Chapter 4 represents one of the first peptidomic studies of a small nucleus, the 
supraoptic nucleus (SON) of rat hypothalamus. The SON secretes peptides having many 
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functions. The main hormones secreted are vasopressin (A VP) and oxytocin (OXY), 
which are involved in water regulation of the kidney in case of A VP and lactation and 
parturition in case ofOXY. In collaboration with the Martha Gillette Laboratory, this 
study investigates and characterizes neuropeptides cxtracted from SON region using a 
unique and innovative methods of tissue isolation from ex vivo brain slices followed by a 
multistage peptides extraction protocol. What peptides are in SON? What are the PTMs 
of neuropeptides? What are the cleavages of neuroprohormones of SON somata? Thesc 
are the main questions answered. Based on the neuropeptidomies study we report 
identification of 85 peptides, including 20 novel compounds from known prohonnones. 
In addition, a single mammalian neuron is isolated and profiled without the usage of a 
staining method or enzymatic digest. 
In Chapter 5 we developed a novel neuron-to-neuron, serum-free, co-culture 
approach that was used to study the higher-level cellular peptidome of individual primary 
mammalian neurons. Proteomic studies of brain regions of specialized function provide 
evidence that cOimnunication among neurons is mediated by systems of diverse chemical 
messengers. These analyses arc largely tissue- or population-bascd, whereas thc actual 
communication is from cell-to-cell. To understand the complement of intercellular 
signals produced by individual neurons, new sample preparation methods are required. 
Magnocellular neurons (MCN) from the SON were isolated from the early postnatal rat 
supraoptic nucleus and the MCN was maintained in serum-free low density cultures 
without glial support layers; Lmder these conditions the MCN required low-density 
neuronal co-cultures. Co-culturing MCN with hippocampal neurons permitted local 
access to individual neurons within the culture for MS. Using direct sampling, peptide 
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profiles were obtained for spatially distinct, identifiable neurons within the co-culture. 
There were 10 reproducible peaks that were assigned to previously characterized peptides 
and 17 peaks that remain Lmknown. Pcptides from the vasopressin prohormone and 
seeretogranin-2 are attributed to magnocellular neurons, whereas neurokinin A, peptide J, 
and neurokinin B are attributed to cultured hippocampal neurons. This approach enables 
the elucidation of cell-specific prohOlIDone processing and the discovery of cell-ccll 
signaling peptides. 
In Chapter 6 there are investigated different sample preparation procedures that 
enhance OXY detection. Why is endogenous OXY challenging to detect in SON? Is it a 
matter of ionization? Is a matter of abundance? Is it released and detected only under 
certain conditions such as KCI stimulation? In addition to our SON study, a considerable 
focus was in analyzing low abundant peptides. A VP and OXY arc the main hormones 
that are secreted from SON into posterior pituitary 56·59 In the brain, the two peptides are 
released locally and they are involved in different behavior such as aggression, maternal, 
and social behavior. 60-64 The ratio of neurosecretory granules estimated as being 
involved in the local release ofOXY versus AVP is 1:5. 
Chapter 7 includes a study of peptides using MS with role in the pituitary 
development. Located at the base of the brain, the pituitary gland controls the release of 
hormones responsible for growth, metabolism, fertility, and the body's response to stress. 
Normal functionality ofthe pituitary gland is essential for the development of many 
organs. During embryonic development, the expression of Hes} genc influences 
differentiation of the pituitary progenitor cells into the endocrine cells. Hes} deficient 
mice have abnormally small pituitary glands with a reduction in all cell types and an 
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absence of the mclanotrope cell population, as detected by immunohistoehemitry for the 
melanocyte-stimulating hormone (MSH) peptide. Chapter 7 is a work in collaboration 
with the Lori Raetzman Laboratory. To assess the role of Hesl in telminal differentiation 
of pituitary progenitors, we identified peptides present in extracts of wild type and Hesl 
mutant embryonic mice. 
Research described in this thesis is focused on the sample optimization and 
preparation for mass spectrometric measurements of small tissues such as single nuclei, 
about 1 mm volume, embryonic tissue, less than 1 mm volume, primary neuronal cell 
culture, and single neurons, less 40 ftm. Analytical investigations reveal chemical 
information of peptides that function as cell-cell signaling compounds within different 
mammalian neuronal systems. Overall, this research demonstrates the powerful 
capabilities of MS, which ensures the rapid and direct analysis of peptides in biological 
complexes. 
12 
1.5 Figures 
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:i-+ - -
A. B. 
Figure 1.1 Ionization schemes for A) MALDI MS and B) ESI MS 
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CHAPTERll 
NEUROPEPTIDOMICS; CHARACTERIZING BRAIN PEPTIDES USING 
MASS SPECTROMETRY 
2.1 Notes and Acknowledgements 
This chapter is adapted from the review chapter manuscript" N europeptidomics: 
Characterizing Brain Peptides Using Mass Spectrometry" published in the book "Mass 
Spectrometry of Proteins and Peptides in Drug Discovery" edited by "John Wiley & 
Sons". The book chapter was written together with Dr. Fang Xie and Prof. Jonathan 
Sweedler. I would like to acknowledge Dr. Fang Xie for writing other different section 
of the chapter. I want to acknowledge Prof. Jonathan Sweedler for giving me the 
opportunity to write this book chapter. This work was suppot1ed by Award No. P30 
DAO 1831 0 from the National Institute on Drug Abuse (NIDA) and by Award No. 
5ROINS031609 from the National Institute of Neurological Disorders and Stroke 
(NINDS). The content is solely the responsibility of the authors and does not necessarily 
represent the official views ofNTDA, NINDS, or the National Institutes of Health. 
2.2 Introduction 
Endogenous cell-cell signaling peptides (SPs), a diverse group of compounds that 
includes neuropeptides, hormones, and cytokines, play key roles in brain physiology. 
Research on SPs has been accelerating over the past decade with aspects of their function 
established, even for those recently characterized. 1-4 Nevertheless, the function of many 
native SPs remains unknown. SPs and other neuropeptides are important biomarker 
candidates related to a variety of health concerns, including Alzheimer's and 
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cardiovascular disease, schizophrenia, depression, and cancer5 . 11 So that we may 
improve our knowledge of their role in many physiological processes and realize their 
potential as psychopharmaceutical targets, comprehensive analyses of the peptide content 
of specific cells, groups of cells, brain structures, or even entire brains arc required. 
Two recent measurement strategies, proteomies and peptidomies, have 
comparable objectives and employ similar techniques, but there are key differences. 
Proteomics, the large-scale study of proteins in a sample, often uses enzymatic digestion 
to generate smaller fragments, with the resulting peptides analyzed by mass spectrometry 
(MS). When proteomics is used as a "bottom-up" approach, a goal is to identify a protein 
based on the detection and the identification of its peptide fragments. 12 In contrast, 
peptidomics is the study of the "comprehensive suite" of endogenous peptides expressed 
within a specific cell, organ or organism. These peptides are analyzed without enzymatic 
pre-treatment The aim of an MS-based peptidomics experiment is to detect and 
characterize the peptides present, including their post-translational modifications (PTMs), 
at times in a spatially or temporally-defined manner. 
Peptidomics has long been a field of research, even before 2001 13·16 when the 
term was introduced. 17.19 Since these initial studies, other research groups have made 
spectacular progress using peptidomic methods for studying SPs in a range of brain 
samples, from organelle 20, neuronal cel!21.22 and nucleus 23 to brain structures 24.27, 
. '8 29 db' I fl 'd 30 31 I b h II . entIre nervous systems -. , an cere rospma U1.' t can e c a engmg to 
characterize and measure SPs in a biological sample given the variety of bioactive 
peptides, the large number of PTMs that result when producing them from prohormones, 
their low concentrations and wide dynamic range, and at times, their localization in small, 
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spatially segregated structures or under specific physiological conditions. This chapter 
focuses on the sample preparation techniques and analytical methods for detecting and 
characterizing endogenous SPs in the central nervous system (CNS). 
2.3 Neuropeptidomics: Characterizing Peptides in the Brain 
Ncuropeptidomies, the measurement of pcp tides in CNS-relevant samples, has 
been used by several research groups to identify neuropeptides and measure changes in 
their expression levels.23-27 , 32 There are a number of inherent challenges in 
neuropeptidomics; these include the extremely wide dynamic range of endogcnous 
peptides (even for those from the same prohormone) as compared to the lower dynamic 
range of mass spectrometers, the post-mortem degradation of proteins and peptides, and 
the difficulty of detecting or sequencing neuropeptides of low abundance. Bceause of 
these factors, proper sample preparation is often crucial to a successful neuropeptidomics 
experiment. As discussed below, many studies have optimized extraction or direct tissue 
preparation procedures to maximize neuropeptidome coverage and facilitate the mass 
spectrometric detection of novel peptides. 
2.4 Neuropeptides: Actions and Functions 
SPs include neuropeptides, trophic factors and other endogenous peptides 
produced and secreted by populations of cells in the brain, with roles in neuromodulation, 
eell-ecll signaling and neuronal network formation. Aftcr SPs arc synthesizcd and 
released, they can exert their actions either locally or at long distance, and hence, directly 
impact a number of physiological parameters and even organism behavior. For example, 
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oxytocin and vasopressin, secreted by the hypothalamic magnocellular neurons in the 
supraoptic nuclei, directly affect many physiological systems. Discovered and chemically 
identified in 1953 by Du Vingneaud 33, these two peptide hormones, conserved in 
vertebrates, have similar chemical structures but distinct physiological activities. In the 
peripheral nervous system, oxytocin is associated with reproductive functions and 
vasopressin with water balance in the kidney.34 In the brain, they have robust effects on 
social and maternal behavior, as well as pair bonding35 
The biosynthesis of neuropeptide formation starts with the production of the 
preprohOlIDone in the cellular cytosol. The preprohormone contains an N-telIDinal signal 
peptide, typically between 15 - 30 amino acids, which guides the fornling preprohormone 
to the rough endoplasmic reticulum where it is cleaved by a signal endopeptidase. I I. 22 
The complete prohormone (now without the signal peptidc) is transferrcd to the trans-
Golgi network where it is sorted and packed into large dense core vesicles or secretory 
granules. Here a number of processing enzymes become active and cleave the 
prohormonc at specific sequence motifs, such as basic amino acid residues (Figure 1 )36 
Additional modifications, such as C-terminal amidation, acetylation, phosphorylation, 
sulfation, and glycosylation, may also occur during this process. 37 The PTMs of 
endogenous neuropeptides provide resistance to enzymatic degradation and regulate 
binding affinity to receptors, and thus directly impact bioactivity.38 After intracellular 
processing, pep tides can be secreted at the axon termini (presynaptic release), the soma or 
d dr · 35 39-41 F II' . . . h f h II I . h en ·ltes.· ... 0 owmg secretIOn, at llmes WIt LUi er extracc u ar processmg, t e 
peptides interact with their cognate receptors. They are then degraded in the extracellular 
space by peptidases or even taken up by cells. As an example, neprilysin and neurolysin 
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are essential metalloenzymes in the formation and degradation of angiotensin and 
endothelin, respeetively.42 
Present in the brain, spinal cord, cerebrospinal fluid, gastrointestinal tract, 
00 31 40 45 pancreas, and blood' ... ,- ,SPs act as neurotransmitters, neuromodulators or 
hormones.36• 46 They may have other functions as well, such as eytokine or trophic 
aetivity47 A single gene encodes a single prohOlmone; however, the prohormone often 
encodes multiple bioaetive SPs (Figure l). For example, multiple peptides processed 
from the proopiomelanoeortin hormone have distinct functions: adrenocorticotropic 
honnone stimulates the adrenal glands to release c0l1isol; melanocyte-stimulating 
hormone increases the pigmentation of skin by increasing melanin production in 
melanocytes; and beta-endorphin and Met-enkephalin are endogenous opiates with a 
broad spectrum of functions36 
However, it is not necessarily a given that all peptides derived from a prohormone 
will be bioactive. Pep tides may be expressed in a tissue-and/or time-specific manner. 
Some peptides are present in neurons at high levels under normal conditions, others 
remain at low or undetectable levels, while others arc present only transiently during the 
early phase of development and then significantly downregulated after birth. For 
instance, substance P in primary sensory neurons, galanin in hypothalamic neurons, and 
neuropeptide Y and vasoactive intestinal peptide in cortical neurons arc detectable at high 
levels; on the other hand, these pep tides are present at low levels in sensory neurons 
under normal conditions. Other peptides are only transiently expressed, for example, 
during early development; such peptides include somatostatin, which is expressed widely 
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in the eNS, substance P in spinal guiding neurons, and galanin in primary sensory 
neurons. 37 
2.5 Sample Preparation for Mass Spectrometry 
Several analytical techniques offer a number of performance specifications that 
make them well suited for peptide discovery and characterization. Specifically, the fast 
analysis speed, low detection limits and excellent mass accuracy of the mass 
spectrometric approaches now available are particularly useful for peptide 
characterization. As stated earlier, sample preparation also plays an important role in the 
success of an SP characterization. The objectives of the sample preparation process arc 
usually the recovery of as large a fraction of the SP complement as possible, minimizing 
interference from protein degradation, and matching the appropriate separation/mass 
analyzer specifications to the analyte of interest. Presented here are various sample 
handling methodologies that lead to improved detection and identification of SPs from 
neural tissues using direct MS, as well as separations hyphenated to MS. 
2.5.1 Direct Tissue Profiling 
A variety of analytes in a wide range of biological samples have been measured 
directly by matrix-assisted laser desorption/ionization (MALDl)-time-of-flight (TOf) 
MS. This method provides high sensitivity and enables the analysis of small specimens 
h . d' 'd I II I II 20 48 . I 21 49 SO . I I . 51 . I suc as m lVl ua ce u ar organe es ' , smg e neurons .. ", smg e nuc el ,smg e-
cell-sized tissue samples 52, and brain slices. 51 Sample preparation consists of three steps: 
tissue isolation, mounting on the MALDI target, and introducing the MALDI matrix. 51 
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Often, sample preparation for direct-tissue MALDl involves obtaining fresh frozen 
sections with a cryostat. 51 After mounting, the sample surface is usually sprayed with an 
acidic matrix solution, which allows analytes to be extracted locally and incorporated into 
matrix crystals. 53 An interesting direct profiling approach for investigating neuropeptides 
was developed by Monroe et al. 52; a thin tissue section is placed on an array of -38-llm 
glass beads attached to an elastic, hydrophobic membrane (Figure 2). By stretching the 
membrane, the tissue is divided into single-cell-sized pieces. This method of direct tissue 
analysis will be explored in further detail in section 6.2.4. 
In recent years, MALDI MS has become an efficient tool to investigate the 
'd f' 1 ll"b 22 49 d b 50 S 1 neuropepll orne 0 smg e-ce s m mverte rates .. an vertc rates: amp e 
preparation requires the ability to select the cell(s) of interest. To study peptides from the 
invertebrate nervous system, one can use manual isolation of single cells or cell clusters, 
which is the easiest and fastest method (e.g., less than 1 min)48 More recently, single cell 
MALDI has been applied to mammalian cells 50 and hypothalamic neurons.23 Once 
isolated, the cells are plated on a MALDI target and treated with the appropriate sized-
matched volumes of matrix solution. Another approach is laser capture microdissection, 
which is used to isolate cells from thin mammalian tissue seetions.54 
Rubakhin et al. 50.55 developed a protocol to analyze the peptide content of 
indi vidual mammalian cells with sizes as small as -8 Ilm. This method employs 
micromanipulation to transfer the isolated cells onto a MALDI target and remove the 
extracellular solution to reduce the chemical background. Prior to this cell transfer step, 
glycerol is used for stabilization, maintaining cell morphology and preventing 
neuropeptide redistribution. Guided microdeposition ofMALDI matrix is used as a last 
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step to create the optimal analytc-to-matrix ratio, thereby minimizing pcptide dilution. 
These sampling protocols enable investigation of neurobiological systems with cells in 
the range of -8 - 100 ~lm and low analyte amounts (-amol). 
Another method of direct tissue profiling is to apply mass spectrometry imaging 
(MSI) to the identification and localization of peptides in a sample. A typical preparation 
procedure includes mOLmting a section of frozen tissue (e.g., lO-flm thick) on a stainless 
steel target plate, coating it with a matrix solution, and drying it prior to MALDl-TOf 
MS analysis. 56 MSI has been used to study neuropeptides and proteins from well-defined 
regions of mouse brain and human brain tumor sections. 56 It also has been used to locate 
specific compounds that are highly cxpressed in a treated or diseased sample relative to 
normal tissue. 54, 56 This technique will also be discussed in more detail below. 
2.5.2 Extraction-Based Strategies 
for many experiments, one of the first steps is to extract the peptides from the 
analyte of interest into the appropriate solution. Various extraction-based protocols for 
post-mortem biological specimens have been develop cd, with the overall goal being to 
preserve the peptides in as close to their original state as possible. Post-mortem 
degradation becomes a critical issue in neuropeptidomics due to proteolytic enzyme 
activity, which can rapidly degrade SPs in sample tissucs. Deactivating these enzymes by 
thermal treatment appears effective. A variety of procedures, including focused 
microwave irradiation (before or after freezing) 57, Sg, rapid microwave irradiation of the 
entire brain 24, boiling the tissue immediately after decapitation 23, or a combination of 
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snap-freezing, cryostat dissection and boiling extraction buffer 25, have improved the 
recovery of SPs for mass spectrometric characterization. 
After protease deactivation, the next step is to extract the peptides. Several 
laboratories have investigated various techniques to enhance the reproducible recovery of 
'd d ... h' d . f . d d' ti '3 25 59 60 peptI es an to mmlmlze t elf etectIon rom protem egra atlOn ragments.-· ,. 
Acidified organic extraction buffers, including acidified acetone, cthanol and methanol, 
have been successfully employed to extract peptides from biological samples and 
deactivate proteases via denaturation and precipitation. This approach has proven 
effective for invertebrate samples2g As for mammals, when different extraction buffers 
(e.g., diluted acetic acid, acidified methanol, and sodium dodecyl sulfate with KCI) are 
compared, diluted acetic acid was shown to have a higher overall extraction yield?5 
Samples treated with hot or boiling water followed by cold acidic extraction resulted in 
the reproducible recovery of many hypothalamic peptides, including a few novel 
d '3 25 59 B b' . h . h .. . h d compoun s.-' , y com mmg tec l1lques, sue as SOl1leatlOn WIt etergent 
treatment, Parkin et al. 61 found a three-fold increase in nemopeptide identities. 
Subjecting samples to sonication and heated water at 70°C for 20 min followed by cold 
acid enabled the efficient extraction of many neuropeptides without the formation ofthe 
protein degradation fragments seen with hot acid extractions. 
Recently, a less complex extraction protocol was developed by Romanova et al. 62 
for both invertebrate and vertebrate samples. Tissues are stored in saturated 2,5-
dihydroxybenzoic acid (DHB) solution, leading to effective extraction of endogenous 
peptides as well as long-term preservation of tissue samples without freezing. Additional 
advantages of this protocol are its technical simplicity, reproducibility, and ease of 
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remote sample preparation. More recently, Altelaar et al. 63 introduced a novel extraction 
protocol using 8 M of urea solution, a well-known cell lysate factor and protein 
denaturant (Figure 3). A higher number of putative novel bioaetive peptides were 
characterized in a concentrated urca extract than in an acidic extract. Urea may solubilize 
the tissue more efficiently than the acidic solution, liberating and dissolving the peptide 
content. An alternative method for sample preparation without microwave fixation is to 
select and isolate cellular subcompartments that have high levels of SPs such as 
synaptosomes or even dense core vesicles. 
When analyzing complex systems (e.g., the mammalian brain), samples of 
relatively large morphological structures arc preferred, such as an entire hypothalamus, 
. h' 25 64 65 F MS lb" d I stnatum, or Ippocampus. . , . or ana yses, 0 ta1l11l1g a equate ana yte amounts 
typically requires these large sample sizes. Fortunately, sample handling protocols have 
been developed and optimizcd to encompass a range of samplc sizcs, including single 
nuclei isolated from ex vivo brain slices via tissue puneh.23 Unlike the majority of 
previous mammalian peptidomie studies, these samples do not require immediate heating 
or microwaving. The preparation of brain slices is a well-established technique; the slices 
remain functional for more than 24 h ex vivo 66.67, allowing the recovery of altered 
neurosecretory vesicles and other cell organelles6g Furthennore, the isolated tissue 
punches from freshly prepared hypothalamic slices are processed through a multistage 
peptide extraction protocol, including boiling as a primary extraction step and 
deactivation of proteolytic enzymes, followed by a two-stage acidic extraction solution of 
acidified acetone and acetic acid.23 This multistage extraction, wherc the boiling water is 
followed by an organic and a slightly acidic solution, increases the recovery of the 
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peptidome of a small brain region. Advantages of the method include the ability to 
combine functional tests of peptide release with peptidome measurement, and to clearly 
delincatc small and anatomically well-defined brain structmes, such as individual brain 
nuclei from fresh (non-heat-treated) samples.23 
As noted above, direct tissue profiling with MS enables a number of unique 
studies, such as the classification of individual mammalian cells by peptide profiling, the 
localization of different compounds within a tissue, the elucidation of cell-specific 
prohormone processing, (ineluding PTMs of pep tides), the study of neuronal transport by 
measming peptides below the level of a single cell, and the discovery of novel signaling 
peptides on a cell-to-cell basis. On the other hand, extraction-based strategies, when 
combined with the appropriate separation and MS techniques, are essential methods for 
qualitative and quantitative measmement of brain peptides. 
2.5.3 Collecting Peptide Release 
The release of endogenous nemopeptides represents a fundamental and dynamic 
component of cell-cell signaling within the brain. Neuropeptides are secreted locally at 
moderate concentrations but are quickly diluted after release. Both direct tissue profiling 
and analysis of tissuc extracts arc mcthods that generate valuable infOlmation about the 
content of peptides and their locations in a biological sample. Although we are able to 
detect and identify the fully-processed pep tides and pro hormone processing 
intermediates, these procedures do not provide direct information on their biological 
function. Peptides derived from a single prohonnone may have diverse bioactivities, but 
only a small number of them may be involved in cell-cell signaling. Those that are 
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involved in cellular communication are released in the extracellular space at different 
neuronal sites. 39-41 A number ofapproaehes have been employed to monitor activity-
dependent peptide release from the eNS. 
Solid-phase extraction (SPE) collection, combined with elcctrophysiology and thc 
appropriate separation and mass spectrometric techniques, has been successful in 
generating functional insights regarding peptides. 1,69.70 In addition to using micrometer-
sized SPE beads as region-specific sampling probcs 69.71.72, other methods to collect and 
concentrate releasate directly from hypothalamic brain slices (500 /lm) using SPE 
material embedded within pipettes 1 or in porous monoliths fabricated in capillaries 70 
have been reported (Figure 4). In both cases, the releasates are elutcd from thc SPE 
material and characterized offline with MALDI-TOF MS. This novel approach to peptide 
collection using individual bead probes has a number of advantages for peptide studies. 
Not only can they be placed separately at discrete locations, they concentrate compounds 
present in the immediate extracellular region and provide a method for desalting, which is 
essential for quality MALDI MS. SPE material placed directly on intact nervous tissue 
before and after stimulation using chemical or electrical depolarization minimizes sample 
loss and facilitates removal of salts that unevenly suppress peaks in the mass spectra. 1 
Spatially resolved neuropeptide sampling combined with electrophysiology and MS has 
been developed to measure site-specific peptide releasates within the neurohormonal 
system and single neurons 69,71; detected peptides are then sequenced by tandem mass 
spectrometry (MS/MS). Following this strategy with mammalian models, ex vivo 
hypothalamic rat brain slices or in vitro rat pituitary, relcasates can be screened spatially 
and temporally for multiple compounds.1,69 The same assay can be used for functional 
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testing of specific molecules. This method demonstrates the feasibility of collecting 
peptides locally from discrete locations of biological tissues and extracellular media in an 
activity-dependent manner. It also allows a close interface between biological release and 
SPE collcction, thereby decrcasing sample dilution resulting from analyte diffusion and 
degradation in the extracellular space. 69 
Perhaps the most common approach for monitoring the release and metabolism of 
the brain is in vivo microdialysis. A scmi-pcrmcable mcmbranc is implantcd in discrete 
brain regions of nonanesthetized freely moving animals. The analytes present in the 
extracellular space diffuse into the probe as a fWlction of their concentration gradient and 
are collected into fractions for chemical analysis73• 74 Neuropeptide measurement with 
microdialysis is usually performed with radioimmunoassay, a highly sensitive technique; 
however, it does require analyte preseleetion75• 76 Due to the sample complexity and low 
concentration of peptides, the collected material is often separated using nano-liq uid 
chromatography (LC)/capillary electrophoresis (CE) followed by sensitive MS 
detection73• 74. 77. 7H Important advantages of these assays over other methods include 
using live animals and providing higher temporal and spatial resolution, high sensitivity 
and selectivity, multi-analyte monitoring, and identification of peptide sequences along 
with their PTMs. 
Compared to direct tissue profiling and extraction-based methods, measuring 
brain releasates with MS can also shed light on the putative functions of peptides because 
context-specific release patterns are obtained. These methods have had significant 
success in peptide detection and identification, but do keep in mind that each assay must 
be optimized for the specific analysis. 
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2.5.4 Sample Preparation for MSI 
An important requirement for MSI sample preparation is to preserve the native 
spatial distribution of analytes within the specimen. A general sample preparation 
protocol for MALDI MSI involvcs frcczing or drying thc samples immcdiately after 
collection, slicing them into thin sections (typically 5 - 20 ].lm) on a cryomicrotome just 
before analysis, and then transferring the sections onto a MALDI target plate. Limited 
fixation, cithcr via thaw-mounting or chcmical approaches, is somctimcs used. Ncxt, 
sample sections are coated with a MALDI matrix solution; analytes are extracted and 
incorporated into the matrix as it crystallizes (Figure 5). 
Choosing the appropriatc matrix dcpcnds on the mass rangc and analytcs of 
interest. The commonly used matrix, a-cyano-4-hydroxycinnamic acid, works well for 
compounds under -3000 Da, such as neuropeptides. DHB is less used in MSI because it 
tcnds to form large hetcrogcneous crystals. Howcvcr, it is commonly uscd in 
neuropeptide profiling experiments, with such profiling being a form oflow spatial 
resolution mapping. Tissues are surrounded by physiological saline, in which case a 
washing stcp may bc helpful bcforc matrix deposition. This ensurcs formation of unifonn 
and small-sized crystals. Typically, a brief 70% ethanol wash can eliminate both salts and 
debris, followed by a subsequent 90 - 100% ethanol wash to help complete tissue 
dchydration and tcmporarily fix thc tissuc. 79 Thc addition of glycerol has also bccn used 
for this purpose.48 The matrix application step is critical for MSI analysis, and a balance 
must be achieved between extraction efficiency and spatial resolution. Specifically, the 
longcr a sample is exposcd to thc matrix solution, thc greater thc amount of extracted 
analytes and thus, improved sensitivity. However, longer exposure to the matrix solution 
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allows analytes to migrate further from their original positions, leading to decreased 
spatial resolution and blurred images. This is especially true for neuropeptides because 
they arc small, hydrophilic analytes.4s 
To address issues related to peptide migration versus analyte extraction, Monroe 
et al. 52 developed a unique stretched sample method (Figure 2). A thin tissue section is 
adhered to an array of glass beads that arc mechanically attached to a Parafilm M 
membrane. The membrane is stretched and the tissue is rapidly divided into thousands of 
cell-sized pieces, and the MALDI matrix is then applied. The physical separation 
between the beads, along with the hydrophobic nature of the membrane, allows peptides 
to be extracted from the tissue into the matrix, without any horizontal redistribution. 
Another way to minimize analyte migration is to optimize MALDI matrix 
deposition techniques, with the goal of delivering small droplets of matrix solution on the 
tissue to fonn a homogeneous layer of crystals. A variety of approaches have been 
developed, such as electrospray deposition RO, automated acoustic printing Rl, and 
nebulizer spray coating. S2 In addition, matrix can be seeded on tissues before deposition, 
either by adding it to the washing solutions (e.g., ethanol), applying during a rinsing 
procedure R3 or, if the solid matrix can be mechanically ground into a fine power, 
spreading it across the tissue seetiong4 Seeding results in greater crystal homogeneity and 
thus, more stable and uniform signals across the tissue sample. As for the choice of 
seeding matrix, sinapinic acid has been shown to minimize spatial redistribution.Ro An 
alternative deposition approach combines matrix seeding and high-density micro-
spotting; a sprayed low-concentration matrix seed layer is followed by inkjet printing of a 
high-concentration matrix solution.85 
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Secondary ion mass spectrometry (SIMS) has long been used in the bioanalytical 
investigation of cells and tissues. It is well suited to analyses of elements, metabolites, 
lipids, phannacologieal agents, and other low molecular weight analytes. However, SIMS 
has seen somewhat limited use in pcptidomics. Only recently has it bcen capable of 
studying physiologically relevant peptides, mostly because of advances in sample 
preparation and instrumentation (discussed in detail in Section 6.4.1). In SIMS, a focused 
primary ion beam bombards the sample surface, and the ejected secondary ions arc 
collected and analyzed. However, during primary impact, surface charging and analyte 
fragmentation can result. One approach for resolving this issue during sample preparation 
is via surface metallization, which prevents charging and "softens" the primary ion 
impact by forming a protective shell over the surface. Another method is to coat tissues 
with a MALDI matrix in a similar manner as in MALDI MSI, so-called matrix-enhanced 
S1MS 86 This technique has greatly increascd the mass range (up to the 1 kDa range) and 
sensitivity of SIMS imaging, but the experimental spatial resolution becomes 
compromised and limited to 2 - 3 flm because of the matrix crystal dimensionsg7 The 
distribution of the neuropeptide APG Wamide in sections of Lymnaea stagnalis cerebral 
ganglia were investigated using a mass spectrometer with an 115In + liquid metal ion gun. 88 
In this study, samples were covered with a layer ofDHB and the subcellular distribution 
of this neuropeptide was visualized with -3-flm lateral resolution. 
2.6 Separations 
In many cases, sample fractionation is required prior to MS analysis due to the 
complexity and wide dynamic range of the peptides present in tissue extracts. Although 
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two-dimensional (2D) gel electrophoresis is a standard method in proteomics 89,90, it is 
not as common in peptidomic analyses due to the lower mass limits of gels (most gels 
have been optimized for analytes larger than 10 kDa)91 At present, reversed-phase (RP) 
capillary LC is more common for separating endogenous peptides, especially those of 
low abundance.92, 93 Typically, a nanoflow LC column (e.g., 75-llm inner diameter (i.d.)) 
is connected to a pre-column with low back pressure to achieve time-efficient loading via 
a colunm switching system93• 94 Moreover, this functions as a desalting mechanism 
because the undesired, less-retained components (e.g., the small inorganic ions) of the 
sample matrix are driven to waste during sample loading. This approach has been utilized 
in many peptidomie analyses, with numerous peptides identified efficiently in a single 
chromatographic run.95 Even smaller columns (e.g., 25-llm i.d.) can be used.96 For 
neuropeptidomic studies, capillary LC is typically either online coupled to electro spray 
ionization (ESl) MS, or offline coupled to MALDl MS (more details in Section 6.4.1).97. 
98 RP chromatography is well suited for peptide separations and easily interfaced to EST 
MS. In the nanoliter flow rate range, the electro spray process becomes a more efficient 
ionization method 53, with the mobile phase additives often chosen to achieve the best 
compromise between separation resolution and detection sensitivity. The effect of 
different ion-pairing reagents on the MS signal intensities in peptide analysis has been 
reviewed elsewhere99 At present, RPLC that employs a water-acetonitrile gradient 
containing trifluoroacetic acid of low concentration (e.g., 0.05 - 0.1 %) is the most 
h · ,. 'd' I 99 100 common c Olce lOT neuropepl! om1c ana yses. . 
Even though one-dimensional capillary LC offers high separation efficiency, its 
peak capacity is insufficient for the complexity of many CNS samples. Thus, multi-
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dimensional chromatography, which couples two or more LC columns with different 
. h' ." d" h d I I' 1111 10' I separation mec antsms, IS olten use to lurt er re uce samp e comp eXlty. . - n 
neuropeptidomics, a common multi -dimensional LC approach is strong cation exchange 
(SCX) chromatography followed by RP chromatography. 1113 This combination can be 
realized either online or offline. In the typical online scheme, peptides are trapped on an 
SCX colLUnn and eluted stepwise to an RP column by using salt fractions of increasing 
concentration. For each set of peptides, an RP linear gradient is used to elute them from 
the reverse-phase column. The subsequent salt fraction is applied to elute the next set of 
peptides from the SCX colLUnn. The online approach allows automated analysis with 
minimal sample loss 1114.105 Wolters et al. 106 devcloped a dual-phase column for protein 
identification. This column is packed with SCX beads followed by RP beads and 
functions essentially as an online 2D LC separation. In the offline approach, peptides are 
eluted from thc SCX column with a linear salt gradient. A series of fractions are collected 
and then subjected to RP HPLC analysis. Larger sample quantities can be analyzed using 
this scheme, since a wider-bore SCX column can be used as the first dimension. lo5 The 
successful application of SCX-RP in peptidomic studies of Drosophila melanogaster 104 
and Caenorhabditis elegans 107 led to the enhanced detection oflow-abundance peptides. 
However, because many endogenous peptides are doubly or triply charged, the majority 
of them elute on the SCX column within fcw and relatively narrow time windows. los 
Other 2D LC schemes, including size exclusion chromatography-RP 1119-111, 
ffi ' h h RP 64 II? RP RP 25 I\l 114 d h dr h'l" . a Imty c romatograp y- . -, - ...., an y op I IC mteractlOn 
chromatography (HILlC)-RP 103. 115.116, have been examined for endogenous peptide 
analysis. Gilar et al. 117 presented a review on the orthogonality of these different 
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combinations. RP usually serves as the second dimension because its high resolving 
power and desalting capability are compatible with an ESI MS interface. For example, 
Dowell et al. 25 reported utilizing 2D RP-RP LC (different pH conditions in the first and 
second dimensions) to successfully increase the neuropeptidome coverage of rat brain. In 
another study, 2D HILlC-RP LC was employed to study rat hypothalamus and 
rhinencephalon samples, and approximately three times more peaks were deteeted as 
compared to the traditional2D SCX-RP LC system. 1 16 This improvement resulted from 
the enhanced fractionation capability and the increased orthogonality of the HILlC 
combination. Affinity cln·omatography is useful for the selection of subsets of peptides; 
an anhydrotrypsin colunm was used to purify neuropeptides with a C-terminal basic 
amino acid extension. 64 However, because neuropeptidomics aims to identify as complete 
a set as possible of the naturally occurring peptides present in a cell, organ or organism, 
this technique is less used for peptidomics53 An online three-dimensional micro capillary 
LC system, RPI-SCX-RP2, was also developed, which further improved the peak 
capacity and resolution for peptide separation. ug This approach has been successfully 
applied to proteomic studies, and has great potential for neuropeptidomics as well. 
As an alternative to capillary LC, CE has also been coupled to MS detection for 
peptide studies, using both online or offline arrangements. CE requires low analyte 
amounts, making it optimal for analyzing peptides, especially those from small cells. It 
also provides some additional advantages, ineluding high efficiency, fast analysis time, 
low reagent consumption, and great versatility. 119 To date, three main CE separation 
modes -- capillary zone electrophoresis (CZE) 120, capillary electrochromatography 
(CEC) 121, capillary isoelectric focusing (ClEF) 122 -- have been coupled with a variety of 
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mass spectrometric approaches to study peptides. 119 Of these, CZE is frequently used; in 
this mode, peptides are separated based on their electrophoretic migration rate, which 
depends on both their charge and size. 123 CEC, a hybrid of HPLC and CE, separates 
peptides via HPLC mechanisms, using elcctroosmotic flow as the driving force. 119 In 
ClEF, peptides are separated based on their pI values in a pH gradient formed by carrier 
ampholytes Lmder an electric voltage119 The various properties ofthe peptides being 
analyzed, such as charge, size, conformation, hydrophobicity, solubility, and chemical 
stability, all factor in to selecting the appropriate CE separation mode. 124 
2.7 Peptide Characterization via Mass Spectrometry 
As indicated in the detailed discussion on sample preparation, there are numerous 
sample fractionation techniques. Likewise, there are a number of mass analyzers 
available, each with considerably different figures of merit. Thus, there is no one ideal 
instrumentation platform for peptide investigation. In what follows, several of the more 
common approaches for peptide characterization and measurement are described and 
categorized based on their applicability for qualitative or quantitative measurements. 
Also included is a discussion of those approaches that either characterize tissues directly, 
or provide spatial and temporal information. 
2.7.1 Qualitative Analyses 
As noted, it is often necessary to reduce the complexity of biological samples 
using one or multiple stages of separation prior to MS analysis. In neuropeptidomie 
studies, the separation method is frequently coupled either online or offline with MS. A 
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successful combination of soft ionization with improved mass analyzers allows the 
detection and identification of pep tides in the attomole range. The MS technologies 
typically used in neuropeptide discovery are briefly discussed below. 
2.7.1.1 Direct Analysis 
MALDI MS is cOimnonly used for direct analysis of the peptidome of a cell 
organelle, a single cell, a specific tissue, or an organ. A sample is placed on a MALDI 
target, mixed with the appropriate organic matrix and ionized in a mass spectrometer, 
generating mass profiles. MALDI is highly sensitive and relatively tolerant to salts and 
detergents. Soft MALDI ionization generates singly-charged ions, facilitating thc analysis 
of complex samples. In many commercial systems, the laser is focused to > I 0 /lm, 
providing an effective tool for profiling cellular samples, and it can work with samples 
such as I - 2 /lm-diameter dense core vesicles 20, 8-/lm mammalian cells 23.50, singlc-cell-
sized tissue samples 52, and cellular nuclei. 51 Although sample contaminants can affect 
the sensitivity, mass accuracy, resolution, and data reproducibility, MALDI allows the 
detection of known and unknown peptides without preselection or tagging. The 
quadrupole ion trap (QIT), TOF and Fourier transform ion cyclotron resonance (FTICR) 
mass analyzers are widely used for peptide identification, with different merits of mass 
accuracy, resolution and fragmentation capabilities. A straightforward setup is MALDl-
TOF MS, which has been used successfully for direct tissue profiling.48 , 50. 52, 54 
Fragmentation tecirniques such as collision-induced dissociation (CID) and post-source 
decay (PSD) arc required for peptide fingerprinting. Both PSD and CLD approaches were 
used for peptide fragmentation when profiling single molluskan neurons.22. 125 CID 
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fragmentation with an in-cell accumulation technique was used for the identification of 
• 126 127 
crustacean neuropeptldes. . 
2.7.1.2 Hyphenated Analysis 
Hyphenated techniques that combine separations and MS are used in analyzing 
complex biological tissue extracts. A key step is sample ionization; ESI is a soft 
ionization mechanism that rcquircs thc analytc to bc in a solvcnt. The samplc is dissolvcd 
in the selected solvent (volatile acids, bases, or buffers) and injected into the mass 
spectrometer through a small high voltage capillary. A noble gas or nitrogen is used for 
the production of solvcnt droplets. As the solvent evaporates, ions that arc usually 
multiply-charged in EST MS are created by protonation or deprotonation. EST, which can 
be combined with separation methods such as LC or CE, is compatible with multiple 
mass analyzers, including QIT, FTlCR or TOF. ESI MS provides high reproducibility 
due to the fact that no crystallization process is involved, but it is not often used for 
molecular imaging. 
2.7.1.3 Liquid Chromatography-Mass Spectrometry 
Various sampling methods, such as microdialysis, SPE or solvent extraction, and 
separations, arc widely used in combination with ESI or MALDl. Setups that combine a 
separation method (e.g., LC) with a detection method (e.g., MS) have enabled high-
throughput analyses of pep tides as well as other molecules in biological samples. Having 
described multiple separation methods in Section 6.3, the coupling of LC with different 
mass spectrometers will be highlighted here. 
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As previously mentioned, smaller flow rates improve sensitivity; micro-/nano-
HPLC and MS systems are frequently interfaced by micro-/nano-EST. 53, 78,93 An online-
couplcd LC-ESI MS setup can analyze thc eluting peptidcs directly. MALDI is a 
complementary ionization technique to ESI and offline-coupled LC-MALDl-TOF MS 
provides an alternative approach.23. 27 The LC eluent is spotted on a MALDI target plate 
and mixed with the appropriate matrix for detection via MS. Nano-HPLC (50-~lm i.d.) 
was coupled offline with MALDl-TOF ITOF MS and employed for the identification and 
quantification ofneuropeptides in microwave-fixed rat brain tissue 27, resulting in the 
detection of multiple compounds (-1 pM) and identification often peptides, including 
three novel peptides. Furthernl0re, quantification of substance P revealed 6.8-fold higher 
levels than previously reported in the rat striatum.27 Andren et al. 73 used in vivo 
microdialysis followed by high sensitivity nano-flow capillary liquid chromatographyl 
microelectrospray MS to quantify and compare extracellular peptides from normal and 
KCI-stimulated discrete regions of the brain. Endogenous Met-enkephalin l2R and 
neurotensin 73 were measured in lO-~lL microdialysate fractions with an ESI-quadropole 
(Q) mass spectrometer. In a study by Haskins et al. 96, an in vivo microdialysis system, 
consisting of fused-silica nano-capillary LC columns (25-~m i.d.) and integrated 
electrospray emitters (3-~m i.d.) interfaced to a QIT mass spectrometer, was cvaluated 
for high-sensitivity LC-MS/MS to monitor endogenous peptides at amollevels. 
Specifically, the analysis of endogenous Met-enkephalin and Leu-enkephalin was 
achieved using nano-HPLC (25-~lm i.d. eolwllil)-ESI-MS/MS in dialysates collected 
from the globus pallid us of rat brain; 1.8 ~L of sample was injected and the detection was 
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achieved at sub-pM (-2 pM). Using these techniques, multiple known and 11 new 
putative bioactive neuropeptides were identified.96 
A number of other innovative LCMS interface designs have been reported. A 
micro-HPLC (25-f.lm i.d. column)-ESI-Q-TOf MS system, in combination with MALDl-
TOF MS analysis, was used to identify a novel neuropeptide in honey bee brain. 129 
Neuropeptide fF -related peptides (NPFF) in rat and mouse spinal cord 130 were identified 
with a micro-HPLC (300-~lm i.d. column)-ESI MS system. In human, two NPFF peptides 
were identified in cerebrospinal fluid and characterized by nano-HPLC (75-f.lm i.d. 
column)-ESI-ion trap (IT) MS.l3l Dowell et al. 25 developed a hyphenated method to 
analyze neuronal compounds in rat brain. Using a novel dissection protocol and an 
enhanced extraction approach, coupled with 2D RP-RP LC-ESI-QTOf MS/MS or 
MALDl-FTICR MS, they identified 56 peptides from known prohormones and 
characterized 17 new peptides. The high resolution and accuracy of the MALDI-fTICR 
MS and 2D LC-ESI-MS/MS approaches enabled improved coverage of the rat brain 
peptidome. Employing a similar method, Altelaar et al. 63 analyzed extracted peptide 
mixtures with high-resolution nanoLC-MS/MS using cm on an LTQ-OrbitrapTM, and 
nanoLC electron transfer dissociation on a linear ion trap. This study characterized 147 
peptides from mouse pituitary tissue with 48 uniquely identified in urea extract, and 11 
novel peptides in acetic acid. These results demonstrate that coupling HPLC with MS 
provides a versatile and powerful toolset for the detection, identification, and quantitation 
f . d . b .. sg 73 74 o neuropeptl es m ram tissues.' . .. 
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2.7.1.4 Capillary Electrophoresis-Mass Spectrometry 
To take advantage ofCE-MS for peptidomic analyses, the limited sample loading 
volume of CE, caused by the small imler diameter of CE separation capillaries, must be 
addressed or the inherent sensitivity of MS is compromised. This is more of an issue 
when using a nanospray sheath flow interface because analytes are diluted by the sheath 
liquid (details about interfaces will be discussed later in this chapter). Sample 
preeonccntration has proven useful in addressing these challenges, and several techniques 
have been developed and applied.132.136 One interesting solution uses a microcartridge 
containing an SPE sorbent or a membrane impregnated with different chromatographic 
stationary phases at thc inlet end of the separation capillary. 137, 138 In another cxample, a 
monolithic column modified by Cu(IT) iminodiacetie acid functional groups was 
developed to preconcentrate low-abundance peptides from complex biological 
samples. 139 
In addition to the chromatographic methods, electrophoretic approaches have 
been employed to preconcentrate samples. For instance, Yang et al. 135 optimized many 
aspects of the field-amplified sample injection procedure, including the type and 
concentration of the acid and organic solvent in the sample solution, the length of the 
water plug, and the sample injection time; as a result, the detection sensitivity could be 
enhanced more than 3000-fold. This technique was successfully used in the analysis of 
low concentration (i.e., picomolar range) bioactive peptide mixtures. Another strategy is 
to introduce a dynamic pHjLmction within the capillary, which narrows the sample 
zone. 140 This method has led to an -lOOO-fold sensitivity improvemcnt whcn analyzing 
peptides. 141 To minimize the sample loss in CE-MS that results from the absorption of 
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peptides onto the inner wall, a number of covalent and physically adsorbed capillary 
coatings have been employed. 134. 142-144 
Unfortunately, the online hyphenation ofESI MS with CE is not as 
straightforward as with LC, for two main reasons. first, the CE effluent is typically in the 
nL/min flow rate range, whieh is too low to establish a stable spray. Second, the 
compounds uscd in thc background elcctrolyte are typically non-volatile, making it 
incompatible with the spray fonnation. To address these issues, several interface schemes 
have been developed and modified, categorized as sheath flow 145, sheath less 146, and 
liquid junction 147 designs. The sheath flow design nOlmally consists of two coaxial 
tubes (one for the nebulization gas, and one for the sheath liquid) interfaced with the 
separation capillary, and is common in peptide analyses. 148 The sheath flow rate is higher 
than the CE flow rate, which allows the usc of high salt concentrations in CE scparation. 
As mentioned previously, this interface suffers from low sensitivity due to the dilution of 
analytes. This issue is avoided with the sheathless interface, where no additional flow is 
uscd to closc the electrical contact. One sheathlcss design is to coat the fine tip of the 
capillary with a conductive metal, usually gold or silver, or with a polymer or graphite 
149, in order to preserve the CE and EST circuits; however, the coated tips have a short life 
span, and the manufacturing tcchniques are not yet well-established. 119• 124 Another 
design is to insert a conductive wire, such as a platina electrode 150, directly into the 
capillary. More recently, a novel sheathless interface was developed and applied to 
peptidc studics by Chen ct al.l5l In this devicc, a Nafion tubing junction was used to 
integrate an open tubular CE capillary and an electro spray. lSI In a liquid junction 
interface, an additional electrolyte reservoir is used to provide the electrical connection. 
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The spray is formed through an emitter capillary placed 10 - 20 fun away, next to the 
outlet of the separatiou capillary. As an example, Fanali et at. 152 developed a pressurized 
liquid junetionnanofiow interface, in which the capillary and the emitter were placed in 
the electrode vessel, and a stable spray was generated in the emitter tip by the hydrostatic 
pressure of the spray liquid. A variety of mass analyzers have been online-coupled to a 
CE setup to analyze peptides, such as single quadrupole, triple quadrupole, IT, TOF, Q-
TOF, and FTICR. 
Matrix-based MS has also been interfaced to CE for peptide analysis. Along with 
the many advantages of MALDI, such as generating mostly singly charged ions, matrixes 
with high acid concentrations afford higher tolerance to a greatcr range of CE buffers. 124 
The online coupling ofMALDI MS to CE usually requires reconstruction of the inlet of 
the mass spectrometer, although the sample handling changes can be minimized. 153 The 
offline interface of MALDI and CE is more popular, and various strategics have been 
developed. The MALDI matrix can be added in the prepositioned droplets 154, through 
the CE running buffer 155.156, or crystallized onto the sample spots prior to 
fractionation. 1s7 In order to enhance sample collection and concentration, Zhang et at. 74 
used a MALDI matrix-precoated membrane target for the continuous deposition of 
effluent using solid-phase preconcentration. This approach is applied to analyses of 
rapidly degraded and complex mixtures of peptides found in high salt concentration 
solutions. The online solid-phase CE transfer allows maximum sample recovery while the 
offline MS analysis pennits each analytical technique to be optimized independently74 
The in vivo metabolism of ncuropeptides in anesthetized rat was investigated with this 
method. 74. 158 Recently, a silicone-coated prestructured MALDI target plate was designed 
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specifically for CE fraction collection and enhanced sensitivity was achieved in the CE-
MALDI-TOF MS analysis of hydrophobic peptides. 153 Despite these advances, CE-MS 
has yct to bc commonly used in neuropeptidomie studies; many reported applications 
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2.7.1.5 Mass Spectrometry Imaging 
Mass spectrometric methods offer unprecedented information on the constituents 
in a sample. In MSI, a tissue is sequentially probed so that an image can be constructed. 
Due to the high sensitivity and selectivity of MSI, it providcs unique capabilities when 
determining the localization of known and unknown analytes in a tissue slice. MALDI-
based MSI is commonly used to study proteins and peptides in the nervous system. 
Generally, the sample is coated with a homogenous thin matrix layer, a series of mass 
spectra from an array of locations across the sample are collected, and finally, ion images 
of different peptides are generated. For any mass of interest, the intensity of the selected 
mass-to-charge ratio (mlz) is plotted from each spatially resolved spectrum to create a 2D 
distribution map. MALDI MSI was applied in the direct spatial analysis of amyloid beta 
peptide in mouse brain sections, achieving 50-f1m spatial resolution with attomole 
sensitivity.159 Using MALDI MS, Rubakhin et al. 4g visualized thc distribution of 
multiple neuropeptides within the processes of single isolated and cultured neurons. 
However, one has to be careful when interpreting peptide distributions because 
MS intensities do not necessarily reflect the amounts of analytes. Some intensity 
distortions may occur due to the inherent heterogeneous nature of the tissue and/or the 
ion suppression effect. 160 Unlike extracted peptide samples used for separations, the 
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chemical environment of the peptides in the tissue section will impact peptide extraction 
and MALDI crystallization occurring on the tissue, and hence MALDI performance. An 
illustration of this can be seen in spinal tissues; grey matter and white matter have 
different hydrophobicities, and so different peptide extraction cfficicncies will result. 
Thus, the differences in the amount of peptides observed in the MSI of these two areas 
will be due to differences in peptide abLmdance as well as these other factors 
In addition to the advances discussed in the sample prcparation section, a great 
deal of effort has been devoted to the development of instrumentation to improve the 
spatial resolution and acquisition speed ofMS!. Notably, cellular length scales have been 
attained using stigmatic imaging 161.162 and spatial resolution bctter than the laser beam 
diameter has been achieved via oversampling the raster pattern. 163 MS/MS has been used 
with MSI to enable de novo sequencing of novel peptides. For example, DeKeyser et al. 
164 perfonned an organ-level MSI study of crustacean neuronal tissucs with MALDl-
TOF/TOF MS, followed by MS/MS to identify and confirm novel neuropeptides. This 
study illustrated not only the spatial relationships between multiple neuropeptide 
isofonns of the same family, but also the distributions of different neuropeptide families. 
Similarly, neuropeptide imaging of insect neurosecretory tissues was carried out on an 
L TQTM ion trap mass spectrometer equipped with an intelmediate pressure MALDI 
source (vMALDFM) 165; imaging the distribution of diagnostic fragmcnt ions across a 
sample helped distinguish different compounds with the same nominal molecular mass. 
The imaging approach mentioned previously, SIMS, was developed earlier than 
MALDI. However, its application has traditionally been limited to atoms and smallcr 
molecular ions because of its more energetic ionization mechanism. SIMS uses primary 
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ion impacts to desorb and ionize analytes from a sample, and thus large molecules are not 
ionized intact. However, the development of "softer" primary ion sources, along with 
advances in sample preparation, have significantly increased the mass range and 
sensitivity of SIMS and expanded its application to neuropeptidc imaging. Cluster ion 
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in tissues and even isolated cells possible. Other research efforts have focused on the 
optimization of primary ion flux and the ion beam size84 To date, however, SIMS is not 
used as much as MALDI MS in the field ofneuropeptide imaging. 
Nonetheless, both SIMS and MALDI MS accomplish the same ultimate goal of 
attaining spatially resolved, high-sensitivity imaging of peptides. They do however, start 
with different performance specifications. SIMS achieves a higher spatial resolution over 
a lower mass range «1000 Da), while MALDI MS covers a higher and much broader 
mass range (-500 Da to >25 kDa), but with a lower spatial rcsolution87, 160 Recently, the 
spatial distribution of multiple neuropeptides in rat spinal cord sections was analyzed 
using both SIMS and MALDI MS.169 More infonnation about MSI can be found in 
Chapter 5, Part 1. 
2.7.2 Relative Quantitative Analyses 
MS is not often used for absolute quantitation without using standards for each 
peptide of interest. This is due to the non-linear relationship between each peptide and it 
peak height and the dependence of the peak height on other sample eonstituents91 
Internal standards that contain heavy stable isotopes (e.g., 2H, 13C, 15N, or 180 ) have been 
d " fh b I . f . I 'd 14170171 use lor accurate measurement 0 tea so ute quantity 0 a parhcu ar peptl e.' . 
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However, it is impractical to usc this approach for every peptide present in a biological 
sample. Nevertheless, MS is widely used for relative quantitation. 
Although absolute quantitative analysis may be desirable, the ease of obtaining 
relative changes makes this an important aspect of many neuropeptidomic studies. 
Oftentimes, relative changes in peptide amounts between two different samples (e.g., 
knockout versus wild type) are reported; the incorporation of isotopic labels into peptides 
allows a global-scale measurement of such peptidc level variations. In general, an 
isotopic label can be introduced into peptides either metabolically or chemically. One 
method is to feed a cell culture system or an organism a diet that contains isotope-labeled 
amino acids, so that the isotopes will be incorporated into the peptides during 
b· h' 172-174 F' Ch I 172 d I b I' d' Ill' IOsynt eSls. or mstance, e et a . reporte a e mg neuroen oenne ee mes 
with L-leueine containing 10 deuterium residues (Dlo-Leu), and determined the peptide 
biosynthesis rate successfully. The drawback of this approach is that it can only be used 
to study living cells in vitro. The discussion below focuses on analyses of peptides 
labeled with isotopic reagents after they are extracted from tissue samples. 175 
Subsequent to labeling with light or heavy tags, samples arc mixed and subjected 
to LC-MS analysis. A variety of mass spectrometric approaches have been used for 
peptide quantitation, such as ESI-IT, ESI-Q-TOF, and MALDI-TOF. The relative 
amounts of a peptide present can be revealed from the ratio of the peak intensity or the 
peak area of the two isotopic forms in the MS spectrum (Figure 6). Recently, DeKeyser 
et al. 176 developed a novel quantitation method using an Fourier transfOlm mass 
spectrometer cquipped with a MALDI ion source. With this unique configuration, analyte 
ions in two differentially-labeled and separately-spotted samples were combined in the 
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ion cyclotron resonance cell prior to detection. Only a single mass spectrum containing 
isotopically paired peaks was generated for quantitative comparison of relative ion 
abundanccs. Quantitation via this in-ccll combination mcthod has shown potential for 
quantitative comparisons of neuropeptides directly from neurons or tissues. 
There are several factors to consider when choosing a stable isotopic reagent.26 
First, the reagent should react with a functional group eonunon to peptides. For example, 
an isotope-coded affinity tag 177, which reacts with the sulfhydryl group of cysteines, is 
widely used in quantitative proteomics 17R. 179; however, it has limited use in peptidomics 
because few peptides contain cysteines26 (More details about quantitative proteomics arc 
described in Chapter 4, Part 1.) Amine and carboxyl groups are found on most peptides. 
HJiD3-methanol has been used to label free carboxyl groups (i.e., aspartic and glutamic 
acid side chains, and C-terminal carboxyl group) 175, while H2/D2-formaldehyde has been 
employed to target primary amines (i.e., lysine side chain and N-terminal amine 
group). I 80 However, because some common neuropeptide PTMs (e.g., C-terminal 
amidation, N-tenninal pyroglutamic acid formation and N-telminal acetylation) cause 
issues when such schemes are employed, many common neuropeptides are not 
detectable. A second criteria is that the reagent should be reactive enough to achieve 
complete peptide labeling and thus, provide reproducible results. It is possible that the 
light and heavy forms of labeling reagents may react differently with the peptides under 
investigation; to avoid errors resulting from such differences, a reversed labeling is 
II I d . II 1'4 )S) )S' Th' d' d . h 'd h usua y emp oye m para e. -. , - lr, once mcorporate mto t e peptl es, t e 
isotopic tags should be stable during the analysis, including during the ionization 
processes required for MS. Fourth, both the light and heavy forms of the labeled peptides 
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should co-clute from the LC system so that they can be analyzed by MS simultaneously; 
otherwise, the ratio of the light and heavy forms may not be accurate for relative 
quantitation.lg3.1H5 For bonds that interact with the stationary phase, peptides labeled with 
hydrogen and deuterium will clute at slightly different times93 • 186 finally, the isotopic 
tag should not interfere with MS detection, and the mlz peaks of the two isotopic forms 
should be well separated in the MS spectnrm, with the required separation depending on 
the mass analyzer and sample complexity. for instancc, H6iD6-acetic anhydride (HdD6-
I . .. f h ·d I I f d·f" . . m 186 re alive quanlitatlOn 0 t e neuropepli e eve SOl lerent mouse pitUitary extracts. . 
More peptides were resolved in thc MS spectrum aftcr succinylation than after 
acetylation, and this resulted from the larger mlz resolution between the two isotopic 
forms for SUC20 labeled peptides than for AC20 labeled peptides (4 Da versus 3 Da). As a 
practical matter, the rcagent should be either easy to synthesize or commercially 
available. 
A wide range of isotopic labeling approaches have been rep0l1ed for quantitative 
neuropeptidomic applications. Both lc4iD4-SUC20 and H(/D6-Ac20 arc commercially 
available amine-based labeling reagents; compared to AC20 labeled peptides, SUC20 
labeled peptides have better MS spectrum resolution and improved co-elution from RP 
HPLC. However, both approaches suffer from the negative charge imposcd by thc 
labeling reagents, which reduces the MS signal intensity of many peptides when analyzed 
in the positive ion mode. 1H1 If a peptide does not contain any histidine or arginine 
residues, it will be poorly dctected in positive ion MS mode due to reduced positive 
charge. Zhang et al. 184 used trimethylammonium butyrate (TMAB) to address some 
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drawbacks of other amine-based labeling reagents. Although TMAB is not commercially 
available, it is relatively easy to synthesize from inexpensive reagents (i.e., gamma-amino 
butyric acid and methyl iodide).IH4 TMAB was successfully used in the quantitative 
studies of endogenous mouse pituitary peptidcs. 181 Besides the cxcellent rcsolution in MS 
due to the 9 Da difference between the light and heavy forms, TMAB contains a 
pennanent positive charge, so that the positive charge of the peptides is preserved during 
MS analysis. Moreover, thc positive quaternary amine group significantly reduccs the 
hydrogen/deuterium bonding between the hydrogen or deuterium atoms and the reverse 
phase resin; as a result, TMAB-Iabeled peptides have better co-elution from RP columns. 
However, a reported shortcoming ofTMAB labeling is the loss ofthe trimethylamine 
group in MALDI-TOF MS and EST-IT MS, but not in EST-QTOF MS.26.181 This 
drawback has also been observed with some other isotopic labels, such as 
trimethylammonium acetyl, trimethylammonium propyl and methylnicotinic acid26 It has 
been suggested that the use of multiple labeling reagents will lead to better peptidome 
. h b· I . I I 26 jgj coverage m t e 10 oglca samp e. . 
Differential peptidomics reveals the putative function of endogenous peptides in a 
specific physiological state. The emergence of new stable isotopic labeling reagents that 
have multiple labels in one set makes differential peptidomies more promising since 
multiple samples can be analyzed and compared in a single peptidomics experiment. For 
instance, Morano and co-workers 187 synthesized four different forms ofTMAB labels 
(i.e., H9/ HoD)/ H3D(/D9-TMAB), which allow multivariate analysis in a single LC-MS 
experiment. I 88 The iTRAQ MS strategy is another promising method for quantitative 
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peptidomics studies. It can have up to eight differently labeled samples in one analysis 
189; however, this technique has yet to be applied in neuropeptidomics. 
2.8 Data Analysis with Bioinformatics 
The plethora of MS-based techniques described herein demonstrate their 
capability to provide valuable information about peptide function. A typical peptidomics 
experiment generates large amounts of data for analysis. Bioinformatics plays a critical 
role in extracting and decoding the relevant data and translating it into neuropeptide 
identitics. Depcnding on thc experimcntalmethodology, instrumcnt capability, and thc 
species of interest, a number of different bioinformatics tools can be used for 
neuropeptide identification. 
To many proteomics practitioners, a pcptidomics expcriment may simply appear 
to be a proteomics experiment after the peptides have been digested by the cells; 
however, the prohormone processing is actually quite different from exogenous enzymes. 
As mcntioned previously, the processing of ncuropcptide prohonnones into biologically 
active neuropeptides requires multiple enzymatic processing steps, so that one cannot 
normally predict the final products without measuring them via MS or some other 
approach. Sevcral bioinformatics toolsets have been dcveloped to aid in prcdicting 
prohormone cleavages and hence, the resulting neuropeptides. Utilizing a variety of 
available resources, such as expert systems and logistic regression models, these tools 
"·1· d·· f 1 d d 1 db· .. h 190-196 lacl ltate prc lctlOn 0 c cavc an non-c eave aSlc SltCS m a new pro ormonc. 
Consider that in ma111111ais, only about 30% of the basic amino acid sites are cleaved; how 
do you determine which ones are or are not? Using models trained on the neuropeptide 
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cleavages characterized in a number of common neuronal animal models, well-informed 
predictions can be made about the expected neuropeptides from a novel prohormone. 
These prediction tools are accessible via the NeuroPred application suite at 
http://neuroproteomies.scs.uiuc.edu/neuropred.html. I91 The resulting mass list of 
expected neuropeptides is useful when directly profiling a cell or a tissue. Many pep tides 
from a specific prohormone can be detected at the same time with accurate mass data, 
enhancing the ability to assign peptide identities confidently without MS/MS data, similar 
to how the detection of multiple peptides from the tryptic processing of a protein 
improves the confidence of the protein identification. 197 Neuropeptidomic examination of 
a single cell with direct MALDI MS measurement is an excellent example in this 
category; at times, almost complete characterization of the peptides from a prohormone 
can be accomplished. 
When dealing with larger samples, such as extracts or larger brain regions that 
have many more prohormones present, it is critical to obtain the sequence information of 
the peptides, typically via MSIMS. Database search is the simplest and fastest way to 
identify neuropeptides. There arc a variety of database search engines currently available, 
such as SEQUEST 198, Mascot 199, and X!Tandem 200, although these programs were 
originally developed for protein identifications. When using such programs, the proteins 
in the database arc virtually digested into peptides by particular enzymes (e.g., trypsin, 
Asp-N protease, Lys-C protease). The MS/MS spectrum is then compared with these 
virtual peptides. The disadvantage associated with applying such programs to 
neuropeptide identification is that there is no virtual enzyme that has the same cleavage 
sequences nor creates the same suite ofPTMs as the endogenous suite of enzymes, such 
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as the convertases that cleave the neuropeptide prohormones. Moreover, ncuropeptides 
are relatively short and often contain PTMs, which further impairs the possibility of 
obtaining good MS/MS data for a significant identifieation201 One potential way to 
identify neuropeptides with PTMs is via sequence tag searching, which docs not rely on 
the parent masses but uses short contiguous amino acid strings to match against the 
sequences in the database. Both Mascot and MS-Seq (available at 
http://prospector.ucsf.edu) offer this function. 
To enhance the confidence ofneuropeptide assignment, database search requires 
as complete a list of neuropeptide prohOlIDones as possible. Searching against a standard 
protein database, such as the UniProt Knowledgebasc or the non-redundant protein 
sequence collection from the National Center for Biotechnology Information, will reduce 
the sensitivity of peptide identification due to the high possibility of obtaining false-
positivc hits. Currently, therc are several peptide databascs available. For example, thc 
EROP-Moscow oligopeptide database contains bioaetive peptides extracted directly from 
literature; no peptide in EROP is larger than 50 amino-acid-residues in length.202 The 
SwePep databasc is designed for the identification of endogenous peptides and small 
proteins (below 10 kDa) using MS-derived data?Ol Most peptides in SwePep are 
collected from Uniprot, and stored in three categories: i) biologically active peptides, 
such as neuropeptides and peptidc hormones, ii) potential biologically active peptides, 
and iii) uneharaeterized peptides. More recently, Liu et al. 203 constructed three databases 
that consist of currently known peptides, peptide precursors, and peptide motifs in 
Metazoa, respectively. These databases (available at http://peptidcs.statik.be) will help 
identify new members of a particular peptide family, as well as provide information on 
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the evolutionary relationship of a group of organisms that share peptide homologues. 
Moreover, incorporating SwePep peptide identification into this database suite is 
expected to have great potential in characterizing bioactive peptides.203 
Besidcs the currcntly available databases, one can build a neuropeptide precursor 
database if the genome of the studied species is sequenced. One way is to use sequences 
of known neuropeptides in other species as homologues and use BLAST to search the 
sequenced genome of that spccies204• 205 Another way is to scarch for the conserved 
patterns or motifs ofneuropeptides or their precursors in the sequenced genome.203 
Neuropeptide genes not discovered previously can be found via such bioinformatics 
methods (if present)53 Having a neuropeptide precursor databasc helps in deducing the 
correct amino acid residues of peptides, which otherwise can be problematic when it 
comes to differentiating Leu and Ile using MS detection alone. 
Neuropeptide identification via database search is only feasible for thosc species 
with complete genome (protein) databases. Ifno such database is available for the species 
of interest, de novo sequencing is often required to interpret the MS/MS data. This 
method uses linear amino acid combinations to derive the best possible peptidc sequencc 
from the MS/MS data. Several programs have been developed to perform automated de 
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among widely-used approaches. With experience, de novo sequencing can be done 
manually as well; but this is time-consuming and only practical when high quality 
fragmentation spectra are available. 
Although de novo sequencing docs not always generate full scquences from 
MS/MS data, partial sequences can often be deduced. These partial sequences (sequence 
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tags) can then be used to search against a protein database of a closely related species; 
homology searches are usually tolerant to possible sequencing errors and homologue 
mutations 53 In fact, homologues of the peptide query, rather than the exact and complete 
sequences, can be identified in this manner and results can shed light on the evolutionary 
origins and potential functions of the partially sequenced peptides. Recently, pattern-
finding programs, such as SPIDER (Software for Protein Identification from Sequence 
Tags) and MEME (Multiple EM for Motif Elicitation) 209.210, have provided improved 
partial sequence homology searches over the traditionally-used BLAST. 
2.9 Conclusions 
The rapid development of improved mass spectrometric approaches, which offer 
high mass resolution and sequencing capabilities, in parallcl with advances in separation 
systems, has significantly accelerated the pace of SP discovery. Direct MS analysis is the 
method of choice for peptide profiling of brain regions, clusters of neurons, single cells, 
and even cell organelles, while interfacing MS to various separation techniques such as 
LC and CE provide powerful modalities for detecting peptides from complex samples. 
Besides chemical identity, location and temporal information can also be obtained. Due 
to the advances in microdialysis that have hclped us monitor the dynamic mosaic of 
released peptides, we now have a greater understanding ofthe fundamental mechanisms 
underlying the complex aspects of physiology and behavior. The development of MS 
imaging, including sample preparation procedures, instrument designs and data 
acquisition methods, have provided us with unique opportunities to investigate not only 
the chemical information of brain peptides but also the relative distribution and 
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abundance of a broad range of analytes in a spatially-resolved manner, directly from 
complex environments. 
2.10 Fntnre Perspectives 
Despite the tremendous and accelerating neuropeptide discovery rate of the past 
few decades, a substantial number of signaling peptides may still be unidentified. In fact, 
given that the number of novel neuropeptides discovered has increased after every 
technological innovation producing higher sensitivity, this appears assured. Thus, further 
developments and improvements in analytical instrumentation and methodologies are 
required, including sample preparation protocols, separation techniques, MS detcction, 
and bioinformatics tools. Through a combination of improved sample handling protocols 
and new approaches, unknown neuropeptides, especially those of low abundance, will be 
characterized. New in vivo sampling approaches will allow the detection of SPs released 
in an activity-dependent manner that are more likely to function as neurotransmitters, 
neuromodulators, or hormones. To further overcome the challenge of sample complexity, 
improvements in small-volume separations arc needcd, perhaps realizcd via miniaturizing 
LC and CE using lab-on-a-chip approaches, creating novel LC packing materials such as 
monolithic colLUnns, and developing multidimensional separations. Another challenge is 
the limited scnsitivity of current detection techniques, and this may be addressed by 
improved ionization techniques. 
Presently, MS imaging techniques can localize neuropeptides with greater 
resolution and without the preselection required by immunocytochemistry and in situ 
hybridization approaches. However, improved spatial resolution and sensitivity are 
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important. Current MSI measurements only provide snapshots of the peptides present in a 
tissue at a specific physiological phase. Tfthe dynamic functional imaging of tissue slices 
can be coupled with MSI snapshots at specific time points, information regarding the 
function of specific peptides will result. 
Besides these methodological improvements, as more genome sequencing 
projects are completed, and the associated increase in transcriptomic data becomes 
available, thc discovcry ofncuropeptidcs will advance concomitantly. The availability of 
the genome sequence expedites the analysis of the neuropeptidome from any Metazoan 
for which the complete genome is available. However, as discussed in this review, the 
intcgration ofbioinformatics into ncuropeptidomics still stands as the bottleneck for 
many applications, and thus leaves room for improvements. 
Finally, although the traditional biochemical and physiological assays of 
neuropeptidcs will not bc replaccd in thc ncar future, neuropeptidomic approaches will 
lead to more profound insights into cell-cell communication in the animal kingdom. 
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2.11 Figures 
Figure 2.1 Processing of proopiomelanocortin (POMC). The top line shows the general 
organization of various peptides within POMC. Black rectangles represent the cleavage 
sites that contain basic amino acids. In most cases, groups of basic amino acids are 
cleaved to the C-terminus of the group, although there are two exceptions, as indicated by 
the arrowheads. Abbreviations: Acet., acetyl or acetylation; CP, carboxypeptidase E 
and/or D; CP0, carboxypeptidase with specificity for C-tcrminal Lcu (not CPE or CPD); 
endor., endorphin. Reproduced with pennission from John Wiley & Sons, Ltd. 32. 
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Figure 2.2 Schematic of the stretched sample preparation method for MS imaging. (A, B) 
Pressure and heat are used to form a layer of glass beads on a Paratilm M membrane 
surface. (C) A thin tissue slice is placed onto the glass bead layer. (D) The Parafilm M 
membrane is manually stretched. As a result, the tissue slice is tragmented into thousands 
of spatially isolated pieces. (E) After MALDI matrix application, individual pieces of 
tissue may then be investigated with MALDI MS. Reproduced with pennission from the 
American Chemical Society 52. 
60 
I 
I 
A 
Add 0,25% HAc 
Combine the HAe and 
the MiIlIQ fraction 
Boli 5 min. In MlillQ 
Decant 
Add 8M Urea 
Combine the urea and 
the MIiIiQ fraction t 10 kOa Filtration i 
Disulfid& bond 
reduction 
NanoLC·MS/MS 
Figure 2.3 Overview of an extraction-based sample preparation approach used to analyze 
and identify peptides from murine pituitary tissue; total ion chromatograms ofthe 
extracted endogenous peptides from murine pituitary tissue using (A) HAc extraction and 
(B) urea extraction. The identity of some of the more abundant peptides, as identified by 
using LC MS/MS, is indicated. Adapted with pennission from the American Chemical 
S · 61 oCiety '. 
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Figure 2.4 Schematic workflow of releasate collection and characterization. (A) Sample 
collection and preparation. (B) MS characterization of SeN releasates. Inset shows a 
zoomed mass range highlighting compounds not clearly observable in the expanded 
spectrum. Labeled analytes are as follows: (a) AVP, (b) proSomatostatin 89-100, (e) 
substance P, (d) PENK 219-229, (e) mclanotropin a, (f) somatostatin 14, (g) pyro-glu 
neurotensin, (h) big LEN, (i) little SAAS, (j) unknown 2028.02 mlz, (k) PEN, (1) 
unknown 2380.10 mlz, (m) unknowns 2481.26/2481.77 mlz, (n) galanin, and (0) 
thymosin ~-4. Reproduced with permission from the National Academy of Sciences 1. 
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Figure 2.5 Schematic workflow of the spatial analysis by MALDI TOF mass 
spcctromctry. A cell, tissue, or tissuc slice is mounted on a mctal platc, coatcd with an 
UV -absorbing matrix and placed in the mass spectrometer. A pulsed UV laser desorbs 
and ionizes analytes from the tissue and their mlz values are determined using a TOF 
analyzer. From a raster over the sample and measurement of the peak intensities over 
thousands of spots, mass spectrometric images are generated at specific molecular weight 
values. Reproduced with permission from Nature Publishing Group 56. 
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Figure 2.6 General strategy for peptide quantification with stable isotopes and mass 
spectrometry. Peptides are extracted trom two groups of animals, and labeled with either 
the heavy (deuterated) or light (hydrogenated) form ofa label such as TMAB. After 
labeling, the two samples are pooled, filtered, desalted, and analyzed by nano-
LCIMS/MS. For accurate quantification, it is important to repeat the above labeling 
scheme with pools of tissues from distinct animals, and to reverse the heavy and light 
labels so that the control tissue receives the heavy label and the experimental tissue the 
light label. (A) and (B) are the MS spectra of peak pairs of a peptide with two TMAB 
tags. (A) used the normal labeling scheme in which the experimental group was labeled 
with the heavy tag and the control group with the light tag, while (B) used the reverse 
labeling scheme. Quantitation of the relative levels of the peptide can be done by 
calculating the ratio of the peak height or peak area of the two groups. (C) shows the 
MS/MS spectrum of the peptide tagged with two TMAB groups. Adapted from with 
permission from Wiley Periodicals, Inc., A Wiley Company 26. 
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CHAPTERlll 
A PEPTIDOMICS FEASIBILITY STUDY OF RAT SUPRA CHIASMA TIC 
AND SUPRAOPTIC NUCLEI 
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the Jonathan Sweedler Laboratory, Dr. Larry Millet and Dr. Norman Atkins from the 
Martha Gillette Laboratory, and Dr. Andrew Forbes from the Neil Kellher Laboratory for 
their contribution to this study. Dr. Hatcher analyzed the rat suprachiasmatic nucleus 
(SCN) using mass spectrometry, and Dr. Andrew Forbes helped analyzing the sample 
extracts using an additional analytical tool, Fourier-transfoffil mass spectrometry 
(FTMS). In addition, Dr. Larry Millet isolated the rat supraoptic nucleus (SON), and 
trained me to manipulate brain samples. Dr. Norman Atkins not only provided brain 
slices tissues but also worked in close collaboration with Dr. Hatcher in the SCN 
analysis. Dr. Suresh Annangudi performed liquid chromatography (LC) separation on 
biological sample tissue extracts. My contribution was to optimization the SON sample 
preparation for mass spectrometry and mass spectrometry analysis. 
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3.2 Abstract 
The goal in this study was to optimize brain sample preparations isolated from a well-
defined hypothalamic nucleus, the SON, for a peptidomics study. At the same time, we 
showed that the same approach could be applied to analyze peptides isolated from a 
similar hypothalamic region, the SeN. Tn addition, we were interested in detecting 
peptides with a possible role in the circadian rhythm that are released within SeN-SON 
region. For this purpose we used the microwave irradiation approach, as previously 
developed, for rapid denaturation of enzymes and lower sample degradation. Using a 
combination of analytical tools such as matrix-assisted laser/desorption ionization 
(MALDl) MS and FTMS, we detected different peptides from 23 known prohormoncs. 
Although there were some overlaps regarding the detection of the peptides in the two 
brain nuclei, different peptides were detected specific to each nucleus. Among other 
peptides provasopressin fragments were specifically detected in the SON while 
angiotensin T, somatostatin-14, neurokinin B, galanin, and vasoactive-intestinal peptide 
(VIP) were detected in the SeN only. Lists of peptides were generated from both brain 
regions for comparison of the peptidome of SON and seN nuclci. 
3.3 Introduction 
In mammals, the endogenous circadian clock, the SeN, was first discovered in 
1972 using combined studies involving lesion and transplantation.3• 4 Found in the 
anterior hypothalamus, the SeN coordinates the activity of physiological, hormonal, and 
behavioral processes within an organism?' 4 The locations of intrinsic neurochemicals 
synthesized within SeN divide the nucleus into a 'shell' and a 'core,.5 The neurons 
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within the shell are A VP- and somatostatin-producing eells, while VIP- and gastrin-
releasing peptide (GRP)-produeing eells are found in the 'eore,.5 The VIP-eontaining 
SCN neurons receive inputs from the retina and they are stimulated by light. In addition, 
the electrophysiological rccordings of SCN during exogcnous application in vivo and in 
vitro of VIP affects the circadian clock with effects similar to changing light conditions.s 
Thus, the SCN has an intrinsic organization that regulates the processes of circadian 
timing. 
The behavioral sleep/wake or rest/activity cycles are the most obvious evidences 
for the SCN being the master circadian pacemaker. In addition, the hOlmone rhythms 
wcre also at the basis ofthc SCN discovcry3. 6 Thc daily variations of vasopressin (A VP) 
in the cerebral spinal fluid (CSF) are the outcome of the day/night rhythm in the firing 
rate of A VP-containing SCN neurons 7 In the supraoptic nucleus (SON), described in 
dctails in Chaptcr 4, A VP is releascd into the brain in a circadian rhythm by 
magnocellular neurons. R. 9 At the same time, studies done in rat and human show that the 
release pattern of oxytocin (OXY), one of the key peptide markers of the SON, varies 
during a 24 hour cyclc as well.3, 6,10, II The diurnal fluctuations of AVP conccntration in 
plasma effects plasma osmolality, suggesting that the circadian rhythm controls AVP 
release within the neurohypophysial system, and thus within the SON. 12 It is well 
documcntcd that togcthcr with thc retina, the SCN sends afferent inputs that control the 
hormone release of the SON; therefore, the SCN plays an important role in the generation 
of the circadian activity pattern ofmagnocellular neurons (MCNs) of the SONB • 9 
The SCN and SON arc two highly peptidcrgic hypothalamic brain regions that 
communicate directly and indirectly, and represent a great model for analyzing peptides 
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involved in the circadian rhytlnn mechanism or released under the influence of circadian 
system. There is growing evidence, in mammals, that the release of eell-eell signaling 
peptides from different brain regions receiving inputs from SCN is influenced by 
circadian rhythms. At the same time, the process of circadian timing is under the 
influence of the cell-cell signaling peptides. Many peptides in the SCN and SON have 
been studied using in-situ hybridization, and immuno-based techiniques. 13-22 
The first goal in the current work was to usc the SCN and the SON as models for 
an MS-based platform to validate that peptidomics studies can be applied to study small 
brain regions. The second goal was to detect the peptides within the SCN-SON regions 
with a possible role in circadian rhythm. Rapid microwave irradiation was used as a 
strategy for minimizing post-mortem degradation followed by acidified acetone 
extraction. Diverse peptides were identified, including their post-translational 
modifications (PTMs), from about 20 precursor prohormones, including AVP, Substance 
P, neuropeptide Y, galanin, somatostatin 14, proenkephalin A [219-229], 
proopiomelanocortin (POMC) [205-235], Little SAAS, and several unidentified peptides. 
Little SAAS was studied using a functionally MS-based method, which offers a new 
prospective on peptidergic signaling within the SCN.2 Although the current work offers 
insights regarding the peptidomics of the SCN and SON, more advanced studies are 
needed to obtain infoffilation regarding peptides and their roles within the well-defined 
circadian network. 
82 
3.4 Experimental Methods 
3.4.1 Animal Sacrifice and Peptide Extraction 
Six animals were used in this study, which were killed by guillotine during 
daytime, and the head was immediately microwaved for few seconds. The SCN/SON 
were isolated from the same horizontal brain slices (500 ~m) in two separate vials and 
immediately extracted with 300 pL of acidified acetone (40:6: I acetone: water: HCI). 
The extraction solution was subjected to liquid chromatography (LC) and analyzed by 
mass spectrometry eMS). 
3.4.2 Instrumental and Data Analysis 
The LC-MS, matrix assisted laser-desorptionlionization (MALDI) MS, and data 
analysis of MS/MS and FTMS data are described in great detail in Chapter 4. 
3.5 Results and Discussion 
In the previous study, Svensson et al. introduced microwave irradiation as a 
strategy for lowering the post mortem degradation?' For a similar purpose, Che et al. 
used a microwave oven.24 Microwaving the head of the animal immediately after 
decapitation and before the acidic extraction greatly reduced the levels of degradation 
fragments of proteins in the brain samples, hypothalamus, hippocampus and striatum. 
Using the same approach of sample preparation, both the SON and SCN were MS-based 
analyzed and compared. Table 1 includes the detection of 43 peptides from 23 known 
prohormones extracted from about 12 punches (I mm size each). There are peptides 
detected in both nuclei and others specific peptides detected in the SON but not in the 
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SCN. As mentioned above and based upon intrinsic neurochemicals, the SON is a 
relatively homogeneous nucleus while the SCN neurons are divided into a shell and 
coreS, 25 The A VP and OXY peptides represent the main markers for the SON but at the 
same time, A VP-relcasing cells arc found in the SCN as well. Table I shows that AVP is 
detected in both nuclei, which agrees with previous studies. The other key marker for the 
SCN is VIP, which is fowld in the 'core' of the nucleus. Using the same protocols, VIP 
was detected in the SCN by mass match identification. In addition, two peptides of 
somatostatin hormone were also detected in the SCN, which is consistent with the 
previous finding that somatostatin-releasing cells are fOWld in the 'shell' of SCN. On the 
other hand, in the SON, OXY was not detected using the microwave irradiation 
procedure followed by extraction. The sample preparation strategies for detection of 
OXY are discussed in detail in Chapter 6. 
Neuropcptide W-23 plays a regulatory role in the organization of neuroendocrine 
signals in the hypothalamic-anterior pituitary axis, and stimulates water drinking and 
food intake26 In this study, neuropeptide W -23 is detected only from the SON. Similarly, 
different fragments of provasopressin, progonadoliberin, chromogranin, corticotropin 
releasing hormone, somatotropin, cocaine-and amphetanime-regulated transcript protein 
(CART), and proenkephalin A are detected in the SON but not in the SCN. In contrast, 
angiotensin 1, somatostatin-14, neurokinin B, and galanin arc detected in the SCN only. 
Immuno-based studies showed that galanin is expressed in the SON as well.27-29 In the 
SCN, it is colocalized with substance P, neuropeptide Y, and VIP and in the SON, it is 
expressed together with AVp?5,27,30 In this chapter, galanin is detected only in the SCN 
(Table I) while substance P was detected in both nuclei and neuropeptide Y was not 
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detected in neither. In this experiment, it is possible that the level of undetected peptides 
within both nuclei is below their detection limits. 
Big SAAS, little SAAS, big PEN-LEN, PEN, PEN-20 and big LEN are the 
known processed peptides of proSAAS. 31 The functions of these peptides remain 
unknown. In this study, Big LEN, little SAAS, and PEN are detected in both nuclei. 
Interestingly, Hatcher et al. identified these peptides by MS from releasates of the rat 
SCN.2 Using solid phase extraction (SPE) coupled with mass spectrometry and 
electrophysiology, Hatcher et al. showed that little SAAS is released in high levels from 
SCN as a result ofretinohypothalamic tract stimulation that induces a phase delay when 
applied exogenously on the SCN? This finding may point to the functional role oflittle 
SAAS. In a similar manner, each detected peptide can be further investigated for 
functional insights within the SCN-SON peptidergic network. 
The MS/MS capability allowed for detection ofthc PTMs present in 
neuropeptides. Described in Table 1 are amidation, acetylation, and pyro-Glu formation. 
Amidation and acetylation are the most common PTMs identified in mammalian tissue 
that increase peptide stability and receptor affinity binding32 CART [28-36], neurotensin 
[150-162], chromogranin B [597-611], and progonadoliberin [24-33] contain a pyro-Glu 
PTM, which is formed by the glutaminyl cyclase converting enzyme found in the 
mammalian brain.33 In the SON, chromogranin B [597-611] and neurotensin [150-162] 
are newly characterized peptides including the N-terminus PTM, pyro-Glu. Tn situ 
hybridization studies showed the presence of the glutaminyl cyclase converting enzyme 
within SON.33 In addition, CART [28-36] and progonadoliberin [24-33] are cndogenous 
b·· 'd .. N' GI '3 33-3\ B d h fi d' h lOacl1ve peptl es contammg -termmus pyro- u. -. - ase on t ese m mgs, t e 
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pyro-Glu fonn of chromogranin [597-611] and ncurotcnsin [150-162] arc endogenous 
PTMs and not artifacts of sample preparation. 
Somatostatin [52-63], substance P, proenkephalin A[219-229], melanotropin 
alpha, big LEN, little SAAS, PEN, ncurotensin, and gcphyrin arc dctccted in both SON 
and SCN nuclei. In addition, two aeetylated forms of myelin basic protein S (MBP S) are 
present in both regions. MBP S is one of the most common abLmdant peptides in the 
brain, and it has an important function in axon myelination,36 and is rcsponsible for 
adhesion of the eytosolic surfaces of multilayered compact myelin. MBP S appears to 
have several other functions, and it can interact with actin, tubulin, Ca(2+ )-ealmodulin, 
and clathrin, and ncgatively chargcd lipids. MBP S may act as a membranc actin-binding 
protein, which might allow it to participate in transmission of extracellular signals to the 
cytoskeleton in oligodendrocytes and tight junctions in myelin. It has been shown that 
some sizc isofonns of MBP S arc transportcd into thc nucleus and thus they may also 
bind polynucleotide substrates. 36 MBP S becomes phosphorylated when it receives 
extracellular signals from myelin or cultured oligodendrocytes, suggesting that MBP is 
also involved in signaling.36 In this study, thc acctylatcd form of MBP S is ncwly 
characterized by MS in the SON. In the SCN, MBP S is released after KCI stimulation 
([M+H] 2028.02)2 Together with the commonly detected MBP S, the presence of 
acetylated MBP S, which can influcncc the affinity biding reccptor, and release upon 
stimulation, can lead to a study of function within the two nuclei or other related brain 
structmes. 
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3.6 Conclusions and Future Directions 
This study showed that a peptidomics approach applied in small regions of the 
brain is sufficient to detcet and identify peptidcs. The combination of microwave 
irradiation of brain tissue, followed by acidic extraction and MS detection, made possible 
the neuropeptidomics analysis within the SCN-SON region and lead to detection of 43 
peptides. Furthcr improvcments of the sample preparation arc described in Chapter 4, 
which lead to a better peptidome coverage and the detection of 8S neuropeptides in the 
SON. For functional insights combining methods such as electrophysiology and MS is a 
promising future dircction. 
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3.7 Tables 
Table 3.1 Summary of the pcp tides found within SeN-SON area detected by 
MS. 
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CHAPTER IV 
NEUROPEPTIDOMICS OF THE RAT SUPRAOPTIC NUCLEUS 
4.1 Notes and Acknowledgements 
This chapter is adapted from the publication entitled "Neuropeptidomics of the rat 
supraoptic nucleus" published in the Journal of Prot eo me Research. 2008 
Nov;7(11):4992-5003 and reproduccd with permission 1 Copyright 2009 American 
Chemical Society. This work was performed in collaboration with the Martha Gillette 
Laboratory and Neil Kellher Laboratory. Together with Dr. Larry Millet, Dr. Suresh 
Annangudi, and Dr. Andrew Forbes we characterized the supraoptic nucleus of rat 
hypothalamus. This study is a first peptidomies study done using brain tissues isolated 
from a hypothalamic nucleus. I want to acknowledge Dr. Larry Millet for isolating the 
supraoptic nucieus, Dr. Suresh Annangudi and Dr. Andrcw forbes for additional mass 
spectrometric analysis. Dr. Stanislav Rubakhin played a major role in manual 
manipulation of mammalian brain tissue isolating a single neuron without using 
enzymatic treatment. I thank Dr. Jennifer Mitchell and Dr. Sufang Huang from the 
Gillette Lab for tissue preparation and useful discussions. This work was funded in part 
from the W. M. Keck foundation, the National Institute of Drug Abuse under Award No. 
DAOl7940 and Award No. DAOl8310 to the UIUC Neuroproteomics Center on Cell-Cell 
Signaling. 
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4.2 Abstract 
The mammalian supraoptic nucleus (SON) is a neuroendocrine center in the brain 
regulating a variety of physiological functions. Within the SON, peptidergic 
magnocellular ncurons that projcct to the neurohypophysis (posterior pituitary) arc 
involved in controlling osmotic balance, lactation, and parturition, partly through 
secretion of signaling peptides such as oxytocin and vasopressin into the blood. An 
improved understanding of SON activity and function requires identification and 
characterization of the peptides used by the SON. Here, small-volume sample preparation 
approaches are optimized for neuropeptidomic studies of isolated SON samples ranging 
from entire nuclci down to single magnocellular neurons. Unlike most previous 
mammalian peptidome studies, tissues are not immediately heated or microwaved. SON 
samples are obtained from ex vivo brain slice preparations via tissue punch and the 
samples process cd through sequential steps of peptide extraction. Analyses of the 
samples via liquid chromatography mass spectrometry and tandem mass spectrometry 
result in the identification of 85 peptides, including 20 unique peptides from known 
prohormones. As the sample size is further reduced, the depth of peptide coverage 
decreases; however, even from individually isolated magnocellular neuroendocrine cells, 
vasopressin and several other pep tides are detected. 
4.3 Introduction 
Neuropeptides are involved in behavioral, cognitive, and homeostatic functions 
throughout the brain and body. Feeding behavior, circadian rhythms, sleep, learning, and 
memory are just a few physiological functions regulated by these biologically active 
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peptides2 ,3 Neuropeptides are synthesized as larger protein precursors and undergo a 
series of processing steps to produce bioactive neuropeptides, Processing steps include 
cleaving thc precursor at mono or dibasic sitcs, as wcll as numerous post-translational 
modifications (PTMs) such as amidation, acetylation, pyroglutamination, and disulfide 
bond formation,3-s Modifications such as acetylation can be required for resistance to 
dcgradation as well as biological activity6 
Before the advent of modern mass spectrometry (MS), neuropeptide characterization 
was performed by isolating and sequencing one peptide at a time using N-terminal 
sequencing methods such as Edman degradation. After the peptide has been 
characterized, appropriate antibodies are created and quantitative peptide measurements 
performed using radioimmunoassay. Although largely effective, one disadvantage of 
Edman degradation is that peptides containing N-telminal PTMs (acetylation, cyclic 
glutamate or glutamine) cannot be directly sequenced. furthennore, the peptide 
concentration required for sequencing is lypically higher than what is required for MS 
structmal characterization. 
Recent developments in sample separation and MS analysis have improved 
identification and characterization of peptides from biological samples ranging from 
b . 7-11· I II 14-1S Wh I' I h h ram structurcs . to smg e ce s. en ana yzmg comp ex systems suc as t e 
ma111111alian brain, MS has been restricted to relatively large morphological structures: as 
examples, an entire hypothalamus, striatum, or hippocampus.7- ll In many cases, obtaining 
adcquate amOLmts of analytc requires large sample sizcs or working with high 
concentration peptides from neuroendocrine structures such as the pituitary that have 
significant amounts ofpeptides. l9 Post-mortem degradation also becomes an issue due to 
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proteolytic enzymes present in sample tissues2 (),21 To improve sampling efficacy, 
enzyme deactivation has received recent attention, with studies using a variety of 
techniques that include using preservatives such as dihydroxybenzoie acid (DHB),13 
focused microwave irradiation before decapitation 11 . 11.22,23 or microwave irradiation 
after decapitation, 8,21 or boiling the tissue immediately after deeapitation,1O The effects 
of protein degradation on rodent tissue have been studied using MS-based approaehes.~' 
10.21 For instance, Che and colleagues8 found variations in the levels of some 
hypothalamic peptides when a 20-s delay was introduced between decapitation and 
microwaving, and Sk6ld and coworkers21 showed that detectable neuropeptidc levels 
greatly decreased when the time between animal sacrifice and microwaving was as brief 
as one minutes. Moreover, levels continued to decrease during longer delays. 
Although data demonstrating the effectiveness of microwave treatment in preventing 
peptide degradation makes inherent sense and the research is certainly of high quality, it 
is also surprising when considering the large body of literature on ex vivo brain slice 
experiments. The brain slice preparation is a well-established technique used in studies 
investigating mechanisms of circadian rhythmicity, learning, neuronal repair and synaptic 
plasticity. Typically, brain slices are kept functional for more than 24 hex ViVO.24-26 
Furthennore, it has been shown that altered neurosecretory vesiele pools and other cell 
organelles recover and stay constant for hours following brain slice preparation?6. 17 
Advantages of the method include the ability to combine functional tests of peptide 
release with peptidome measurements,n and to clearly delineate small, anatomically 
defined brain structures such as individual brain nuclei from fresh (non heat-treated or 
microwaved) samples. 
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Here, we test the ability to isolate peptides using the established physiological 
preparation of the fresh brain slice. We combine the aforementioned protocols for 
peptidomie studies of the brain with a specific focus on the supraoptic nucleus (SON). 
Although the SON has been intensively studied,29.39 this may be the first mammalian 
neuropeptidomies examination of this small, functionally and morphologically defined 
cluster of cells by means of mass spectrometry. In addition to the characteristic products 
of the SON, oxytocin and Arg-vasopressin, there arc many SON-derived peptides eo-
localized within this nucleus, presumably at lower levels. Tn-situ hybridization, 
immunohistochemical and MS studies have rep011ed several bioactive peptides in the 
SON coming from different precursors such as secretogranin 11,40 chromogranin A,41 
eoeaine- and amphetamine-regulated transcript (CART),42.43 and neuropeptide y'44 
However, we speculate that these peptides are a subset of the total peptides present in the 
SON. 
Due to its physiological importance, abundance of neuropeptides, and easy isolation, 
we identify and characterize the SON peptidome. In analyses using liquid 
chromatography (LC) clectrospray ionization (ESl) tandem MS (MS/MS) as well as LC 
matrix-assisted laser desorption/ionization (MALDI) MS/MS, we identify 85 peptides, 
the majority of which correspond to known or previously characterized peptides g -ll 
Moreover, 20 peptides have been unambiguously identified with MS/MS and appear not 
to have been reported previously. 
In addition, we examined selected sections of the SON. In mmmnals, the 
hypothalamic-neurohypophysial system contains populations of well-defined 
neurosecretory cells producing cell-to-cell signaling peptides that participate in a variety 
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of peripheral regulatory mechanisms. These cells, the magnocellular neurons (MCNs) of 
the SON, are part of the hypothalamic neuroendocrine system. They are relatively large 
for mammalian neurons (-30 [lm in diameter) and produce significant amounts of 
neuropeptides, which are released into the circulatory system. Interestingly, MCNs 
appear to release their peptides dendritically,45.46 making them an interesting target for 
cellular, and potentially even subcellular, studies on dense core vesicle targeting and 
release. 
Can we adapt single cell MS to interrogate individual MCNs? Due to its high 
sensitivity and salt tolerance, MALDI MS allows analysis, not only of the peptidomc of a 
neural tissue extract, but also ofa single-cell. 14. ,8 Investigation of an individual neuron 
using single cell MALDT MS enables identification of peptides processed from the same 
precursor, and also determination of co-localized neuropeptidcs from different 
precursors. Jimenez et al. '5 used -I OO-[lm diameter molluscan neurons to mass 
fingerprint the neuropeptides, and several have worked with smaller, -20-[lm insect 
neurons. 16. 47, 48 More recently, Rubakhin et al. 17, l~ successfully performed MALDI MS 
on individuaI8-1O-[lm diameter mammalian pituitary cells and characterized a number of 
pro-opiomelanocortin (POMC) and CART-related peptides. We profile a single MCN 
with MALDI, without introducing exogenous labels or enzymatic treatments, in order to 
characterize peptide precursors and their products found within this cell population. 
4.4 Experimental Section 
Chemicals. All reagents were obtained from Sigma-Aldrich Chemical Co. (St. Louis, 
MO, USA), unless otherwise noted. Water was prepared by a Milli-Q filtration system 
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(Millipore, Bedford, MA, USA). The peptides standards used for external calibration 
were provided by Bruker Daltonies Inc. (Billerica, MA, USA). 
4.4.1 Animal Sacrifice and Brain Slice Preparation 
The animals and sacrifice procedures used are delineated in greater detail elsewhere.49 
Briefly, six-to twelve week old Long-Evans/Blu Gill male and female rats (University of 
Illinois at Urbana-Champaign) were sacrificed by decapitation in accordance protocols 
established by the University ofIllinois Institutional Animal Care and Use Committee 
and in accordance with all state and federal regulations. The brain was quickly removed 
and the hypothalamic coronal brain slices (500 ~lm) containing the paired SON were 
prepared as previously reported.24 Slices were maintained in Earle's balanced salt 
solution pH 7.2 at 37°C supplemented with 24.6 mM glucose, 26.2 mM sodium 
bicarbonatc and 5mg/L gentamicin and saturated with 95% O2 -5% CO2 . Brain slices 
were transferred to physiological phosphate buffered saline (PBS) and the SON (1 mm3 
of brain tissue) removed from the ex vivo coronal brain slice by punching a l-mm plug or 
cutting out the nucleus on the surface of a plastic Petri dish placed on a bed of icc. 
Because the SON is situated directly adjacent to the optic tracts, these structures served 
as easily identifiable landmarks for SON collection. These samples may include small 
amounts of tissue from the nearby optic tract. After the SON punchcs wcre collected, the 
PBS was removed and the tissue processed for peptide extraction. 
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4.4.2 Multistage Peptide Extraction 
SON from both hemispheres were pooled and collected in 1.5-mL plastic vials. To 
increase the number of peptides extracted and eventually detected with MS, tissue 
extraction was perfomled in multiple stages. During the fIrst stage of peptide extraction, 
300 ilL of sterile deionized (DT) water (MilliQ), preheated to 90° C, was added to the 
SON tissue samples, capped and placed into a boiling water bath for 10 min. Next, the 
samplcs wcre centrifuged (Mini Centrifugc, model C1301, Dcnvillc, Woodbridge, NJ), 
supernatant transferred to a new vial, and the resulting pellets frozen at -80° C until the 
second stage of extraction. The second stage extraction was processed using 300 ilL of 
acidifIed acetone (40:6:1 acetone:water:HCI) for 1 hat 4° C. The sample was vortexed 
for 1 min and centrifuged at 14,000 rpm for 5 min and the supernatant collected. The 
third extraction stage used 300 ilL of 0.25% acetic acid and followed the same sample 
processing as stage two. All extracts were dried using a SpeedVac concentrator (Thermo 
ScientifIc, San Jose, CA) and reconstituted with 10 ilL of solvent A (aqueous 5% 
acetonitrile (ACN) containing 0.1 % formic acid (FA) and 0.01 % trifluoroacetic acid 
(TF A). After reconstitution, the three samples were pooled and fIltered through a 10 kDa 
molecular weight cut-off tube (Millipore) (see Appendix, Figure 1). 
4.4.3 Liquid Chromatography- Mass Spectrometry (LC-MS) 
Chromatographic separation of the extracted peptides and mass spectrometric 
analyses were performed using a capLCTM (Micromass, UK) LC system coupled to an 
HCT Ultra-PTM Discovery system ion-trap mass spectrometer (Bruker Daltonics) 
equipped with an electro spray ionization source. For LC-MALDI-time-of-flight 
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(TOf/TOF)-MS analysis, the capLC was coupled to a robotic fraction spotter 
(ProteineerFCTM, Bruker Daltonics). The samples were loaded onto a trap column 
(PepMap, C 18, 5 [lm, 100 A, Dionex, Sunnyvale, CAl using a manual injector (Valco 
Instruments Co. Inc., Houston, TX) and washed for 5 min. The trapped peptides were 
then eluted in reverse direction onto a reverse phase capillary column (LC Packings, 300-
[lm inner diameter x 15 cm, CI8 PepMaplOO, 100 A) using a solvent gradient at 2 
~lLlmin flow ratc. The solvent gradient was gcncrated using solvent A and solvent B 
(aqueous 95% ACN containing 0.1 % FA and 0.01 % Tf A). The 70-min gradient run for 
LC separation ineluded three steps: 5-80% solvent Bin 15-55 min (linear); 80% solvent 
B for 55-60 min (isocratie); 80-5% solvent B in 60-65 min (linear). 
The MS data acquisition and the subsequent MS/MS of selected analytes were 
perfOlmed in a data-dependent manner using the Esquire software (Bruker Daltonics). 
for each MS scan, three peptides were selected to be fragmented, for 300-500 ms, based 
on their charge (preferably +2) and intensity. Dynamic exclusion of previously 
fragmented precursor ions was set to 2 spectra for a period of 60 s. The MS and MSIMS 
scans were performed in the range of mlz 300-1500 and 50-2000, respectively. 
for LC-MALDI-TOf/TOf-MS analysis, chromatographic separation was performed 
using a 45-min gradient run comprising the following parameters: 5-80% solvent B in 
10-30 min (linear); 80% solvent B for 30-35 min (isoeratic); 80-5% solvent Bin 35-45 
min (linear). The chromatographic elutant was monitored using a UV detector (Waters, 
Milford, MA) and subsequently spotted onto a ground steel MALDI sample plate at the 
rate of 60 s/spot using ProteineerfC. Immediately after spotting, I [lL of a-cyano-4-
hydroxy cinnamic acid matrix was applied to each spot. 
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for LC-fourier transform (fT) MS analysis, separations were accomplished using a 
ProteoPep II CIS column from New Objective (Woburn, MA), with an inner diameter of 
75 [lm and length of 10 cm. The eln·omatographic gradient was performed using aiD 
NanoLC pump from Eksigent Technologies (Dublin, CA) operating at 300 nL/min with 
the following gradient parameters: 10% solvent B for 0-10 min (isocratie); 10-30% 
solvent B for 10-20 min (linear); 30-100% solvent B for 20-80 min (linear); 80-5% 
solvent B for 80-100 min (linear). Peptides were detected on a 7 Tesla linear trap 
quadrupole (L TQ)-FT instrument from Thermo Scientific, and a setting of 15 V was used 
for mild ion activation in the ESI source. The LTQ-FTMS method consisted of three scan 
events, all in profile mode with four microscans used per full scan. An initial, full scan 
event was performed at a high resolution (100,000) in fT mode. The second scan event 
was a data-dependent collision-activated dissociation (CAD) MS/MS scan of the most 
abundant peak in the previous full scan, again with FT mode detection (50,000 
resolution). MS/MS settings were as follows: isolation width ~ 4 mlz; minimum signal 
threshold ~ 50,000 counts; normalized collision energy (NCE) ~ 40%; duration ~ 200 ms, 
and q-factor ~ 0.5. Dynamic exclusion was used for a duration of 6 min per precursor to 
avoid redundant fragmentation datasets. The third scan was a full scan detected in the ion 
trap (low resolution). All neuropeptide identifications for this system were accomplished 
using ProSightPC software (Theffilo Scientific) as described below. The intact and CAD 
fragmentation data were used to search a database of predicted neuropeptides. 
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4.4.4 Matrix Assisted Laser Desorption/ionization Time-of-Flight Mass 
Spectrometry (MALDI TOF/TOF MS) 
Each sample spot was analyzed by a Bruker Ultraflex II TOF/TOF instrument with a 
delayed ion extraction and a frequency tripled Nd:YAG laser operating at 1064 nm and 
50 Hz (Bruker Daltonics). Mass spectra were accumulated over 2-3 individual 
acquisitions of 300 laser shots each. Intense peaks from the MS scan of samples were 
manually analyzed and selected for further analysis using thc MS/MS feature of the 
Ultraflex II instrument. Several peaks were assigned based on accurate mass matches 
without MS/MS data, normally with the confidence of these assignments enhanced by the 
detection of other rclated peptides from the samc prohormone. 
4.4.5 Single Cell Analysis 
Individual SON neurons and small groups of cclls were isolatcd in accordance with 
the detailed protocol described previously.18 Briefly, brain sections were immersed in 
solution containing 33% glycerol and 67% of modified Gey's balanced salt solution 
(mGBSS, in mM, 1.5 CaCh, 4.9 KCI, 0.2 KH2P04, II MgCh, 0.3 MgS04, 138 NaCI, 
27.7 NaHCOJ, 0.8 Na2HP04, 25 HEPES and 10 glucose, pH 7.2) and kept in this solution 
during all isolation steps. Addition of glycerol stabilizes cellular structures during tissue 
and cell manipulation as well as prevents dehydration of the specimen. Small, several-
hundred micrometers in diameter, regions of the SON were removed from the slices and 
placed on a glass slide positioned on an inverted light microscope (see Figure 3A). Under 
visual control, fine-tipped glass ncedles were used to isolate, pick up, and transfer 
individual neurons and small groups of cells onto a metal MALDI sample plate. Pipettes 
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pulled from borosilicate glass were used to deposit MALDI matrix-saturated DHB in 
water onto specimens. 
4.4.6 Data Analysis 
Tandem MS data obtained from the ESI-LC-MSIMS and MALDI-TOFiTOF systems 
were selected and exported to the Biotools software program (Bruker Daltonics) for 
further analysis. The data were converted to a Mascot (Matrix Science, London, UK) 
generic file format and searched against mouse and rat IPI databases using Peaks 
software (Bioinformatics Solutions Inc., Waterloo, CA) software. Search parameters for 
the Peaks software included unsuspected cleavage site, N-terminal pyro-glutamic acid 
and C-terminal amidation. Subsequently, the search results were confirmed by manual de 
novo analysis using the Data Analysis software (Bruker Daltonies). Complimentary 
searches were also performed with Mascot using the MSDB database and an in-house 
database of neuropeptide prohormones. Parameters for the Mascot search included 
enzymc specified as "none," and variable modifications werc considered, such as 
acetylation of N-terminal, amidation of C-tenninal, pyro-Glu of Q and pyro-Glu of E. 
The peptide mass tolerance for MSIMS data was set at 0.5 Da. The MSiMS data were 
manually verified to contain at least three consecutive amino acid fragment ions for 
eonfinning positive identification of a peptide. In addition, MALDl MS data were 
analyzed by direct comparison of measured molecular weights of the putative 
neuropeptides to the N euroPred prediction engine 
(http://neuroproteomics.scs. uiue.eduineuropred.html)5o. 51 using an in-house-generated 
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database of known rat prohormoncs. Mass matches within 150 ppm wcrc rcquired for 
positive identifications. 
4.4.7 Analysis of FTMS Data 
Data files (*.raw) were reduced to a ProSightPC Upload Format file (*.puf) using an 
in-house program (cRAWler), which groups MSIMS data from all precursors of the same 
protein into one experiment. An experiment consisted of one precursor mass and all 
fragment ion masses derived from it. Within this program, molecular weights of 
precursor and product ions were also determined using a highly modified THRASH 
algorithm52 Fragment ions for all MS/MS scans were required to have an SIN ratio of 5: 1 
or greater to be considered for database searching. Each *.puffile typically contained 
hundreds of experiments from a single LC-FTMS nm. The experiments within these files 
were then searched against two types of databases using ProSightPC53. 54 (Thermo 
Scientific) and/or neuroProsight (http://neuroprosight.scs.uiuc.edu/), a highly annotated 
mouse proteome database of intact proteins, and a database of predicted mouse 
neuropeptides generated by the NeuroPred tool described above. Two types of searches 
were performed against these databases. First, an Absolute Mass Search was done to find 
any proteins/peptides that were identified as they appeared in the database. Second, a 
Biomarker search was done to retrieve any endogenously cleaved pieces of 
proteins/peptides in the databases. Tn all cases, the mass tolerance for fragment ions was 
±5 ppm. All retrieved proteins and peptides needed to meet two requirements to be 
considered a positive identification: (l) an expect score ofless than 10-5 and, (2) no 
unexplained mass shifts between the observed and theoretical intact masses.55 
104 
Identifications that could not be assigncd unambiguously were validated using thc 
Sequence Gazer tool to account for errors in detennination of the monoisotopie mass of 
the protein. 
4.5 Results 
Peptidomics studies provide detail on the peptides present in entire brains to selected 
brain regions. This study represents a downscaling of sample sizes for mammalian 
neuropeptidomics analysis to the level of an identified nucleus, here the hypothalamic 
SON. In comparison with previous neuropeptidomies methods devised for larger brain 
regions, our analyses show a comparable number of pcptide identifications. Because the 
ability to work with select, anatomically well-defined nuclei requires precise registration 
of the samples, it is easier to work with intact brain slices than heat-treated or 
microwaved tissue, especially as the anatomical features required for identification of the 
region may be altered by such treatments. S,2] 
One question of particular interest was whether or not neuropeptides would be 
detected in such samples, given that prior work showcd a large rcduction in neuropeptide 
levels and an increase in peptide fragments from proteins shortly after decapitation.]2. 22 
Our results demonstrate that even if peptides are released and degraded immediately after 
death, the ncurosecretory vesicles and peptide levels recover. After sampling the SON by 
tissue punch from a brain slice, the sample is denatured using heat. Increasing sample 
temperature by heating with 90°C DI water reduces protease activity and serves as an 
extraction solution. We sec almost no difference bctwcen extracting peptides using DI 
water extraction and an acidified acetone extraction (Appendix, Figure 1); however, 
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fewer peaks were seen in the acetic acid extraction. Although thcre is variation in the data 
between extraction solutions, each approach produced reproducible mass spectra. 
Because some pep tides are extracted more efficiently using different conditions, our final 
mcthod involves treating the SON tissue with a sequential series of solvent extractions. 
By increasing the tissue temperature in water, followed by two-stage extraction using 
acidified acetone and acetic acid, we achieve an increased recovery of the SON 
peptidome. 
Using this optimized approach, we detect 20 peptides characterized using MS/MS 
that were not reported in prior hypothalamus peptidome studies (Table I). The quality of 
mass spectra (Appendix, Figure I) and the number of products dctected (Appendix, Table 
I) indicates that the peptides are not affected by the lack of immediate microwaving and 
the delay between slice preparation and sample extraction. 
Here we characterized and identified 85 peptides, many of which include peptides 
derived from known prohormones (see Tables I and 2). Che et al. 8 reported 41 
neuropeptides from three brain regions (hypothalamus, hippocampus and striatum) using 
a quadrupole time-of-flight mass spectrometer equipped with a capillary/nano-LC 
system. Dowell and coworkers 10 detected 56 neuropeptides from the rat hypothalamus 
and striatum using a different extraction protocol and ID LC-MS/MS, 2D LC-MS/MS 
and MALDI-FTMS. Our approach uses a smaller brain region from ex vivo brain slices 
and multistage extraction protocols along with LC-MALDI MS, LC-ESI MS and LC-ESI 
FTMS, resulting in the identification of several umeported peptides. The results are 
consistent with previous studies that characterizcd peptides in larger brain regions 
discussed above. 
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The usc of multiple MS-based platforms, LC-MALDl MS, LC-ESI MS and LC-ESI 
FTMS, enhances peptide and protein coverage as each platform excels at specific types of 
samples and analytes. Therefore, their combination facilitates detection of larger 
numbers of peptides from the SON samples. The majority of detected peptides have been 
previously observed and characterized in different parts of the mammalian brain sueh as 
the hypothalamus, striatum, pituitary, and hippocampus. 
Our data enhances prior peptidome studies on thc hypothalamus and striatum. 10 As 
previously reported pep tides from these regions, we also observe the provasopressin[24-
32] (AVP), the pyro-Glu form of CART (Figure IA),ll POMC[124-136] (melanotropin 
alpha),8,10 somatostatin[103-116] (somatostatin 14), somatostatin[89-100],8, 10 
proenkephalin A[I 00-1 04] (met-enkephalin), proenkephalin A[2 I 9-229], proenkephalin 
A[198-209],8, 10 secretogranin 1[585-594],10 proSAAS[245-260] (Big LEN), 
proSAAS[42-59] (little SAAS)8, 10 and proMCH[131-143]10 Figurc I shows the MS/MS 
fragmentation spectra of the known peptides CART[28-36] (Figure lA) and 
provasopressin[154-168] (Figure IB) identified in the SON, with Figure 2 showing 
MS/MS results from two MS platforms. In addition to products from known 
prohormones, several different protein fragments have been identified in this analysis, 
most of which cOlTespond to pieces of myelin basic protein (MBP), the second most 
abundant protein in the brain (Tablc 2).56 
Twenty novel peptides (Table I) are identified using MS/MS from various 
precursors: provasopressin, somatostatin, secretogranin I, secretogranin 3, proenkephalin 
B, cortistatin, somatotropin, proSAAS, and neurotensin. Figure IB shows an example of 
the tandem MS (MS/MS) fragmentation spectra for a novel peptide derived from 
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provasopressin. This peptide presents an unconventional cleavage site at Leu-Ala, a 
potential product of Leu-X specific protease.R The majority of sequenced peptides in the 
SON arc generated by enzymatic cleavage of mono or dibasic sites of the eon·esponding 
prohormones. However, in several cases of the newly discovered peptides, the 
prohormone cleavage occurs at uncommon processing sites: C-terminus of 
provasopressin, somatostatin, N-tenninus of secretogranin I, N-tcnninus of secretogranin 
Ill, N-tenninus signal peptide of cortistatin, N-tenninus of proenkephalin B, proSAAS 
(Table I). The possibility that these cleavages occur due to extracellular peptide 
degradation in situ cannot be ruled out. 
The peptidome of the SON is as complex as the previously reported peptidome of the 
entire hypothalamus. At what stage of sample reduction does the peptide complement 
simplify? To investigate the peptidome of even smaller samples, individual MCN were 
manually isolated-without enzymatic treatment or in vivo or in vitro labeling of the 
SON- by using coronal brain slices stabilized with glycerol (Figure 3A). Here, MALDI 
MS of a small group of MCN s provides a cleaner spectrum as comparcd with the mass 
profile of single cells, which is not surprising considering the significant increase in the 
amount of pep tides available for analysis. Using MS measurements, AVP (mlz 1083.45) 
can be unambiguously identified in a low mass range (Figure 3) and neurophysin II (mlz 
9842.29) was identified in the higher mass range (Appendix, Figure 2), corroborating 
previous reports ofneurophysin prohormones being present in MCN neurons. Different 
peaks are visible in the higher range mass spectra (supplemental data). Because the 
amount of material in an individual cell is too small for MS/MS approaches, we assign 
these peaks based on sequenced peaks from the SON study and the mass match within 
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the individual MCN.Interestingly, using such mass matching, wc idcntified a CART-
related peptide, CART[28-36] (Figure 3B). Many peaks were unidentifiable due to the 
low amount fOLmd in a single cell. Reduction of sample size to the single cell level 
rcduccs the depth of peptide coveragc but provides a morc strcamlined linkagc of 
functional, morphological and biochemical information. 
4.6 Discussion 
For the current neuropeptidome study of the SON, hypothalamic coronal brain slices 
kept in an oxygenated media are used and a complement of peptides detected. How can 
this bc reconcilcd with prior work showing that tissue denaturation immediately aftcr 
animal death is required, or large scale protein and peptide degradation is observed?8, 21 
The prior peptidome comparisons have been between tissue that is heat- or microwave-
trcatcd with various timc delays, and not with living brain slices. In fact, pcptide-
containing dense core vesicles of neurosecretory cells in brain slices lose a fraction of 
their content initially; however, the contents recover and stay constant for at least 9 hr, as 
shown by Hatton et al.26 furthcnnorc, it has bcen well established that living brain sliccs 
can be used to successfully study the suprachiasmatic nucleus (SCN), the master 
biological clock. In this case, the experiments demand the maintenance of active tissue 
for longcr than 24 h?4,49 Similarly, Chen et al.57 found that pituitary adcnylate cyclase 
activating peptide (P ACAP) remained active in SCN brain slices longer than 19 h in 
continuously perfused chambers. Based on these studies, and with the infonnation in 
prior pcptidome studics/· 1o we infcr that thc relcasablc pool of peptides is rapidly 
depleted but recovers before the SON is isolated. 
109 
Once the SON punch is made and the tissuc is removed from the chamber, 
degradation will occur; we stop this process by using a hot water treatment that also 
serves to facilitate the peptide extraction processes. After protease deactivation, we 
employ acidic extraction to complete the peptide extraction. Comparison of the number 
of characterized SON peptides with the number of identified peptides reported for larger 
b . 7-10 h ffi' f ram structures supports tee IClency 0 our strategy. 
Wc used a combination of mass spectrometric approaches (LC-MALDI, LC-ESI, and 
LC-ESI-FTMS) to increase the coverage in this proteomics investigation and 
unambiguously identify the peptides. Each approach has its advantages, excelling at 
characterizing different peptides and modifications. For example, LC-FTMS/MS is a 
great tool for unambiguously identifying peptides through high-resolution measurements 
of precursor and product ions. The major drawback to this technique is the lower 
sensitivity inherent to FT-ICR mass spcctrometry. Thus, it is a great tool for making 
peptide assignments when the ions signals are sufficient, but it is trails other techniques 
in terms of the number of peptides identified. 
The detected peptides arc the result of proccssing of known prohonnones, with these 
processing steps either being intercellular (before peptide release) or extracellular (after 
peptide release), the later possibly being the result of degradation during sample 
preparation. A number of detected peptides originate from unconventional cleavage sites, 
which may be due to extracellular enzymes. In the case of interleukin-3[54-62J, the 
removal of the C-telminal Asp residue may be due to the acidic extractiong , 10 Peptides 
originating from provasopressin precursor indicate that multiple uncon vcntional, non-
specific cleavages may occur either during the acidic extraction or through enzymatic 
110 
processing. Because it is difficult to directly relate peak heights of structurally distinct 
peptides to the amount of peptide present (at least without using calibration standards), it 
is difficult to know whethcr somc of these unusually processcd peptides arc prescnt at 
trace levels compared to the known biologically active peptides. 
Surprisingly, one peptide that we did not detect is oxytocin, even though it is in an 
ideal mass range (mlz 1006.44) for characterization. It should be noted that when the 
entire hypothalamus was extracted, oxytocin was not reported in at least one prior 
study; 10 Nevertheless, there are reports of oxytocin in the hypothalamus identified by 
mass7 as well as following N-tenninal modification9 Considering that 90% of the content 
in the SON peptides is released dendritically and not somatically or axonally, oxytocin is 
expected in the SON. Two novel peptides, cortistatin[20-33], and provasopressin[154-
168], and a previously characterized peptide, provasopressin[151-168], have Leu-X or 
Leu-Leu cleavage sites. Che et al. 8 assumed the presence of a Leu-specific-enzyme in the 
processing of corticotropin-like intermediary peptide ofPOMC prohormone, and 
HLUnmon et al.5g reported Leu-Leu cleavage sites in Aplysia cali/arnica prohormones. It 
is known that in vertebrates, the enzyme renin specifically cleaves Leu-Leu sites.59 
Another enzyme, chymotrypsin, previously characterized in the human, rat and pig, 
cleaves Leu-Ala sites.60 Based on these studies, we aSSLUne that cortistatin[20-33] and 
provasopressin[ 154-168] are cleaved by either rennin-like or chymotrypsin-like enzymes. 
We further speculate that provasopressin[15 1-168] and provasopressin[154-168] are 
processed in intracellular secretory vcsicles since they also werc observed in prior 
microwaved samples (data not shown). According to Che et al.,8 rapid microwave 
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irradiation before decapitation prevents vesicle fusion and neuropeptide release, hence 
the peptides remain in secretory vesicles and are available for extraction. 
MS/MS is capable of characterizing the PTMs present in neuropeptides, which is 
important as these PTMs often directly modify the activity or lifetime of the peptide. The 
most common PTMs in mammalian tissues are N-terminal acetylation and C-terminal 
amidation3 In 1987, Fischer and Spiess61 identified a glutaminyl cyclase converting 
enzyme in mammalian brain responsible for the fomlation ofN-tenninal pyro-Glu. 
Additionally, in situ and immunocytochemical studies showed that the SON contains a 
glutaminyl cyclase-converting enzyme required to create pyro-Glu fonns of several 
peptides61 • 62 Here, we detect pyro-Glu fonns of CART[28-36], II neurotensin 
preeursor[150-164], progonadoliberin I precursor[24-33]. We also detect amidation of 
AVP, substance p,63 POMC[103-120],8 and POMC[124-136],63 as shown in Table l. We 
also identify novel N-terrninal acetylated peptides such as proenkephalin[198-209], 
POMC[124-137], seeretogranin 2[287-297], secretogranin 5[198-210], secretogranin 
5[ 180-195], the pyro-Glu fOlIDS of secretogranin 1 [597-611], proenkephalin B[228-248], 
and neurotensin precursor[ 150-162] (Table 1). Although our processing steps reduce 
protein degradation, we did detect several pep tides from proteins that are not 
prohormones (Table 2). MBP is the second most abundant protein in the central nervous 
system and is present in the peripheral nervous system as wc11.56 MBP can have different 
PTMs such as phosphorylation of serine and threonine residues, deamidation of Asn or 
Gin, citrullination and methylation of arginine residues, and N-terrninal acetylation of 
Thr residues.64-67 MBP plays an important function in axon myelination, but other 
possible roles ofMBP are hinted, such as significant changes in mRNA levels on 
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exposure to coeaine68, 69 Three peptides derived from MBP are detected in the current 
study of the SON peptidome, one of which exhibits N-terminal acetylation of Thr 
residues (Table 2). 
Our ncuropeptidomics study of this small nucleus extends to the single ccillevcl 
using MALDI MS. Although in SON extracts we are able to identify several fragments 
derived from provasopressin, our single cell experiments detect the characteristic 
peptides processed from this homl0ne. The major drawback of single cell MS is the low 
amount of material available for analysis; some peptides are often present below the 
detection level of the employed MS approach. Because of our careful isolation approach, 
extracellular degradation products from peptides and proteins are not nonnally detected. 
Thus, our detection of CART -related peptide in a portion of the studied MCN cells is 
exciting and suggests that we are observing cell-to-cell differences in the peptide 
complement in a "homogenous" population of MCNs. 
With the ability to perform peptidome studies in well-defined, smaller anatomical 
regions from the brain slice, coupled with novel methods of characterizing stimulation-
dependent peptide release recently reported,28 the ability to link peptide complement to 
function has become possible. 
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4.7 Figures and Tables 
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Figure 4.1 MALDT-TOFITOF (MSIMS) data allows the identification of several 
peptides in the SON sample: (A) CART[28-36], A.pQEDAELQPR.A, mlz 1067.52 
(which was previously characterized in a mouse brain sample); (B) a novel peptide from 
the vasopressin prohormone: provasopressin[ 154-168] L.AGTQESVDSAKPRVY, mlz 
1606.69. Reprinted with permission from reference 1. 
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Figure 4.2 Sequencing of known peptides from somatostatin; somatostatin[89-100] 
R_SANSNP AMAPRKR, mlz 1243.56, using two tandem MS approaches: (A) MALDl-
TOF/TOF and (B) LC-ESI ion trap. Reprinted with permission from reference 1. 
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Figure 4.3 (A) Photomicrograph of a neuron isolated manually from a glycerol-treated 
brain slice. (B) Mass spectra acquired from individual MeN neurons using saturated 
DHB matrix: top trace, mass spectrum from a neuron isolated from a brain slice treated 
with glycerol; middle traces, individual neuron spectra; bottom trace, a group of SON 
cells. Reprinted with pennission from reference 1. 
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Table 4.1 Peptides from known neuropeptide precursors. Reprinted with pem1ission from 
reference 1. 
Precursor Sequence 
Arg-vasopressln[24-32] A.C'YFQNC·PRGamide.G 
Provasospressin[24-35] A.CYFQNCPRGGKRA 
Provasopressin[157-168] T.QESVDSAKPRVY 
Provasopressin[156-168] G.TQESVDSAKPRVY 
Provasopressin[155-168] A.GTQESVDSAKPRVY 
Provasopressin[158-168] Q_ESVDSAKPRVY 
Provasopressin[154-168] L,AGTQESVDSAKPRVY 
Provasopressin[151-168] L,VQLAGTQESVDSAKPRVY 
Provasopressin[160·168] S.VDSAKPRVY 
Provasopressin[36-43] R.ATSDMELR.Q 
CART[28-36] 
CART[82-86] 
TRH[178-199] 
Proenkephalin A[l 00-1 04] 
Proenkephalin A[198-209] 
A.pQEDAELQPR.A 
R.IPIYE.K 
R.FIDPELQRSWEEKEGEGVLMPE.K 
R.YGGFM.K 
R.SPQLEDEAKELQ,K 
Proenkephalin A[198-209] R(Ac)SPQLEDEAKELQ.K 
Proenkephalln A[219-229] 
Proenkephalm A[114-133] 
RVGRPEWWMDYQ.K 
K.MDEL YPVEPEEEANGGEILA.K 
Proenkephalin A[219-238] RVGRPEWWMDYQKRYGGFLKR.F 
Protachykinin 1[58-68] RRPKPQQFFGLMGamide.K 
Protachykinin 1[98-110] RHKTDSFVGLMGKRA 
VIP[111-124] R.lSSSISEDPVPVKRQ 
VIP[156-169] RSSEGDSPDFLEELE.K 
POMC[103·120] 
POMCI[124-136] 
POMC[124-137] 
Somatostatin[89·100] 
Somatostati n[91-1 00] 
Somatostatin[103·116] 
RAEEETAGGDGRPEPSPREamlde,G 
RSYSMEHFRWGKPVamlde.G 
R(Ac)SYSMEHFRWGKPVG.K 
RSANSNPAMAPRE.R 
A.NSNPAMAPRE.R 
K.AGCKNFFWKTFTSC 
Secretogranin 1[585-594] RSFAKAPHLDL K 
Secretograinin 1[597-611] RpQYDDGVAELDQLLHY.R 
Secretograinin 1[435-451] 
Secretogranin 1[49-61] 
Secretogranin 1[47-56] 
R.LLDEGHDPVHESPVDTA.K 
S.SAPTITPECRQVL.R 
S.KSSAPTITPE.C 
Secretogranin 1[21-34] S.APVDNRDHNEEMVT.R 
Secretogranin 1[383-395] RNHPDSELESTANRH 
Secretogranin 1[383-394] RNHPDSELESTAN.R 
Secretogranin 1[572-584] R.PFSEDVNWGYEKRS 
Secretogranin 2[571-583] RIPAGSLKNEDTPN.R 
RVPSPGSSEDDLQEEEQLEQAIK 
Secretogranin 2[529-568] EHLGQGSSQEMEKLAKVS.K 
Secretogranin 2[287-297] R.(Ac)SGHLGLPDEGN.R 
Secretogranin 3[23-36] A.FPKPEGSQDKSLHN.R 
Secretogranin 5[198-21 0] K.SVPHFSEEEKEPE 
Secretogranin 5[198-210] K.(Ac)SVPHFSEEEKEPE 
ESIMS 
(m/z) 
534.68 
633.34 
873.40 
693.80 
735.10 
941.97 
811.80 
622.70 
543.80 
549.73 
879.00 
915.90 
707.80 
514.25 
678.22 
792.30 
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Obs 
mass 
(Da) 
1083.49 
1427.67 
1377.59 
1478.69 
1535.69 
1249.59 
1606.69 
1947.09 
1033.56 
921.47 
1067.52 
633,34 
2617.24 
573,23 
1385.67 
1427.67 
1465.65 
2203.56 
2571.30 
1347.70 
1474.74 
1512.73 
1552.75 
1881.90 
1621.76 
1721.91 
1243.50 
1085.60 
1638.80 
1097.44 
1760.87 
1829.82 
1413.70 
1028.45 
1625.74 
1468.73 
1312.48 
1625.74 
1354.67 
4366.08 
1136.49 
1582.78 
1542.79 
1584.84 
Error 
(ppm) 
-42.5 
-7.0 
65.3 
33.8 
39.1 
320 
62,2 
·41.1 
-9.7 
-54.3 
·26.2 
4.7 
0.0 
·10.5 
·7.2 
7.0 
·6.1 
190.6 
0.0 
5.2 
20.3 
52.9 
-70.8 
·31.9 
12,3 
-63.9 
47.4 
-101.3 
-42.7 
132.1 
-45.4 
10,9 
21.2 
97.2 
-18.5 
-54.5 
53.3 
6.2 
0.0 
-2.3 
17.6 
-6.3 
-71.3 
-94.7 
LC· 
ESI-
FTMS 
x 
x 
x 
x 
x 
x 
x 
LC-
MALDI-
TOF/TOF 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
LC-ESI 
Ion 
Trap 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
LC-
MALDI-
TOF MS 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Table 4.2 Other peptides and proteins identified. Reprinted with permission from 
reference I. 
ESI Dbs Error LC· LC· LC·ESI Precursor Sequence MS mass (ppm) ESI- MALDI (m/z) (Da) FTMS TOF/TDF 
MBP 5[2-18] M.(Ac)ASQKRPSQR HGSKYLATA.S 2026.99 34.0 X 
MBP 5[2-16] M.(Ac)ASQKRPSQRHGSKYLA.S 1854.90 45.8 X 
MBP 5[2-11] M.(Ac)ASQKRPSQRHG.S 1292.59 61.9 X 
MBP 5[183-195] G.GRDSRSGSPMARR 1431.69 14.0 X 
OBI[2-14] M.(Ac)SQADFDKAAEEVK.R 1478.70 -6.8 
PEBP[9-25] W.AGPLSLQEVDEPPQHAL. R 1800.03 -72.2 
Cholecalcin[33-44) K.LLlQSEFPSLL.K 1258.74 1258.74 -15.1 X 
T-kininogen 1[378-385] S.RPPGFSPF.R 903.44 903.44 18.8 X 
M.ADKPDMGEIASFDKAKLKK 
Thymosin beta-10[2-44] TETQEKNTLPTKETIEQEKRSEIS 4932.52 -2.0 X 
M SDKPDMAEIEKFDKSKLKKTETQEKNPL 
Thymosin beta-4[2-44] PSKETIEQEKQAGES 4960.49 -2.9 X 
MQIFVKTL TGKTITLEVEPSDTIENVKAKI QD 
KEGIPPDQQRLlFAGKQLEDGRTLSDYN 
Ubiquitin[1-76] IQKESTLHLVLRLRGG 8559.62 -1.2 X 
Tubulln beta-5 chain[1-7] MREIVHI.Q 896.03 896.03 110.9 X 
Cullin 5-AVP-activated 
calcium-mobilizing 
receptor 
VACM-1 D.KVPGGIEP.M 795.45 5.0 X 
"." Indicates cleavage sites. 
"Bold" Indicates putative novel peptides. 
"x" Indicates type ofMS instrument used to identifY peptides. Tandem MS data was 
obtained in all cases except for the last column, indicating MALDI TOF data. 
118 
Ion 
Trap 
X 
X 
X 
LC· 
MALDI-
TOF MS 
X 
X 
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CHAPTER V 
DIRECT CELLULAR PEPTIDOMICS OF SUPRAOPTIC MAGNOCELLULAR AND 
HIPPOCAMPAL NEURONS IN LOW-DENSITY CO-CULTURES 
5.1 Notes and Acknowledgements 
This chapter is adapted from the manuscript of the publication entitled "Direct cellular 
peptidomics o{supraoptic magnocellular and hippocampal neurons in low-density co-culture" 
and reproduced with the pennission1• Copyright 2009 American Chemical Society. The authors 
are Dr. Larry Millet, Adriana Bora, Prof. Martha Gillette and Prof. Jonathan Sweedler. This work 
is donc in collaboration with Martha Gillette Laboratory. In this study I want to acknowledge Dr. 
Larry Millet for optimizing the primary mammalian neuronal cell cultures; I analyzed the 
coverslips cell culture with mass spectrometry. I want to thank Ann Knolhoff for the advice and 
help she gave us regarding sample preparation. Highly acknowledged are Prof. Jonathan 
Sweedler and Prof. Martha Gillette for the scientific and financial support we had for this 
project. I want to acknowledge W.M. Keck Foundation as well for providing the funding for the 
project. 
5.2 Abstract 
Genomic and proteomic studies of brain regions of specialized function provide evidence 
that communication among neurons is mediated by systems of diverse chemical messengers. 
These analyses are largely tissue- or population-based, whereas the actual commlmication is 
from cell-to-cell. To understand the complement of intercellular signals produced by individual 
neurons, new methods are required. We have developed a novel neuron-to-neuron, serum-free, 
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co-culture approach that was used to detennine the higher-level cellular peptidome of individual 
primary mammalian neurons. We isolated magnocellular neurons from the supraoptic nucleus of 
early postnatal rat and maintained them in senun-fi-ee low density cultures without glial support 
layers; under these conditions they required low-density co-cultured neurons. Co-culturing 
magnocellular neurons with hippocampal neurons permitted local access to individual neurons 
within the culture for mass spectrometry. Using direct sampling, peptide profiles were obtained 
for spatially distinct, identifiable neurons within the co-culture. We repcatcdly detected 10 pcaks 
that we assign to previously characterized peptides and 17 peaks that remain unassigned. 
Peptides from the vasopressin prohonnone and secretogranin-2 are attributed to magnocellular 
neurons, whercas neurokinin A, peptide J, and neurokinin B arc attributed to culturcd 
hippocampal neurons. This approach enables the elucidation of cell-specific pro hormone 
processing and the discovery of cell-cell signaling peptides. 
5.3 Introduction 
Cell-to-cell commLmication in the brain is achieved via a complex interplay of diffusive 
moleculcs, including peptides, neurotransmitters, ncurotrophins, and eytokines. Signaling 
molecules of the mammalian nervous system have been isolated and identified from the complex 
chemical milieu of brain tissue extracts 2-6 and neuron cultures 7 The goal of this work is to 
rcsolvc ncuron-specific profiles of signaling peptides from culturcd mammalian neurons using 
mass spectrometry (MS). 
A recent advance in peptide measurement is the ability to perfonn MS to detennine the 
peptides found in individual cells. A number of earlier studies demonstratcd thc ability to 
characterize unique neuropeptides and prohormone processing in larger invertebrate neurons 8-10. 
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Recently, single cell protocols and instrument performance have improved to the point where 
individual mammalian cells can be profiled for their pep tides 11.12. 
To expand on this prior work and to profile neuron-specific peptide cues, we selected 
ma111111alian neurons from the central nervous system that produce known peptides in abundance. 
Magnocellular neurons from the rat supraoptic nueleus are large neuroendocrine cells that form 
long axons that transp011 oxytocin and vasopressin to the pituitary where they are released into 
the blood via the portal system. The neuroendocrinc functions ofthese neuropeptides are well-
characterized and inelude regulation of parturition, lactation, and osmoregulation 13-15. 
Magnocellular neurons also are capable of region-specific, somatic, dendritic and axonal peptide 
release 16-19, although the total complemcnt and functional context ofthesc pcptides is not 
established. While these neuroendocrine cells are conventionally stndied in the intact brain and 
acute brain slice, cultures of dissociated magnoeellular neuron can be achieved 20-25, but are 
rarely used due to the lcvel of culture difficulty and low yields 23. 
To analyze the peptide complement of individual magnocellular neurons, defined cultnre 
conditions that remove serum and glial supp011layers are necessary_ We hypothesized that by 
developing low-density primary cultures and then directly applying MS to individual cells, we 
could obtain peptide profiles ofmagnocellular neurons and their networks. To this end, we 
optimized conditions for establishing magnocellular neurons in primary culture with serum-free, 
defined media conditions compatible with MS. However, through systematic investigation, we 
found that these neurons required additional cellular support. Because hippocampal neurons are 
easy to culture in defined media, we incorporated them in co-cultures to support magnocellular 
neurons for direct matrix-assistcd laser desorption / ionization time-of-flight (MALDl-TOF) MS. 
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The hippocampus, a key brain structure in memory acquisition and recall whose function 
is altered in Alzheimer's disease, schizophrenia, depression and epilepsy, is a well-defined 
anatomically. Hippocampal neuronal morphology, connectivity and cell culture protocols are 
very well established 26.28. Bccause we found that hippocampal neurons arc bcneficial for 
sustaining magnocellular neurons in serum-free cultures without glial support layers, we 
extended our MS analysis to include hippocampal neurons. By profiling the neuropeptide 
contcnt of indi vidual hippocampal neurons in co-culture using MS, we expand the peptidome 
profiles that have been produced for homogenized hippocampi 4,29. 
To identify candidate signaling compounds involved in hippocampal neuron-assisted 
magnocellular neuron dcvelopment, co-culturcs wcrc directly analyzcd for thcir pcptide content 
following the application of a one-step sample extraction method utilizing 2,5-dihydroxybenzoic 
acid (DHB) 30. This approach preserves, extracts and stabilizes signaling peptides for MS. As is 
typical with single-cell or low-cell number MS, instrument parameters arc optimized for 
sensitivity and not resolution; in addition, the low amount of material often precludes tandem 
MS. Nonetheless, we recently completed a peptidomic analysis of the supraoptic nucleus 2 and 
similar lists arc available for the hippocampus 4. Using this infonnation along with common 
prohormone processing information 31,32 and our accurate mass data, we reliably detect 27 
masses, 17 of which are cUlTently unassigned, and 10 assigned as being from provasopressin, 
protachykinins A and B, sceretogranin-2 and proopiomclanoeortin. 
Our work demonstrates that magnocellular neurons from the supraoptic nucleus of early 
postnatal rat require contact with other cells to develop long, peptide-rich processes in defined 
media and that mass-to-eharge-based neuropeptide profiles of cultured mammalian neurons 
using MALDI-TOF MS permit the classification of mammalian cells by the profiles observed. 
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5.4 Experimental Methods 
Chemicals: All reagents were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA), Lmless otherwise noted. 
5.4.1 MCN and Hippocampal Mammalian Primary Cell Cultures 
To generate cultures of magnocellular neurons and hippocampal neurons, postnatal (P 1-
P2) Long-Evans BluGili rats (University of Illinois at Urbana-Champaign) were used in 
accordance with protocols established by the University of Illinois Institutional Animal Care and 
Use Conunittee and in accordance with all state and federal regulations. Procedures for culturing 
each neuronal type are defined below. Neurons were grown on glass coverslips for microscopic 
imaging and MS. Prior to cell culture, coverslips were cleaned by inunersion in undiluted 
sulfuric acid (overnight minimum) and rinsed with copious amouuts of sterilc-filtered deionized 
water (dH20, MilliQ, Millipore, Bedford, MA). Dry coverslips were coated for at least 2 h with 
laminin (100 fig/ml) for initial magnoeellular neuron cultures at high density, and with poly-D-
lysiue (PDL,I-2 h, 100 fig/ml; MW = 30,000-70,000) for hippocampal neuron co-cultures and 
magnocellular neuron low-density cultures. 
Supraoptic nuclei were isolated by dissecting the optic tracts and immediately adjacent 
tissue using a modified brain dissection (Appendix B fig. I) from Bilinski and colleagues 20. 
Dissection, enzymatic digestion, trituration and centrifugation steps were carried out in 
Hibernate-A without phenol red (Brain Bits, Springfield, IL) and supplemented with 0.5 mM L-
glutamine (Invitrogen, Eugenc, OR), B-27 (Invitrogen), 100 U/ml penicillin and O.lmg/ml 
streptomycin. For each experiment, <:: 8 supraoptic nucleus regions were pooled and digested 
with papain (25.5 U/ml, Worthington, Lakewood, NJ) for 45 min at 37°C; the number of 
128 
supraoptic nucleus regions used were -1.0-1.5 per high-density coverslip (500 cells/mm2), or 1.0 
supraoptic nucleus for 5-6 coverslips at 100-125 cells/mm2. After papain incubation, the 
enzyme was removed and the tissue rinsed and mechanically dissociated through trituration 
using a fire-polished Pasteur pipette. After the undissociated optic tracts settled, the 
supematant was trans fen-cd to a new l5-ml vial and ccntrifuged at 1400 rpm for 5 min. 
Hibemate supematant was aspirated and the cellular pellet resuspended in culture media. 
Viable cells, identified by Trypan-blue exclusion, were counted with a hemacytometer, 
diluted in culture media, and plated at 500 cells/mm2 for high-density cultures, and 100-125 
cells/mm2 for low-density cultures. By dissecting neurons in this manner from early postnatal 
development (Pl-P2) animals, we achieved a nearly 6-fold increase of total magnocellular 
neurons in culture over a previous report by Kusano et aZ. 23. Based on their work, we used the 
media formulation ofNeurobasal-A media without phenol red (Invitrogen) supplemented with 
2% B-27 (Invitrogen), 100 U/ml penicillin, 0.1 mgiml streptomycin and 50 ng/ml recombinant 
human brain-derived neurotrophic factor (BDNF, PeproTech, Rocky Hill, NJ). Fetal bovine 
serum (Hyclone, Logan, UT) was initially at 10% and systematically reduced through separate 
experiments, then eliminated over the course of developing the scrwn-frec culture protocol. 
Finally, magnocellular neurons in serwn-free culture were plated onto cultures of differentiated 
hippocampal neurons, established previously for at least 4 d, and examined with MS. 
For co-cultures with magnocellular neurons, hippocampal neuron cultures were prepared 
with a similar tissue digestion and cell isolation process 33. Postnatal tissue was used to reduce 
glial proliferation evident with embryonic tissue 34. Briefly, the hippocampi of postnatal (PI-P2) 
Long-Evans BluGill rats were dissected, enzymatically digested (30 min), rinsed, dissociated, 
centrifuged, counted, then plated (100-125 cells/mm2) on PDL-coated coverslips. Due to our 1) 
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usc of postnatal brains as the cell source 35, 2) method of cell isolation and 3) choice of 
Neurobasal-A media with B-27, which substantially eliminates glial cells in serum-free cultures 
2g, we observed the viable cell yield to be between 30-40% of initial plating density. We 
estimated final hippocampal neuron yield to be 30-50 cells/mm2 when plated at 100-125 
cells/mm2 . For MALDI-TOF MS and microscopy, Hibernate-A and Neurobasal-A were both 
phenol red-free solutions, and both were supplemented as defined above to include 0.5 mM L-
glutamine, B-27, 100 U/ml penicillin and O.lmg!ml streptomycin. BDNF was omitted during the 
establishment of the hippocampal neurons prior to the addition of the dissociated magnocellular 
neurons; fetal bovine serum was not used in hippocampal neuron cultures or co-cultures as 
serum-free mcdia is rcquired for MS, but is not necded for magnoccllular neuron co-cultures. 
Phase contrast and differential interference contrast images of co-cultures and crystallized DHB 
on cultures were acquired using a Zeiss Axiovert 40 microscope. 
5.4.2 Immunocytochemistry 
The following protocol is based on previously reported methods from Banker and Goslin 
26 Cell cultures were immediately rinsed and incubated with 4% paraformaldehyde (37°C) for 
30 min, then with PBS (Fisher Scientific, Pittsburg, P A), followed by 0.25% Triton X-I 00 
(Biorad, Hercules, CA) application for 5-10 min to permeabilize the membrane. for 3,3'-
diaminobenzidine (DAB) immunochemistry, samples were treated with hydrogen peroxide « 
15%) in PBS to inactivate endogenous peroxidases prior to blocking (10% BSA for 30 min). 
The primary antibody was incubated for 1-2 h at room temperature, or overnight at 4°C in 2.5% 
BSA in PBS. Primary mouse monoclonal antibodies against oxytocin-neurophysin (PS-38) and 
vasopressin-neurophysin (PS-4l) were kindly supplied by Dr. Harold Gainer, NIH, Bethesda, 
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MD. A rabbit polyclonal anti-neurophysin (NP) antibody (Product number: V2045, Biomeda, 
Foster City, CAl that recognizes both forms ofNP was used in low-density cultnres and co-
cultures to identify all magnocellular neurons of the supraoptic nucleus that were present. The 
neuron-specific marker, microtubule associated protein 2 (MAP2), was immunolabeled with 
rabbit polyclonal antibodies (AB5622, Chemicon, Temecula, CAl. 
After primary antibody incubation, cultures were thoroughly rinsed with PBS, and then 
secondary antibodies were incubated for I h at room tcmperature in 2.5% BSA in PBS, followed 
by PBS washes. For MAP2 and NP immunofluorescence double labeling, the magnocellular 
neurons were first labeled with the polyclonal NP immunoreagent, then Alexa 633 secondary 
antibody, followed by the MAP2 immunoreagent, and Alexa 488 secondary antibody (Alexa 
antibodies, Molecular Probes, Eugene, OR). When rhodamine phalloidin (Invitrogen) was used 
to label F-actin, it was applied to fixed cells in PBS for 20 min followed by PBS rinsing for at 
least another 20 min. for DAB labeling, only monoclonal antibodies were used; the Vector 
ABC Biotin Kit (Burlingame, CAl was used in conjunction with biotin-conjugated secondary 
antibodies. Prior to mounting samples, coverslips were briefly rinsed with dH20 to prevent 
crystallization of salts. Thc samples were dried and mounted with Prolong Gold Antifade 
reagent (Molecular Probes) for fluorescent samples, and Permount (Fisher Scientific) for DAB-
labeled samples. Images were acquired using a laser-equipped, confocal microscope (Zeiss 
LSM-SIO Mcta NLO). 
131 
5.4.3 Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 
(MALDI-TOF MS) 
Peptide standards used for external calibration were applied to corners of the coverslips, 
regions where no cellular profiles were analyzed, but in close proximity to the cells of interest. 
Standards were obtained from Bruker Daltonies, Inc. (Billerica, MA). Standards used included 
Angiotensin II, Angiotensin I, Substance P, Bombesin, ACTH clip 1-17, Bradykinin, ACTH clip 
18-39, and Somatostatin 28 covering a mass range: -700 Da - 3200 Da. Coverslips containing 
magnocellular neuron-hippocampal neuron co-cultures were prepared for MALDI-TOF MS 
following an optimized modification of a previously published protocol of a one-step sample 
extraction method 30. In addition to this protocol, we attempted to extract peptides from neurons 
cultured on coverslips using standard protocols and using solid-phase extraction beads. We were 
unable to obtain any reliable signal with these standard methods being applied to cultured 
neurons from the postnatal rat brain. 
For the one-step extraction protocol, co-cultures were quickly and carefully rinsed three 
to four times with approximately one ml of DHB (20 mg/ml, 70% acetonitrile, 0.1 % 
trifluoroacetic acid); small crystals of various morphologies fonned over the cell surface of the 
coverslip. Samples were dried for 1-2 days under desiccation at room temperature. Crystals of 
various sizes and morphology were surveyed across the coverslip. Experimental results were 
acquired from neurons embedded in, sharp DHB crystals found on the glass (Fig 5.3C). Slender 
crystals (50-100 !lm in width) for MS measurement form on the coverslips that are barely wetted 
by the matrix, rather than in higher volumes of salts, media, and cellular debris. Due to the 
coverslip size, shape (22 mm square) and the rinsing process, the corners and coverslip periphery 
are rapidly rinsed clean. The central portion (-25-50%) is difficult to clean completely and is 
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often rendered unsuitable for reliable MS analysis due to residual media salt retention that 
accumulates in matrix crystals. To control crystal formation, each culture application should be 
optimized with the following considerations: the precise method of application (rinsing, or 
dipping) of DHB matrix solution and removal of excess matrix (wicking, or aspirating), 
coverslip size and shape, and cell density on the glass. Even though MALDI-TOF MS is salt 
tolerant, maintaining a clean, dry sample with good crystal formation is essential (Fig. 5.3C). 
Coverslips were mounted on a MALDI target for MS analysis. Samples were grounded 
using silver paint to prevent charging of the glass to achieve optimal peptide signals (Appendix 
B Fig. 2.A). The single cell resolution can be noticed in Appendix B Fig. 2.B). Each cell culture 
was analyzed by a Bruker Ultraflex 11 TOf /TOf instrument with a delayed ion extraction and a 
frequency-tripled Nd:Y AG laser operating at 1064 nm and 50 Hz (Bruker Daltonies). Mass 
spectra were accumulated over 2-3 individual acquisitions of 300 laser shots each. The 
instrument settings were optimized for reflection mode and internal calibration peptides covered 
the mass range of 700-3000 Da. 
5.4.4 Data Analysis 
To determine the neuron content of the baseline cultures, total neurons per coverslip were 
tallied by scamling the entire coverslip in a serpentine fonnation using a Plan IOx/0.3 N.A., dark 
low (DL) objective mounted on a Nikon Optiphot-2 microscope equipped with fluorescence. 
Smaller neuron identities were confirmed at higher objectives (Plan 20x/0.5 DL, and Plan 
40x/0.7 DL). To estimate soma size, the DAB-labeled magnocellular neurons were imaged 
using a Zeiss laser-scanning confocal microscope (LSM) with an Argon laser and a transmitted 
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light photomultiplicr tubc. Dctcmlination of soma sizc was pcrfomlcd by mcasuring perikaryon 
diameter at the long and short axis with Zeiss LSM software, as defined previously 36. 
Mass profile peaks were selected and exported to the FlexAnalysis 3.0 software program 
(Bruker Daltonies) for mass identification. Whilc thc amount of matcrial from thc crystals on thc 
coverslip precluded tandem MS, a number of pep tides were confirmed via tandem MS from our 
previous peptidomics analysis of the supraoptic nucleus tissue.(l) The MS results presented here 
arc assigncd by matching our observcd mass values to those of our previous study( I) and to 
databases. Using binary logistic models, the predicted mass of expected cleavage sites was 
obtained with the web-based tool NeuroPred 
(http://neuroproteomies.scs.uiuc.cdu/ncuropred.html) 32.37 For NeuroPred, thc rat model was 
used for cleavage prediction of the provasopressin hormone with a confidence interval of95%. 
All observed molecular weight masses were searched using the SwePep rat database (www. 
Swepcp.org) 38 For all mass matching, the mass toleranec used was 0.50 Da for masses lowcr 
than 2000 Da and 1 Da for masses higher than 2000 Da. For peptides forms not observed 
previously, the assignments should be considered tentatively. 
5.5 Results and Discussion 
A variety of MS-based peptidomic studies have characterized a number of known and 
novel peptides from whole brains to brain regions. Most prior MS studies have used microliters 
of tissue containing hundreds of thousands of cells. These samples include neurons, glia, immune 
cells and vasculature, and so it becomes difficult to assign peaks/peptides to specific cell types. 
When moving from the tissue to single-cell level, the signal-to-noise ratio of the peptide peaks in 
the mass spectra is reduced, but not to the extent that the cell population is reduced. This is 
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because some peptides are present at locally high concentrations in specific types of cells, such 
as the magnocellular neurons. 
While neuron-specific peptide studies using single-cell MS have been perfonned using a 
variety of preparations 9. 12, investigations profiling cultured mammalian neurons have been 
limited. One reason has been that the complexities of heterogeneous cell populations in the brain 
do not pennit precise analysis of only the neurons, but include multiple cell types. Consequently, 
some peaks have yet to be assigned to a specific cell type. Given thc importancc of neuron-to-
neuron communication for brain information processing, compared with other types of cell-to-
cell signaling, such data are of considerable interest. 
A second issue is that mammalian neurons are small with long, delicate neurites; thus 
isolation and manipulation of individual mammalian neurons directly from tissue for MS 
analysis is challenging and cellular yields are low. In acute isolation of single dissociated 
neurons from brain tissue, longer neurites often are lost. Because axons and dendrites transport, 
store, and release neuropeptides, the desired analytes may be reduced or even eliminated in acute 
neuron isolation protocols. 
Third, neurons of the mammalian central nervous systcm are sensitive to their chemical 
. d h . . I d' . " . I h 23 J7 28 39" h envIronment an t us reqUIre precIse cu lure con Itlons lor optIma growt . -. , ; olten t e 
ideal media fonnulations contain sugars, salts, and other components, which are problematic for 
MS. Neverthelcss, cell culture approaches offer great advantages by eliminating competitive 
signals and confounding variables of tissue preparations, thereby allowing single mammalian cell 
detection 11,12 For successfully profiling the peptides ofmagnoeellular neuron, senun-free 
culturing conditions are optimum. The serum used in media preparation contains a surprising 
range of peptides that make spectra from serum-containing media problematic to interpret with 
135 
direct proteomic analysis. To this end, we developed neuroendocrine magnocellular neuron 
cultures in serum-free conditions compatible with MALDI-TOF MS. 
To establish baseline characteristics, initial cultures of magnocellular neurons were plated 
at 500 cells/mm2 in 10% serum (see Materials and Methods) and analyzed at 7 days in vitro 
(DrV) (Fig. 5.1 A). Under these conditions, glia rapidly proliferate to confluence and support 
magnoeellular neuron development in culture. Magnocellular neurons were evaluated via 
immunochemistry. Coverslips from parallel cultures werc labeled separately using PS-38 and 
PS-41 antibodies against oxytocin-neurophysin and vasopressin-neurophysin, respectively. The 
numbers of individual oxytocin-neurophysin and vasopressin-neurophysin magnocellular 
neurons per coverslip were counted from coverslips of five independent cultures (fig. 5.lA). 
The viability of vasopressin -, but not oxytocin-, producing magnocellular neurons in culture is 
influenced by media osmolarity, with lower osmolarity (255 mOsm) increasing survival over 
higher media osmolarities (300-330 mOsm) 23 Neurobasal culture mcdia has low osmolarity 
(205-245 mOsm), therefore, vasopressin-neurophysin survival is favored under these conditions. 
Our baseline data are in general agreement with a previously published trend 
demonstrating a preponderance ofvasopressin-neurophysin over oxytocin-neurophysin in 
dissociated cultures 23. The morphological development ofmagnocellular neurons in culture was 
measured at 2, 4, 7 and 14 DIV. The product of perikaryon length and width demonstrates 
scatter of magnocellular neuron sizes from a single postnatal dissociated culture (fig. 5.1 B) and 
is representative of the general trend of increasing soma size across three separate cultures. At::> 
4 DIV, magnocellular neurons in culture develop characteristically long axons and short broad 
dendrites; fig. 5.1 C displays a single axon bifurcation with distinctly different, pcptide-rich 
terminals. 
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To evaluate serum- and density-dependent growth of perikaryon size, we measured the 
number of neurons obtained from IS high-resolution images per sample acquired at random 
intervals across the coverslips from a single magnocellular-neuron culture at 14 DIV (Fig. 5.1D; 
500 cclls/mm2, 1%, and 100 cclls/mm2, 1%). By comparing thcse data with those of Fig. S.IB 
(500 cells/mm2, 10%, 14 DIV), we found that magnocellular neuron soma size did not change 
with serum reduction, but as cell density decreased, soma size increased substantially. 
While we show that baseline cultures of postnatal magnocellular neurons express 
oxytocin- and vasopressin -producing neurons (Fig. 5.IA) and soma size expands throughout 14 
DIV (Fig. 5.1B), cultures of embryonic magnocellular neurons also have been shown to increase 
cell size in culture depending on the age of tissue harvest (embryonic day 15-19) 36 In culture, 
magnocellular neurons develop long axonal processes with many varicosities and elaborated 
axon tenninals for peptide transport and release. These terminals appear to recognize cell-to-cell 
contacts and develop into specialize structures (Fig. 5.1e). The data indicate that magnocellular 
neurons undergo density-dependent development in vitro that influences perikaryon size (Fig. 
5.ID). While the serum reduction does not have a pronounced influence on magnocellular 
neuron soma size, growth factors in serum may provide beneficial signals to sustain extensive 
growth. Such benefits may include other changes than those we measured, for example, in rates 
ofneuropeptide production. By using serum-free culture conditions and neuron-permissive 
media, non-neural support cells (i.e., glial arc eliminated almost completely 28, further reducing 
confounds for peptide analysis. 
To establish culture conditions for neuropeptide analysis through direct MS, we analyzed 
magnocellular neuron development under serum-free conditions. To generate low-density 
cultures devoid of serum and glia, we plated cells at 100 cells/mm2 in serum-free media. Under 
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these conditions, we observed two diffcrent fates for magnocellular neurons. In one casc, when 
they attached only to laminin- or poly-D-Iysine-eoated eoverslips, neuron development appeared 
stunted (Fig. 5.2A); in the other case, when magnocellular neurons were in contact with another 
cell, development improved substantially yielding highly differentiatcd neurons with ramified 
axons (Fig. 5.2A-B). Both outcomes were repeatable between cultures, and they were internally 
consistent within the same culture dish. Under these conditions, the numbers of magnocellular 
neurons with extensive neurite development are few. 
Under low-density, serum-free culture conditions, magnoeellular neurons in contact with 
other cells demonstrate elaborate process maturation compared to those growing in isolation 
(Fig.5.2A-B). Relatively few cell contacts produced a pronounced difference in magnocellular 
neuron growth that enabled the formation of elaborate axon terminals that extended well over 
one millimeter (Fig. 5.2B). This example was selected because the axon terminal demonstrates a 
bilaterally symmctric morphology on laminin and occurs in thc absence of any direct cellular 
contacts. We conclude that cell-to-eell contacts provide some key, undefined support for optimal 
magnoeellular neuron growth. 
If cell-to-cell contact of non-neural, substrate cells support and improvc magnocellular 
neuron development, then heterogeneous neurons may as well. To test this, we generated serum-
free, hippocampal-neuron/ magnocellular-neuron co-cultures and evaluated magnocellular 
neuron development. Hippocampal neurons were tested due to their identifiable neuronal 
characteristics, easy dissection and well-defined culture conditions. First, we established 
hippocampal neuron cultures for 4 to 9 d to allow the neurons to undergo axo-dendritic 
specification and axon elongation prior to seeding magnoccllular neurons. To assess 
magnocellular neuron presence and development, cultures were double-labeled with antibodies 
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against NP and MAP2, which recognize magnocellular neurons and all neurons (Fig. 5.3), 
respectively. By plating magnoeellular neurons onto established cultures of hippocampal 
neurons, development of the magnoeellular neurons was improved to yield nearly pure neuronal 
populations consisting of arborized magnocellular and hippocampal neurons at low densities 
(Fig. 5.3). In these co-cultures, hippocampal neurons were the predominant neuronal type. 
As demonstrated in Fig. 5.3A, hippocampal neurons effectively support magnocellular 
neuron development in serum-free conditions. Previous studies detennined that hippocampal 
neuron density influences neuron viability, possibly due to achieving threshold concentrations of 
diffusive cues or neuron connectivity 2S We improved the microenviromnent for magnoeellular 
neurons by pre-plating hippocampal neurons to provide the close associations produced by co-
culturing. In this way, hippocampal neurons can provide both trophic and synaptic support to 
magnoeellular neurons. We recognize the possibility that other neuronal populations also may 
be able to support maguocellular neuron development, by directly innervating magnocellular 
neurons or otherwise. 
In contrast to our methods, prior protocols for dissociated magnocellular neuron cultures 
require serum and/or high-density feeder layers to achieve survival and magnocellular neuron 
differentiation 20.25 . 36. While the magnocellular neuron-hippocampal neuron co-culture protocol 
is more labor intensive than the culture process of an individual brain area, this co-culture 
process produces a chemical environment that is free of the observed serum-derived mass 
spectral peaks. Not only does this heterogeneous co-culture have promise for profiling candidate 
neuropeptides from cultured maguocellular and hippocampal neurons, it reveals a novel 
developmental dependence relating to the cell biology of magnocellular neurons. 
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By incorporating magnocellular neurons in co-culture, we retain a positive control for 
validating our approach using the aforementioned single-step sample preparation. Due to the 
presence of magnocellular neurons, levels of expected peptides, such as arginine vasopressin, 
provide a meaningful baseline against which unidentified neuropeptides can be compared. 
The supraoptic nucleus and hippocampus are regions of the brain that are known to 
exhibit neuroplastieity throughout the lifespan; therefore, our direct peptidomie approach 
provides a potential means for identifying bi-direetional, signaling molecules involved in neuron 
development and repair. To generate neuropeptide profiles of individual magnoeellular and 
hippocampal neurons in co-cultures, a total of six coverslips from three separate co-cultures were 
used. DHB matrix rinse applications removed media from the cells, leaving a trace amount of 
matrix solution barely wetting the coverslip. As the crystals form on and around the neurons, 
endogenous peptides are locally extracted from the neurons and incorporated into the crystal 
matrix. This extraction protocol retains the structural integrity ofthe cultured neurons (Fig. 
5.3C) while enabling peptide detection (Fig. 5.4 and Table 5.1). Coverslips with DHB crystals 
were directly analyzed using MALDI-TOF MS, and neuropeptide content was confirmed (Fig. 
5.4 and Table 5.1). The fonnation of DHB crystals can, but not always, encapsulate neuronal 
soma or neurites (Fig. 5.3). From the MS results, two characteristic profiles emerged repeatedly 
(Fig. 5.4), and with relative consistency. Small variations were observed and are to be expected 
with mass spectrometry; for this reason, we replicated the results using six coverslips from three 
independent co-cultures. Table 5.1 reports the peaks associated with the characteristic profiles. 
One contained predominantly vasopressin and other fi'agments from the same prohonnone, while 
the other profile showed few vasopressin prohormone identifications. 
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On average, 17 peptides were observed per coverslip. This includes the combined total 
of unknown and putative signaling peptides for both magnocellular and hippocampal neurons; 
Table 5.1 lists the masses of the 27 peptides peaks observed. From direct MALDI-TOF MS, two 
reproducible, characteristic peptide profiles were observed (Fig. 5.4). Molecular mass profiles 
show 10 peptides having mass matches to provasopressin, protachykinins A and B, 
proopiomelanoeortin (POMC), and seeretogranin-2 (Table 5.1). Vasopressin was used to 
confinn the identification of putative magnocellular neurons. In addition, provasopressin[24-
32], [24-33], [36-54], [158-168], POMC[1 03-120], and secretogranin2[571-583] of our current 
study (Table 5.1) were mass matched to values of our previous supraoptic nucleus peptidomies 
study, wherein the peaks were characterized by tandem MS2 and by NeuroPred software. The 
cleavage tool NeuroPred predicted four putative provasopressin-related peptides, including 
provasopressin[24-32], [24-33], and [36-54], corresponding to 1084.46 /11/z, 1142.46 /11/z, and 
1920.20 /11/z, respectively. Based on the mass matches from these two sources, we assigned the 
above peaks to magnoeellular neurons. 
Mass profiles characteristic of putative hippocampal neurons are expected to contain a 
different set of peptides. Neurokinin A[98-107] was detected previously in two peptidomic 
studies of the hippoeampus.(3,28) Based on these studies, predicted peptides from neurokinin A 
and B are attributed to putative hippocampal neurons (Fig. 5.4). Under these conditions, six 
unknown masses (/11/z = 2808.30, 2923.80, 2985.70, 3004.60, 3056.38 and 3516.44) present a 
stronger signal in the mass profile of putative hippocampal neurons. A mass peak corresponding 
to the J peptide from pro-opiomelanoeortin (POMC) is observed in profiles characteristic of 
hippocampal neurons. Previous studies have identified POMC in the human hippocampus 40, but 
it was not detected in the mouse hippocampus 4. However, POMC fragments were detected in 
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the rat supraoptic nucleus 2 Either POMe is produced in the rat hippocampus and dctected here, 
or axons from magnocellular neurons intermingled with hippocampal neurons to contribute 
POMe to these spectra; therefore, J peptide could be attributed to either magnocellular neurons, 
hippocampal neurons, or both. A thorough, comparative peptidomic analysis of tissue from the 
rat hippocampus is warranted for future studies, work that would clarify this issue. In addition, 
thymosin ~-4 and thymosin ~-l 0 were dominant features of both type of neurons. These results 
demonstrate that a high number of peptides are detectable from mammalian neurons in serum-
free cu I tures. 
As part of a large neuropeptide family, tachykinins are active peptides that are involved 
in a range of physiological processes 41 and have been detected in the hippocampus of rats and 
humans 42-44, but not the mouse 43. Furthermore, the hippocampal formation contains abundant 
tachykinin binding sites (NKl, NK2, and NK3)45, thus indicating a potential role oftachykinins 
in hippocampal neuron function. The specific localization and functional significance of 
neurokinin A and B, J peptide of PO Me, secretogranin-2 [571-583] in the supraoptic nucleus 
and hippocampus are w011hy of further investigation. Several unassigned peaks are observed in 
the mass range ofmlz 2000-3600 (Table 5.1). Identifying these and placing them within a 
functional context will be important to more fully understand communication within the highly 
complex, interconnected structure of the brain. 
In this direct neuronal proteomic study, we characterized 10 known peptides. The 
presence of several putative provasopressin fragments in the magnocellular neuron profile may 
indicate Lmique prohormone processing or cleavages, as these are often observed in direct 
MALDl MS profiling. Alternatively, these results may be attributed to peptide dcgradation 
during sample preparation, and/or drying. An important finding is the ability to obtain peptide 
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profiles from mammalian neurons in dissociated cell culture while retaining some spatial 
information relative to the neurons. We do observe occasional magnocellular neuron peptides 
from provasoprcssin in hippocampal ncuron profilcs. This can be explained by the fact that 
neurons develop long, branching processes that intenningle with other neurons in culture. As 
demonstrated here, axons can exceed 1.4 mm (Fig. 5.2B); in the intact animal, axons of 
magnocellular neurons navigate several millimeters from the supraoptic nucleus to their pituitary 
target. Thus, it is possible that axons ofmagnocellular neurons can contribute a relatively small 
amount of neuropeptides to hippocampal neuron profiles. 
Although we obtained cell-specific peptide profiles on primary cultured neurons, direct 
peptide sequencing through this approach was not possible due to low amounts of analytes 
available from the cultured neuronal samples. Therefore, not every peptide identified by mass 
was confinued by tandem MS sequencing. For example, oxytocin (theoretical mass of mlz 
1006.44) was not detected even though it is a known magnocellular neuron product and is in the 
ideal mass range for detection. This could be due to low amounts of oxytocin, the low number of 
magnocellular neurons in the culture, or a yet unidentified molecular interaction or post-
translational modification that may alter the ability to detect oxytocin at its expected mass. 
While any of these explanations may be valid, it should be noted that oxytocin was not detected 
in peptidome studies of rat supraoptic nucleus extracts 2, nor was it reported in extracts of thc 
entire rat hypothalamus 46 Nevertheless, it was detected in the mouse hypothalamus via MS by 
utilizing different reagents for sample preparations 4, and after N-terminal peptide modification 5. 
Although extracting brain tissue will provide a greater number of peptides, the present 
approach enables a direct measure of mammalian neuropeptide content within the context of 
specific cell types. In either case, complete profiles are not attained 2. Rather, different 
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preparation methods provide different peptide signatures, and by combining data from the range 
of sample types, extraction methods, and peptide characterization approaches, we arrive at a 
morc completc wldcrstanding of peptidcs in thc contcxt of ccll-ccll signaling. In our prcvious 
work, tissue was collected from 6-12 week old rats 2, whereas cultured neurons used here are 
comparable to 4-13 day-old, age-adjusted rats. Allowing neurons to age longer in culture, or 
culturing from older animals, may enable more, or at least differcnt, pcptides to bc evidcnt in the 
mass profiles. Only a fraction of those peptides observed in our fonner work are observed here, 
possibly due to differences in age-dependent development and peptide production, the amount of 
pcptide in the sample, and/or thc fewer nwnber of cells. Whilc our study demonstratcs the 
ability to directly sample primary neurons from the mammalian brain in culture, we expect that 
technological advances will provide improved opportunities for sample preparation and peptide 
dctcetion toward advancing our Lwderstanding of the eompletc peptidc complement in individual 
mammalian neurons. 
5.6 Conclusion and Future Directions 
In conclusion, we demonstrate that low-density co-culturing of magnocellular and 
hippocampal neurons improves magnocellular neuron development over other methods; our 
results highlight thc importancc of intercellular chcmotrophic support. To better understand the 
chemotrophic neuropeptides of these co-cultures, we confimled the neuropeptide content of 
established magnocellular neuron marker peptides and profiled cultured hippocampal neurons 
using MALDI-TOF MS. We demonstrate the ability to perfonn direct mass profiling of 
(co )cultured mammalian neurons, and to distinguish spectra attributable to each type of neuron. 
This is accomplished in serum-free media, a chemical environment free of interfering mass 
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spectral peaks. Manipulations of tiny samples as small as individual rat neurons directly makes it 
possible to access intact mammalian neurons within co-cultures using MALDI-TOF techniques 
for spatially scnsitive characterization of intracellular neuropeptides. This approach enables 
unprecedented access to individual, developed, intact mammalian neurons for cell-specific mass 
spectrometry. Now, reliable detection ofneuropeptides from dissociated cultures of mammalian 
neurons can be achieved by using a one-step sampling extraction application. 
future directions will focus on improving peptide yield for sequence identification, 
understanding the roles these peptides play in magnocellular neuron development and clarifying 
the nature of previously established peptides, specifically oxytocin. We will explore the 
chemical environment provided by cell-to-cell contacts, whether neuron-to-neuron, or glia-to-
neuron, and how they provide support for optimal magnocellular neuron growth. A thorough, 
comparative peptidomic analysis of tissue from the rat hippocampus is wan-anted to clarify our 
observation of a mass peak con-esponding to the J peptide from pro-opiomelanocortin (POMC) 
in profiles characteristic of hippocampal neurons. To more fully address context-dependent and 
temporal facets of neuropeptide production, neurons can be sustained in low-density culture by 
controlling the local microenviromnent of the neuron 33, which can manipulated to retain 
secreted factors in the immediate proximity for temporal analysis of released peptides 47. Local 
environments can be accessed to stimulate altered cellular functions and local changes in 
peptides can be measured. Our approaches enable unprecedented access to individual neurons 
and their neurite extensions, raising new prospects for sub-cellular peptidomic analyses. 
145 
5.7 Figures and Tables 
Table 5.1 Peptides detected directly from supraoptic magnocellular and hippocampal 
neurons in co-culture. Summary of direct MALDI-TOF MS results for magnocellular neurons 
and hippocampal neurons in serum-free co-culture after a single-step application of DHB matrix. 
Thcnr. Error Putative Putative Presence in Prohormone Obs. (m/z) (mlz) (Do) magnocellular hippocampal supraoptic nucleus 
neuron neuron (I\1SI\1S) " 
Neurokinin A [98-107] 1132.87 1132.55 -0.32 x 
POMC[ I 03-120]1 J peptide 1882.93 1882.83 -0.10 x x x 
Neurokinin B [95-116] 2345.58 2344.51 -1.48 x 
Provasopressin [24-32] 1084.49 1084.44 -0.05 x x 
Provasopressio [24-33] 1142.49 1142.46 -0.03 x Neuropred-rat model 
Provasopressin [158-168] 1250.49 1250.37 -0.86 x x 
Provasopressin [36-54] 1920.36 1920.20 -0.16 x Neuropred-rat model 
Secretogranin2[571-583] 1354.49 1354.67 0.18 x x 
Thymosin beta-I 0 4932.10 4932.51 0.41 x x x 
Thymosin beta-4 4959.30 4960.48 1.18 x x x 
Unknown 863.74 x x 
Unknown 1021.50 x 
Unknown 1044.75 x x 
Unknown 1521.62 x 
Unknown 1586.61 x x 
Unknown 1799.60 x 
Unknown 1870.50 x 
Unknown 1997.85 x 
Unknown 2256.34 x 
Unknown 2481.59 x 
Unknown 2808.30 x x 
Unknown 2923.80 x 
Unknown 2985.70 x x 
Unknown 3004.60 x 
Unknown 3056.38 x x 
Unknown 3516.44 x x 
Unknown 4174.70 x 
"(1) 
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Figure 5.1 Magnocellular neurons soma size in dissociated cultures depends on DIY and 
plating density. (A) The average number of vasopressin - and oxytocin -containing 
magnocellular neurons in baseline neuron cultures as identified through immunochemistry with 
PS-41 and PS-38 NP antibodies, respectively. Baseline cultures were seeded at 500 cells/mm2, 
cultured with 10% fetal bovine semm, and immunolabeled at day 7 DIY. Data (mean ± SEM) 
represents five separate cultures. (B) To assess magnocellular neuron development in high-
density cultures (plated at 500c/mm\ soma size was measured at 2,4, 7, and 14 DIY. (C) Axon 
terminals can develop distinct morphologies, presumably due to the recognition of different 
substrate cell types. Scale bar = 100 f.llll. (D) Magnocellular neuron size in culture is dependent 
on plating density rather than serum level. For comparison, the 14 DIY data of (B) is included 
(500 cells/mm2, 10%) (B-C) Soma size was estimated as the mean product of the length and 
width. Mean ± SEM, unpaired I-test, p = 0.0001. Reprinted with permission from reference I. 
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Figure 5.2 Cell-to-cell contact improves magnocellular neuron development. Neurons 
cultured on laminin show improved development when in contact with support cells rather than 
laminin alone. (A) Magnocellular neuron (green) on laminin alone and adjacent to 
magnocellular neuron on support cell (red). Magnified inset shows stunted magnocellular 
neuron growth; arrowheads identify the axon. (B) Extensive development of magnocellular 
neurons in low-density, serum-free culture for 8 d. The neurophysin-labcled magnocellular 
neurons (green) with soma (*), axon (arrow heads), and dendrites (arrows), are situated on 
support cells (red), which are easily identified with rhodamine phalloidin. Distal dendrite tip to 
distal axon tip measurement: 1750 ~m. Distances: distal dendrite to soma (*) is 256 ~m, soma to 
axon tip is 1494 ~lm. Scale bars: top = 15 ~m, center = 50 ~m, bottom = 100 ~m. Reprinted with 
pennission from reference 1. 
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Figure 5.3 Magnocellular neuron development is improved by hippocampal neurons in co-
culture. (A) Magnocellular neurons were plated onto a S-day-old culture of hippocampal 
neurons and maintained for 7 d. Magnocellular neurons show abundant NP (white) while 
hippocampal neurons lack NP. MAP2 content (green) of the neurosecretory magnocellular 
neuron is abundant, compared to hippocampal neurons. (B) Low magnification, phase-contrast 
image of primary magnocellular neuron-hippocampal neuron co-culture demonstrates neuronal 
connectivity. (C) After cultures were rapidly rinsed with DHB, crystals foml to embed neurons 
and locally extract peptides (differential interference contrast microscopy). For this type ofMS 
analysis, neuronal cells must be embedded in matrix crystals. Samples were dried for 1-2 days 
in a desiccator, prior to perfonning MALDI analysis. All scale bars = 50 f!m. Reprinted with 
permission from reference 1. 
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Figure 5.4 Peptide profiles of primary magnoceUular and hippocampal neurons in co-
culture. Analysis of co-cultures repeatedly produced distinct peptide profiles for each neuronal 
type; putative pep tides are identified, and unknowns are labeled as such. Seventeen "unknown" 
peptides peaks were observed repeatedly. Cultures were analyzed by a Bruker Ultraflex IT 
TOF ITOF instrument; mass spectra were accmnulated over 2-3 individual acquisitions of 300 
laser shots each with external calibration covering the 700-3000 Da mass range. Reprinted with 
permission from reference I. 
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CHAPTER VI 
TISSUE SAMPLING STRATEGIES IN OXYTOCIN DETECTION IN RAT 
SUPRAOPTIC MAGNO CELLULAR NEURONS 
6.1 Notes and Acknowledgements 
I would like to acknowledge several people that were involved in different aspects 
of this work. I want to thank to Dr. Norman Atkins and Dr. Jennifer Mitchell from 
Martha Gillette Laboratory for multiple sample collections and different advice and 
scientific points they made in our multiple conversations. Dr. Norman Atkins provided 
oxytocin-neurophysin I immunochemistry staining images. The conversations and 
support of Prof. Dr. Jonathan Sweedler are greatly appreciated in this work as well. 
This chapter arises as a consequence of our previous neuropeptidomics study of 
the rat supraoptic llLlClcus (SON) found in Chapter 4. In our previous study, oxytocin 
(OXY) is a main peptides secreted from the SON that was difficult to detect by mass 
spectrometry (MS). Here are investigated several sample preparation methods that help 
us to understand why it is challenging to detect this peptide by MS. 
6.2 Abstract 
The goal of this work is to detect and unambiguously identify the endogenous 
OXY found in the SON region using mass spectrometry. To develop the method of 
analysis, there were used highly peptidergic brain regions such as coronal hypothalamic 
slices, SON, and pituitary, of rat or mouse brain. Different sample preparation strategies 
were employed in this work such as rapid enzymatic heat denaturation in boiling water 
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followed by multistage extraction, DHB or acidified acetone direct extraction, and 
reduction and alkylation. Other strategies were used to enhance the detection of OXY by 
stimulating the release of OXY from hypothalamic rat brain slices or from the SON of rat 
or mouse brain. All experiments were designed to answer the challenges cncountered for 
the detection of the basal level of endogenous OXY of the SON of rat brain. In this work 
it was found that rat pituitary extract yielded to detection of OXY using different sample 
preparation methods combined with two main analytical tools such as electrospray 
ionization (ESI) MS and matrix-assisted laser/desorption ionization (MALDI) MS. In 
addition, using a rapid heat denaturation method followed by multistage extraction 
protocol indicates the successful detection of OXY in both SON (by mass) and pituitary 
(by MSIMS sequence). 
6.3 Introduction 
The hypothalamic magnocellular neurons (MCNs) of the SON are among the best 
characterized of all mammalian peptidergic neurons, and therefore are used as model for 
understanding the functionality of peptides within neuronal networks. MCNs cell bodies 
are found ventrolateral in the hypothalamus from where they send processes to the 
posterior pituitary where they release their main peptide hormones, vasopressin (A VP) 
and OXY. Elcctrophysiological and injection of retrograde tracers studies showed that, 
within the brain some MCN axons that terminate in the neural lobe sent collaterals to the 
median eminence, medial amygdaloid nucleus, and lateral septum.! Compared with other 
hypothalamic nuclei, SON is fairly homogeneous with no other cell bodics in the nucleus. 
The MCNs of SON have oval shaped cell bodies (20-40 ~m size, in the rat model) with 
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thick dendrites projected toward thc vcntral surfacc of the brain. The somata and 
dendrites of the MCNs are directly adjacent to each other, and interposed between them 
are astrocytic glial processes. It is essential to mention that during times of high hormone 
demand, the morphology ofthc MCNs is altered, bringing cell bodies and dcndritcs into 
direct contact and increasing synaptic inputs to the neurons. 1 It had been shown that 
MCNsmake somatic and dendritic contacts via gap jWlctions, thus producing cytoplasmic 
coupling. 1 In thc brain, this architecturc allows OXY and AVP to be rcleased not only 
axonally in the posterior pituitary but also somatically/dendritically in the extracellular 
space of hypothalamic SON region. 
Electron microscopy and immunoreactivity techniques showed that a source of 
these peptides is dendritic MCNs release?·5 In addition, dendritic localization of AVP 
and has been shown by in situ hybridization, suggesting that dendrites of the MCNs are 
capable oflocal precursor synthcsis5 Othcr studics indicatcd thc prcscnce of thesc 
peptides within SON region from axon swellings or axon collaterals.6, 7 
RadioimmwlOassay (RIA) and enzyme-linked immunosorbent assay (ELISA) were used 
to mcasure the OXY and A VP within axonal tenninals, plasma, and ccntral spinal fluid 
(CSF). 5,8·10 Basal and stimulated releases of these peptides into hypothalamic nuelei 
have been shown in vitro and by microsampling approaches such as push-pull perfusion 
and microdialysis in vivo. 2, 11,12 Although thc mechanism oflocal release ofthesc 
neuropeptides within hypothalamus is not well understood, these important findings have 
opened questions regarding fWlctions of these peptides within a defined brain region. 
OXY is one of thc brain neuropeptides that has rccently bccome well investigated 
due to the discovery of different behavioral functions regarding social interactions. In 
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mammals, OXY regulates maternal behavior, aggression, pair-bonding, sexual behavior, 
and social memory. 12 In humans, OXY has been discovered as playing important role in 
personality, trust, altruism, and social bonding13 Interestingly, at the same time, 
controversial experimental manipulations showed that central infusion of OXY in virgin 
female rats, which normally ignore or attach pups, stimulates maternal behavior. \3 On the 
other hand, decreasing levels of OXY or blocking its receptor will have a negative impact 
on the maternal behavior.13 Due to the fact that rats or mice do not display pair bonding, 
mate-based pair bonds studies have been done in the monogamous prairie wolves.14 
Similar experiments of centrally infused OXY facilitated partner-preference during 
mating, whereas blocking the receptor inhibited this habit.'4 In humans, due to the great 
diversity of human attachment, similar studies have ambiguous results. However, 
modulation of human behavior has been studied using intranasal administration ofOXY. 
There arc no evidences regarding the measuremcnt of cerebrospinallevcls of OXY after 
nasal insertion, but similar reports indicated consistently that this peptide does affect the 
brain and cognition. 13 An intriguing aspect is the central mechanism of action of this 
peptide when it is administered peripherally, considering that OXY does not efficiently 
cross the blood/brain barrier. Therefore, it is essential to explore every bit of information 
regarding the mechanism of action of OXY within in the brain. 
Since the discovery of nanopeptidcs by Du Vigneau and then Aeher in 1950, 
extensive research on OXY proved to be an essential component of the well-defined 
hypothalamic MCN system. OXY synthesized within the MCN system served as model 
to study the activity of neurosecretory neurons, characterization ofneuropeptidcrgic 
pathways within the brain, neuronal-glia plasticity, development ofneuropeptide receptor 
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hybridization, immunochemistry or even neuropeptide content measurements are used to 
estimate the release pattems of peptides, and more recently advanced techniques of 
analytical chemistry arc used to detect and measure peptides in different brain regions. 
Peptidomics studies of specific brain structures such as mouse hypothalamus and 
pituitary showed the detection of OXY (mlz IO06.44)lg-20 On the other hand, when other 
research groups used the same brain structures isolated from the same animal model but 
used different protocols and mass spectrometers, OXY was not detected.2l ,22 Similar 
negative results were obtained in case of peptidomics studies of the rat hypothalamus22-24 
In the previous study of peptidomic investigations of the rat SON, OXY was not 
characterized by MSfMS, it was identified only by mass even though it is known that the 
SON is one of the main "reservoirs" of this peptide23 Based on these intriguing findings, 
we try to understand why it is difficult to detect OXY in some samples depending on the 
model. This chapter investigates different sample preparation methods using rat or mouse 
to detect basal levels of the endogenous OXY in the rat hypothalamus, SON and 
pituitary. 
6.4 Experimental Methods 
Chemicals. All reagents werc obtained from Sigma-Aldrich Chemical Co. (St. 
Louis, MO, USA), unless otherwise noted. Water was prepared by a Milli-Q filtration 
system (Millipore, Bedford, MA, USA). The peptides standards used for extemal 
calibration wcre provided by Bruker Daltonics Inc. (Billcrica, MA, USA). 
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6.4.1 Animal Sacrifice and Brain Slices Preparation 
Animal sacrifice and tissue brain slices preparation are described in great details 
in the experimental section of Chapter 4. In the same cases, the SON tissue punches were 
stimulated with 55 mM KCl for 10 min prior to the extraction procedure. 
6.4.2 Peptide Extraction 
Tissue manipulation and multistage peptide extraction protocol arc applied to the 
SON, and coronal hypothalamic slices of the rat brain as explained in detail in Chapter 4. 
Before extraction, SON and hypothalamic slices were kept alive in the slice chamber for 
peptides recovery, except pituitary. The rat pituitary is a large pcptidergic "reservoir" that 
was subjected to rapid heat denaturation before extraction. 
6.4.3. Stimulation Followed by Extraction 
One set of experiments used 6 animals. SON tissue punches (I mm) from rat or 
mouse brain tissue were collected in two different vials and stimulated with 55 mM KCl 
for 10 min. After stimulation the samples were boiled in pure water for 10 min at 90°C, 
the aqueous supernatant is saved and the remaining tissue follows extraction with 1 00 ~IL 
acidified acetone. Similarly the control samples represent the non-stimulated tissue. They 
were collected at the same time using the same number of animals following the same 
steps of sample preparation. 
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6.4.4 Direct Extraction Followed by Acidified Acetone Extraction 
Another set of experiments used a number of 8 animals. The animals were used 
for cruel extraction (without boiling) such as 2 coronal hypothalami slices ofrat brain, 6 
SONs and 2 rat pituitaries. The direct extraction is followed by I 00 ~IL aciditied acetone 
extraction for several hours at 4°C. 
6.4.5 Concentrated DHB Extraction 
In addition, 20 mg/mL concentrated 2,5·dihydroxybenzoic acid (DHB) solution 
was used for extraction of peptide from one hypothalamus and one rat pituitary. This 
procedure had been developed by Dr. Elena Romanova in the Sweedler Lab. 21 
6.4.6 Reduction and Alkylation 
The SON extract from animals were used for reduction and alkylation. The 
reduction reagent 200 mM of dithiothreitol (DTT) and the alkylation reagent, 1M 
iodoacetamine ( C2H4INO) were dissolved in 100 mM ammonium bicarbonate (NH4 
HC03) buffer. The tissue extraction samples are preconcentrated in 100 l1L volume of 50 
mM bicarbonate buffer with a basic pH. The I 00 ~IL sample is reduced by adding 5 l1L of 
DTT. It is boiled for 10 min at 90°C, vortex, centritiJged and let to reduce at room 
tcmperature for 45 min· I h. The rcduction of Cys-Cys is followcd by alkylation with 4 
~IL of iodoacetamide, vortex, centritiJged and let it alkylate for 45 min- I hat roOI11 
temperature. The alkylation is stopped by neutralizing the remaining iodoacetamine with 
20 l1L ofDTT, vortex ed, centrifuged and incubated at room temperature for 45 min-I h. 
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The samples are enriched with 10 kDa cutoff filter and subjected to LC-ESI MS. A 
volume of I 0 ~L was used desalted with a ZipTip C 18 and eluted on a MALDT target. 
The tissue samples are homogenized, except DHB extraction, and subjected to 
liquid chromatography (LC}-MALDI or EST MS. 
6.4.7 Instrumental and Data Analysis 
The LC-EST MS and LC-MALDT MS are described in great details in Chapter 2 
and 4. For ESI MSIMS data analysis Peaks Studio 3.0 was used to search against in house 
built rat database and for MALDl MS/MS data analysis Biotools 3.0 was used for ion 
assignments. For MS data, manual analysis was employed. 
6.5 Results and Discussion 
The goal here is to detect basal levels of endogenous OXY in rat SON using MS. 
Fig. I represents an immunohistochemistry of OXY prohormone staining within SON 
obtained in the Gillette Laboratory. Based on these immunohistochemistry results, OXY 
or a moditied tonn of this peptide should be present in the rat SON. However, most of 
the time, in the rat hypothalamic structures OXY is often not detected.22.24 In this study 
there were used rat and mouse samples to detect OXY and different sample preparation 
methods were employed, together with LC-EST MS or LC-MALDT MS. 
In our previous neuropeptidomics study of rat SON we were able to detect OXY 
(mlz 1006.44) by match mass (Fig. 2 B and C). The low peak intensity for OXY did not 
allow the MS/MS sequencing in order to prove unambiguously the identitication of the 
peptide. In addition, the Na adduct was detected as well (Fig. 2 B). It is important to 
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mention that the deteetion of OXY in those experiments was not reproducible (Table I). 
In case of SON, there were run more than 10 experiments using acidic solution as the 
extraction method and OXY was detected only twice by mass. On the other hand, OXY 
salt adducts, [M+Na] 1029.54, respectively [M+K] 1045.46 (fig. 2 A), werc dctected 
reproducibly in the extract solution (fig. 2 B and Fig. 3 B) and OXY standard solution 
(Fig. 2 A). In addition, using LC-MALDI MS to profile SON extract, different fragments 
of OXY prohonnonc were detected and mass matched with proOXY [19-27], proOXY 
[20-29], and proOXY [19-28] (fig. 3). 
Why is it hard to detect OXY? first, it needs to be considered that rat SON 
contains about 3,400 A VP-containing neurons and only about 1,500 OXY -containing 
neurons.
5 Second, MCN is a dynamic system and both hormones are released in different 
amounts during a 24 h cycle period. Third, suckling and pm1urition are the main 
physiological stimuli that activate the OXY -containing neurons. Hencc the detection of 
the basal level of endogenous OXY ofrat SON may be difficult to obtain by MS, because 
at the moment of the sample collection the concentration of OXY can be below the 
detection limit. In addition, the samples were collected at various points in time during 
daytime using non-pregnant female and male rats, without stimuli that might boost the 
OXY release. 
Another aspect that was considered in this analysis is the chemical structure of 
OXY, which can affect the ionization and fragmentation techniques. The mammalian 
honnones OXY and A VP have similar structures, one Cys-Cys bond between amino acid 
1 and 6, although the peptides have different functions. Previous studies showed that 
online LC-ESI-MS with collisionally induced dissociation yielded a better fragmentation 
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ofCys-Cys bonded peptides25,26 Pituitary gland receives projections from both 
paraventricular nuclei (PVN) and SON and appears to contain a higher amount of OXY 
than SON.27 In ordcr to investigate thc dctcction and sequencing pattern of the 
endogenous OXY by MS, we used the most OXY -producing structure available, the rat 
pituitary. As indicated in Fig. 4 A, OXY extracted from the pituitary was sequenceable 
by ESI MS/MS. This result is obtained when multistage protocol was applied using a 
whole adult rat pituitary. It is important to mention that OXY was detected by MALDI 
MS as well, but it was not intense enough to sequence by tandem MS. However, we 
profiled and sequenced the commercially purchased OXY peptide with MALDI MSIMS 
and it yielded a poor fragmentation by tandem MALDI MS, even though the 
concentration of the peptide in solution was in the millimolar range (Fig. 4 B and Fig. 5 
A). Our data show that ESI MS/MS of endogenous OXY extracted from rat pituitary 
gland showed a better ionization and fragmentation than the OXY standard prepared in 
solution. It is important to mention that when standard OXY was diluted to from mM to 
pM, only mM concentration gave a high enough OXY signal to fragment by tandem MS. 
In the hypothalamus, in addition to the SON, the PYN is another source of OXY. 
Fig. 6 indicates the detection of multiple peptides released from coronal slice of rat 
hypothalamus using a multistage extraction procedure. When comparing the two highly 
peptidergic larger structures, hypothalamus and pituitary, using the same sample 
preparation, only pituitary extract yielded to OXY signal. The combined rapid heat 
denaturation method with multistage extraction protocol indicates the successful 
detection ofOXY in both SON (by mass) and pituitary (by MS/MS sequence). 
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As mentioned above, in the literature the detection of OXY by MS is unifonn 
depending upon the model used. Peptidomics studies using mouse hypothalamus showed 
the detection and sequencing of OXY by MS and at the same time similar studies that 
d h h I / .. d'd dOXY 19 20 2)·24 I . . usc rat or mouse ypot a amus pitUitary I not ctect . .. . - t IS Important to 
notice that the aforementioned studies used different sample preparation and different 
mass spectrometers. Che et.al used microwaving of the whole mouse head as a rapid 
enzymatic denaturation, followed by isolation of the hypothalamus and acidic 
extraction. 19 Dowell et. al used boiling for 10 min of the rat hypothalamus as a method to 
decrease the proteolytic degradation followed by acidic extraetion24 Svenson et al. used 
both rat and mouse hypothalamus, and prior to dissection, focused irradiation was 
employed for animal sacriticing followed by decapitation, freezing at _80 0 C and 
extraction with acidified solution22 Romanova et al. used fresh mouse pituitary in DHB 
extract.21 Surprisingly, in the last two studies did not detect OXY in any of the sample. 
Here, we compared mouse versus rat SONs. In order to increase the release of 
OXY, we stimulated the biological tissue with concentrated KCl. As shown in Fig 8 and 
Fig 9, none of the mass protile of either rat or mouse SON extract indicates OXY. On the 
other hand, A VP has a higher intensity during stimulation (Fig. 8 C, Fig. 9 C). 
Stimulating the SON tissues in both models led to the release of multiple peptides that 
might ionize better, and hence suppress OXY detection. OXY remained below the 
detection limit. 
In case of the direct extraction procedure, in this study, OXY was detected using 
pituitary tissue (data not shown) following DHB extraction protocol developed by 
Romanova et al.. 21 Fig. 7 B indicates that DHB extract leads to detection of OXY in 
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pituitary only. Different peaks can be visualized in the mass profile of I ~IL hypothalamic 
sample but OXY was not detected (Fig. 7 A) by MALDI MS. In contrast to Romanova et 
ai., OXY was detected following the same extraction procedure. It is important to 
highlight that OXY detection is not easy to reproduce. 
Disulfide-bonds are PTMs that stabilize peptide structure and are often necessary 
for biological function. As mentioned above, OXY contains one Cys-Cys bond between 
Cys (I) and Cys (6). Inside of neurosecretory granules, OXY is electrostaticaly bounded 
to its carrier protein neurophysine I (NP I) and they form a dimer.27 Dissociation of the 
complex of OXY -NP I is facilitated by a rapid change in pH as soon as the granules 
(pH=5.5) release the complex in the blood stream or plasma (pH=7.4).27 Although 
previous studies showed the crystal structure of the OXY-NP I complex using 
commercially available bovine neurophysin II and OXY, in our biological system the 
processing of proOXY still needs to be elucidated?7. 2R 
The reduction and alkylation procedure is a common sample preparation used to 
elucidate and characterize Cys-Cys bonded peptides. Here, this method is used to break 
Cys-Cys bond of OXY, including the proOXY, and hence facilitates detection through a 
better ionization and fragmentation of peptides in the mass spectrometer. DTT as a 
reduction reagent and iodoacetamide as an alkyling reagent were used to perfonn this 
procedure. The protocol was tested on OXY peptide standard (Fig. 10). The 
iodoacetamide adds a mass shift of 58 Da to each Cys. The total mass shift is 116 Da for 
OXY. Fig. 10 A indicates that the [M+H] 1007.3, which corresponds to unmodified 
OXY, becomes [M+H] 1123.4 Da after reduction and alkylation ofCys-Cys (Fig. 10 B). 
In many cases the biological samples are purified prior to reduction and alkylation. After 
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the procedure was applied directly to SON extract, thc sample was cleaned up using a 
ZipTip CI8 and eluted/preconcentrated on a MALDI target. MALDI profiling of the 
reduced and alkylated sample did not detect OXY. 
6.6 Conclusions and Future Directions 
The detection of low abundant pep tides is a challenging task in peptidomics 
studies. OXY relcased from the SON is one of the cascs of a low abundant peptidc. In 
this work it was found that pituitary extract yielded to detection of OXY no matter what 
sample preparation was chosen, and using both ESI and MALDI MS. ESI MS perfonned 
a better ionization and sequencing of the pcptide, allowing the unambiguous 
identification of the peptide only in rat pituitary extract. 
In peptidomics, the model of study has a great impact on mass spectrometric 
measurements. The method development of peptide analysis is an important aspect that 
needs to be considered. In the Sweedler Lab, developed by Dr. Nathan Hatcher, the 
coupling of electrophysiology with offline mass spectrometry has been a successful 
approach in the detcction and functional investigations of peptidcs within the CNS of 
both vertebrates and invertebrates.29, 30 Application of this method in detection of 
endogenous OXY can resolve not only aspects of the measurement of the basal 
endogenous OXY but can give functional insights well. In this chapter, physiological and 
stressful stimuli were not considered. Perhaps the investigation of different stimuli is the 
main factor that needs to be considered in the context of OXY release using mass 
spectrometry. These future expcriments will open new directions of the functional 
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investigation of the peptide within the eNS and lead to an understanding of the 
neurobiology of the eomplex soeial behavior. 
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6.7 Figures and Tables 
Figure 6.1 Immunohistrochemistry staining of the rat SON in brain slices. OXY (green) 
and Little SAAS (red) within SON (Image obtained with the courtesy of Dr. Lany Millet 
from Gillette Lab) 
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multistage extraction protocol. 
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Table 6.1 Summary of the extraction methods followed up in each experiment. The 
detection of OXY is marked by the instrument that was used. NA-represents that the 
procedure was not applied; The non-detection ofOXY is marked by-. 
Stimulation Stimulation Cruel 
Multistage followed followed extraction 
peptide by extraction by extraction followed by DHB Reduction-
extraction (rat) (mouse) extraction extraction alkylation 
hypothalamus - NA 
pituitary ESI/MALDI NA NA MALDI MALDI NA 
SON MALDI low intensity 
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CHAPTER Vll 
QUALITATIVE MEASUREMENTS OF PEPTIDES DURING PITUITARY 
DEVELOPMENT USING MASS SPECTROMETRY 
7.1 Notes and Acknowledgements 
This chapter is a collaborative work with the Raetzman Laboratory. I 
acknow ledge Prof. Lori Raetzman for supporting this proj cct. Prof. Raetzman provided 
the Hes I samples and gave important feedback on various aspects of this work. I want to 
thank her for training me to dissect embryonic tissue manually as well as to genotype 
embryonic phenotypes, which is a very beneficial and interesting experience for future 
projects. Prof. Jonathan Sweedler is acknowledged for scientific and financial support. 
7.2 Abstract 
The purpose of this study is to detect peptides having a role during pituitary 
development. Hes} KO is a genetically modified mouse that lives only e18.5 (embryonic 
days). Anterior pituitaries of Hes} null mice exhibit hypoplasia due to increased cell 
death and reduced proliferation. At e14.5 in the intermediate lobe, the cells that are 
supposed to become melanotropes differentiate abnOlmally into somatotropes. These 
previous findings demonstrate that Hes} has multiple roles in pituitary development, cell 
differentiation, and cell fate. Using a mass spectrometry-based (MS) approach, 51 
peptides were detected. In addition, 33 peptides were identified by mass as proteolytic ally 
processed from 15 knownprohormones using embryonic pituitaries from Hes} 
heterozygous mice. AVP was detected in all samples. Interestingly, somatostatin [92-
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100], and provasopressin [151-168], were detected in the mutant but not in the wild type 
or heterozygous pituitaries while somatostatin-14 was detected only in the heterozygous 
pituitary. In addition, the mlz 1330.2 and POMC [205-222] arc detected in the mutant and 
heterozygous pituitaries, but not in the wild type. These results indicate that Hes} 
influences the processing of different prohormones having a possible role during 
development and open new directions for filliher developmental studies. 
7.3 Introduction 
Pituitary hormones control growth, the body's response to stress, reproductive 
functions, and metabolism. Nomlal functionality of the pituitary gland is essential for the 
development of many organs. The many effects of pituitary hormones were validated by 
hypophysectomy.! Rat hyphophysectomy resulted in a cessation of growth, and 
degeneration of the thyroid, adrenal glands, and gonads. These effects were reversed by 
the administration of pituitary extracts.! Each endocrine cell type in the anterior pituitary 
is a honnone-produeing cell and differentiates in a temporal manner, ineluding the 
corticotropes, thyrotropes, gonadotropes, somatotrope, and lactotrope cells. Once fully 
differentiated, they start synthesizing hormones such as adrenocorticotripc hormone 
(ACTH), thyroid stimulating hormone (TSH), gonadotropins (FSH and LH), growth 
hormone (GH), and prolactin (PRL). The cells of the intennediate pituitary, however, are 
melanotropes and they secrete melanocyte-stimulating hormones (MSH). 
Dming embryonic development, several transcription factors become active in a 
temporal manner and are essential for specification and differentiation of each cell type 
within the anterior and intermediate lobes of pituitary. The Hes I transcription factor is 
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expressed during embryonic development in the progenitor cells ofthe anterior and 
intermediate pituitary.2 Normal expression of Hes I is important for development of many 
organs including pituitary. Within the anterior pituitary, Hesl null mice have hypoplasia 
due to an incrcase in cell death and rcduccd proliferation2 Within thc intermediate 
pituitary, Hesl influences the differentiation ofmelanotropes, with somatotropes 
appearing instead of melanotropes in the absence of Hes1 2 In addition, a Hesl 
homozygous mousc rcsults in an embryonic lethal phcnotype. Thcsc results suggest that 
Hesl transcription factor plays an important role within pituitary development. 
To assess the role of Hesl in terminal differentiation of pituitary progenitors, the 
goal hcrc is to idcntify pcptides prescnt in thc pituitary cxtracts of Hes] mutant and wild 
type mice embryos using mass spectrometry. Another aspect of this study is to identify 
and characterize peptides resulting from proopiomelanocortin (POMC) hOlIDone 
processed by the enzyme prohoml0ne convertase 2 (PC2). Liquid chromatography 
coupled with MS allows chemical characterization ofPOMC peptides ineluding their 
posttranslational modification (PTMs) and enzymatic cleavage sites. Here, we are 
interested in identifying peptide candidates with a possible role in pituitary development 
using MS. This chapter represents a preliminary study and functional characterization of 
peptides that may be important for pituitary development. 
7.4 Experimental Methods 
Reagents-Acetonitrile (ACN), trifluoroacetic acid (TFA), 2,5-dihydroxybenzoic acid 
(DHB), hydrochloric acid (HCI), a-cyano-4-hydroxy cinnamic acid (a-CHCA), succinic 
anhydride (RdD4-SUC20), dimethyl sulfoxide (DMSO), glycine (HsNC20 2), sodium 
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hydroxide (NaOH), hydroxylamine hydrochloride (NH20H . HCI), monosodium 
phosphate monohydrate (NaH2P04 . H20), disodium phosphate (Na2HP04' 7H20) were 
obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO), unless otherwise noted. 
Water was prepared by a Milli-Q filtration system (Millipore, Bedford, MA). Zip Tip 
Micro-Cl8 (Millipore Corp.) were purchased from Sigma-Aldrich Chemical Co. (St. 
Louis, MO). The external calibration peptides, Angiotensin II, Angiotensin T, Substance 
P, ACTH clip 1-17, ACTH clip 18-39, Somatostatin 28, were provided by Bmker 
Daltonics, Inc. (Billerica, MAl. 
7.4.1 Animal Treatment and Tissue Isolation 
Hesl null mice were obtain as previously described2 The littennate embryos, 
Hesl mutant, heterozygote and wild-type, were provided from Dr. Lori T. Raetzman 
Laboratory at University of Illinois at Urbana-Champaign. The adult pregnant female 
mice were rapidly sacrificed using procedures approved by University of Illinois IACUC. 
All embryos were e 18.5 at the moment of sacrificing. They were quickly removed from 
the utems and rapidly decapitated. Each pituitary was carefully isolated with a pair of 
tweezers under microscope, placed in an individual vial, frozen in dry-ice and stored at -
~WO C until use. To genotype each embryo, DNA from tail biopsies was isolated using 
DNA salt-out technique and PCR was used to distinguish genotypes as previously 
described.' 
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7.4.2 Peptides Extraction 
After freezing, the pituitaries were subjected to extraction. Acidified acetone 
extraction and 2,5 -dihydroxybcnzoic acid (DHB) extraction (20 mg ImL) werc used to 
extract peptides from 2 pituitaries. The same number of embryos was used for acidified 
acetone extraction of the wild type versus Hes 1 mutant. Ten heterozygous pituitaries 
were pooled in a 1.5 vial and extracted with acidified acetone. All thcse samples were 
analyzed with LC-MALDl MS or MALDl MS. 
For genetic variation, 5 embryonic pituitaries were placed on a MALDI target and 
trcatcd with DHB matrix. Serial dilutions of matrix and the sample mixture wcrc necded 
in order to detect the peptides in the samples. These samples were directly analyzed by 
MALDIMS. 
7.4.3 Liquid Chromatography-Mass Spectrometry (LC-MS) 
Chromatographic separation of the extracted peptides was achieved using a 
capLC (Micromass, U.K.). The samples werc loaded onto a trap colLUnn (PcpMap, CIS, 5 
~lm, 100 A, Dionex, Sunnyvale ,CAl using a manual injector (Valco Instruments Co. Inc., 
Houston, TX) and washed for 5 min. The trapped peptides were then eluted in reverse 
direction onto a reverse phase capillary colLUml (LC Packings, 300-flm imler diameter x 
15 cm, CIS PepMap100, 100 A) lIsing a solvent gradient at 2 flLlmin flow rate. The 
solvent gradient was generated using solvent A and solvent B (aqueous 95% ACN 
containing 0.1 % FA and 0.01 %TFA). The 70-min gradient run for LC separation 
included three steps: 5-S0% solvent B in 15-55 min (linear); SO% solvent B for 55-60 
min (isocratic); SO-5% solvent Bin 60-65 min (linear). 
IS5 
for LC-MALDl-time-of-flight (TOf/TOF)-MS analysis, the capLC was coupled 
to a robotic fraction spotter (ProteineerfCTM, Bruker Daltonics). For LC-MALDI-
TOF/TOF-MS analysis, chromatographic separation was perfOlmed using a 45-min 
gradient run comprising the following parameters: 5-80% solvent B in 10-30 min 
(linear); 80% solvent B for 30-35 min (isocratic); 80-5% solvent B in 35-45 min 
(linear). The chromatographic e1utant was monitored using a UV detector (Waters, 
Milford, MA) and subsequently spotted onto a ground steel MALDI sample plate at the 
rate of 60 s/spot using ProteineerfC. Immediately after spotting, I ilL of a-CHCA matrix 
was applied to each spot. A Bruker Ultraflex II TOf !TOF instrument with a delayed ion 
extraction was used to analyze each sample. Mass spectra were accumulated over 2-3 
individual acquisitions of 100 laser shots each. 
7.4.4 Data Analysis 
The singly charged peptides detected by MALDI were mass matched using 
SwePep mouse database. Mass matches within 150 ppm were required for positive 
identifications with the confidence of these assignments enhanced by the detection of 
other related peptides from the same prohormone. 
7.5 Results and Discussion 
In a previous study, Raetzman et al. showed that loss of Hes I prevented the 
nonnal development of the pituitary gland. Hesl null mice die shortly before birth. Hence 
the morphology of anterior and intennediate pituitary were examined in the wild type 
embryo and Hes I KO mice starting at e 11.5 (Fig. 1 ).2 fig. 1 (A-C and E-G) represent 
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sagittal sections, visualized using the hematoxylin and eosin (H&E) staining method that 
allows comparison the morphology of the Hesl mutant and the wild type mice embryonic 
pituitaries. The morphological analysis was done at different time points during mouse 
embryonic development, ell.5, el4.5, and eIS.5. The difference in the size of the Hes} 
mutant and wild type embryonic pituitaries is more pronounced in the coronal sections 
(Fig. I D and H) at clS.5. At this time point, the embryos were considered for mass 
spectrometry analysis. In this figure it can be noticed that Hes} is necessary for 
generating the correct size of the anterior pituitary. 
In this study, the heterozygous embryos were generated at a ratio of 2 to each 
mutant and wild type. Hence they were used to optimize the extraction method for 
embryonic tissues. The DHB extraction protocol was developed by Romanova et al.4 As 
can be seen in Fig. 2, the MALDI MS profile ofDHB extraction of the Hesl 
heterozygous pituitary is more complex than the spectrum of acidified acetone extraction 
of the same genotype. DHB extract yielded an increased number of unidentifiable 
peptides compared with the acidified acetone extract. In the acidified acetone extraction 
there were detected vasopressin (A VP), prohonnone convertase 2 (PC2) peptides, PC2 
[94-103] and PC2 [94-104], melanin-eoneetrating hormone, MCH [110-129], POMC 
peptides such as a-MSH and J peptide (Fig 2B). In the DHB extraction, the MS profile 
there was assigned to AVP, POMC [209-221], [141-16S], ehromogranin A [333-346], 
and multiple unknowns (Fig. 2A). For further analysis, acidified acetone was used as the 
peptide extraction methods, which resulted in identification of an increased number of 
peptides. 
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In the same study, using an immunochemistry approach, Raetzman et al. investigated 
the influence of Hesl mutant on POMC expression within anterior and intermediate 
pituitary2 In this work, the Hesl mutant was shown to be immunoreactive to POMC and 
prohormone convertase 2 (PC2), one of the cnzymes that proccss POMC to bioactive 
peptides, but only within anterior pituitary region (Fig 3). Within intermediate pituitary, 
Hesl mutant lacks MSH and PC2 (Fig. 3). This result suggests that Hesl is required only 
for mclanotropes differentiation but not for corticotropes. 
In the current study, there are differences in the MS profiles between the wild 
type and Hesl mutant (Fig. 4). Interestingly, proAVP [151-168] and SMS [92-100] were 
detected in the Hesl mutant only (Table 1) while somatostatin-14 was detected in thc 
heterozygous phenotype (Table 2). It is known that, within anterior pituitary, 
somatostatin inhibits the release of GH from somatotrope cells5 -9 In case of Hesl mutant, 
GH is expressed normally in the anterior pituitary 2 It is important to mention that SMS 
[92-100] can be a degradation product due to an unknown physiological enzymatic 
activity or the process of sample preparation. It is possible that, in addition to other 
factors in the intemlediate pituitary of the Hesl mutant, somatostatin influences the 
growth of the anterior pituitary and contributes to the abnormal differentiation of 
melanotropes into somatotropes. 
A VP is secreted in the posterior pituitary by neurons in the paraventricular and 
supraoptic nuclei of hypothalamus. 10 In the rat brain, during embryonic development, the 
proAVP precursor peptides were detected as early as e15 and the fully processed AVP 
peptide appears immediately at c16. 11 • 12 Although the proAVP has been intensively 
characterized, the C-terminus of proAVP has an unknown function. In this study, at 
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c1S.5, the AYP was detected in all phenotypes, Hes} mutant, heterozygous, and wild type 
(Table I) (Fig. 7.4 and 7.6). The C-terminus form ofproAVP (m/z 1976.S5) was detected 
only in the mutant (Table I). While the presence of C-tenninus of the proA VP in the 
mutant remains to be investigated, and at c1S.5, Hes} did not influence the expression or 
processing of AVP. It is important to mention that frequently the Hes1 mutant mice do 
not have an identifiable posterior lobe. The signal of A VP is strong in all samples. The 
posterior pituitary, the original source of A YP, is included in the isolated tissue but it is 
relatively small compared with the other two lobes, the intermediate and anterior. In this 
study, the presence of AVP in all samples indicates that AVP is not involved in the 
development of pituitary. At the same time, AYP can be released through an unknown 
pathway in the entire pituitary. Nevertheless, for future directions, it is interesting to 
investigate the release of A VP in these lobes during early development. 
POMC is processed in a tissue-specific manncr depending upon the expression of 
the two processing enzymes, prohonnone convertase 113 (PC 113) in the anterior lobe and 
prohormone convertase 2 (PC2) in the intermediate lobe. 13.16 In the anterior lobe, 
corticotropes process POMC into ACTH 1-39, I"I-lipotropin, and B-endorphins.s In the 
intermediate lobe, mcianotrophs process POMC into a-MSH, B-MSH B-lipotropin, CLIP, 
and B-endorphin. 13-17 In this study, POMC [10S-120], [141-162] and aMSH were 
detected in the wild type and heterozygous type only. The fact that aMSH was not 
detected in the mutant tissue extract correlates with the previous results in Fig. 3. 
One of the limitations of this study was the difference in number of animals per 
genotype. The mutants and wild types were present at low numbers while the 
heterozygous mice were always in greater numbers. The increased number of 
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heterozygous mice enabled several further experiments. Direct tissue profiling was used 
to notice the variation within the same genotype at the peptide level (Fig. 5). In figure 5, 
the same peptides seemed uniformly distributed within the same tissues. The difference 
in peak intensity seen here is due to the "hot spots" of DHB matrix that cause uneven 
ionization of the bioanalytes embedded in the matrix crystals. It is important to mention 
that the yield of extracted peptides from individual pituitaries was greater than the yield 
of peptides from frozen tissues. frozen samples, <I mm, increased degradation and lead 
to irreproducible results. 
An increased number of peptides were detected in heterozygous mice when the 
samples were pooled and followed by acidified acetone extraction and subjected to LC-
MALDI MS (Table 2, Fig. 6). Table 2 includes peptides from the anterior and 
intermediate lobes of heterozygous mice pituitaries. There were detected several POMC 
peptides including two fragments of PC2, the processing enzyme located within 
intermediate lobe. There were detected bioaetive peptides such aMSH, J peptide, and 
CLIP, along with intermediate forms of pep tides as well as, POMC [205-222], and [217-
235]. from previous immunochemistry results, POMC had a low expression within both 
pituitary lobes? In addition, one peptide ofProSAAS was detected. The ProSAAS 
peptide functions are unknown and, together with other peptides, seems to be an 
interesting candidate to study during development. The peptides detected in this study 
provided a mass matching analysis from all the samples. For more unambiguous 
identification MS/MS is needed, particularly for the identification of the unknowns. 
However, this study provides insights and better understanding regarding putative peptide 
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precursors that can play important roles in brain and pituitary development, and opens 
new directions to study novel aspects of the physiological functions of peptides. 
7.6 Conclusions and Future Directions 
In this study, there were detected peptides processed from precursors that can play 
important roles during development. Somatotropin can be one of them that can have an 
influeuce on pituitary cell specification and differentiatiou. A VP is fully processed at this 
stage and seems not to have an influence on pituitary cell fate but it would be interesting 
to investigate the associated neuronal axon guidance during embryonic development. 
How does each peptide candidate influence pituitary development? Do the characterized 
peptides function to restore the normal differentiation/fate of cells within the intermediate 
lobe? These are important aspects for fmiher investigation. 
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7.7 Figures and Tables 
e11.5 e14.5 e14.5 e18.5 
Figure7.1 Pituitary size is reduced in Hes} mutants. Hematoxylin and eosin (H&E) 
staining reveals the morphology of wild-type (A-D) and Hesl null (E-H) pituitaries 
during development. In ell.5 sagittal sections, the pouch of the Hes! mutant is formed, 
but has not completely separated from the underlying oral ectoderm (arrow, E) compared 
with the wild-type sagittal section (A). At eI4.5, wild-type pituitaries have a nearly fused 
cartilage plate undemeath Rathke's pouch (B), but Hesl mutants exhibit a large gap 
between the rostral and caudal aspects of the cartilage (F). Coronal sections at c14.5 
demonstrate that the size of the wild-type anterior pituitary (C, bracket) is substantially 
greater than the Hes! mutant (G, bracket). This size difference between the wild-type (D, 
bracket) and Hes! mutant (H, bracket) is even more pronounced in coronal sections of 
e18.5 pituitaries. Reprinted from Raetzman, L. T.; Cai, J. X.; Camper, S. A., Hesl is 
required for pituitary growth and melanotrope specification. Dev Bio!2007, 304, (2), 
455-66. Copyright 2007, with pennission from Elsevier. 
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Figure 7.2 MALDI MS profile of A) DHB extract, aud B) acidified acetonc extract of 
Hes I heterozygous 
193 
N 
U 
D.. 
~ _____ H __ eS_1_·_'·~ ____ ~I LI ~ ______ H_e_S_1_~_- ____ ~ 
A B 
c o 
. ... - ..... ,. .; 
... .... ; ... '.t; 
.. . :", - .-
Figure 7.3 Intermediate lobe melanotropes are lost in the absence of HesI. Coronal 
sections of wild-type (A, C, E) and Hes I null (B, D, F) pituitaries were examined at 
e18.5. An antibody that recognizes POMC derivatives in the intetmediate lobe (IL) and 
anterior lobe (AL) shows that, in the wild-type pituitary, the posterior lobe (PL) is devoid 
of staining whereas the IL and AL contain many stained cells. In Hes} mutants, thc AL 
contains POMC stained cells, but the TL has a dramatic reduction in staining. MSH and 
PC2 immunoreactivity is apparent in the intermediate lobe of wild-type pituitaries (C, E, 
respectively) but not in Hes I mutants (D, F, respectively). Reprinted from Raetzman, L. 
T.; Cai, J. X.; Camper, S. A., Hesl is required for pituitary growth and melanotrope 
specificationDev Bioi 2007, 304, (2), 455-66. Copyright 2007, with pemlission from 
Elscvier 
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Hes} WT (indicate the AVP on the fig) 
195 
miL 
x10 
8 
2 " ,II I I I J II I I 
[ ,.I 
., I. .. 1 .II J 
/ , j ,1 1 
l~ 1. 1 I I .1 I I 
o 
1000 1200 1400 1600 1800 2000 220R"z 
Figure 7.5 LC-MALDI MS of Hes} heterozygous mice 
196 
xl 0' 
3 
2 
1 
o· xl 
2 .0 
o 
o 
o 
o 
.5 
.0 
.5 
o· 
.25 
.00 
.75 
.50 
.25 
60 100 
40 100 
20 100 
0 
1000 
0 
m 
Ii 
0 
0 
m 
> 
.. .1 
.. ,. 
[ I 
.J 
1200 
= 
0 ~ 
.. 0 
0 ~ ~ I 
m 
0 
< 
,ldll, .. 1 ..• , .c, 
,1,1l J .J, 
,1.11 .,j,. I 
1400 1600 
~ 
• Animal #1 
~ 
~ 
u 
..I. 1"- J. , l. .rr! ., d 
Animal #2 
.• 1....'" .1 .l .J 
Animal #3 
.j. J II.. .1 '-1.1,. 
Animal #4 
j 
.• 1. .1 • ,.I IL' , j 
1800 2000 2200 2400 2600 2800 3000 mIz 
Figure 7.6 Animal variation profile within Hesl heterozygous detected with MALDI MS 
197 
Table 7.1 Summary of pep tides identified by MALDI MS in individual animals KO and 
WT 
Prohormoneipeptide Sequence rnlz KO WT 
Unknown 858.8873 x x 
5MS_MOUSE 92-100 SNPAMAPRE 972.820128 x 
ProAVPIAVP C"YFQNC'PRGa 1084.89528 x x 
ProAVPfAVP+K C'YFQNC*PRGa+K 1122.33641 x 
CCK-3 DY(p04)MGWMDFa 1142.93445 x x 
ProAVP [151-168] VQLAGTRESVDSAKPRVY 1976.85123 x 
Unknown 1330.18911 x 
COLI_MOUSE 108-120 VWGDGSPEPSPREa 1411.59093 x 
COLI_MOUSEl 
Melanotropin alpha 
[124-136] SYSMEHFRWGKP'Va 1622.64912 x 
COLLMOUSE 
Joining peptide[103-120] AEEEAVWGDGSPEPSPREa 1941.71199 x x 
COLI_MOUSE 205-222 (Ac)YGGFMTSEKSQTPLVTLF 2047.84221 x 
COLI_MOUSEl 
R-CLiP RPVKVYPNVAENESAEAFPLEF 2505.78428 x 
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Table 7.2 Summary of peptides detected using LC- MALDI MS in Hes} heterozygous 
samples 
Obs mass m/z Th mass mlz 
Peptide name (M+H) (M+H) Sequence 
Angiotensin 2 1046.37 1046.54 DRVYlHPF 
NEU2_MOUSEI 
Arg-vasopressin 1084.74 1084.43 C"YFQNC"PRGa 
NEU2_MOUSEI 
Arg-vasopressin+K 1122.37 1122.43 C*YFQNC"'PRGa+K 
NEU2_MOUSE/Arg-vasopressin+Na 1106.40 1107.43 C*YFQNC'*PRGa+Na 
NEU2_MOUSE 155-166 1302.98 1302.66 GTRESVDSAKPR 
Bradykinin 1060.13 1060.57 RPPGFSPFR 
Cholecystokinin 12 1614.82 1614.62 ISDRDY(P04)MGWMDFa 
Cholecystokinin 8 1142.41 1142.34 DY(P04)MGWMDFa 
CMGA_MOUSE 392-402 1220.56 1220.59 AYGFRDPGPQL 
COLI_MOUSE 108-120 1411.62 1411.63 VWGDGSPEPSPREa 
COLI_MOUSE 165-177 1467.73 1467.78 ELEGERPLGLEQV 
COLI_MOUSE 107-120 1482.66 1482.67 AVWGDGSPEP$PREa 
COLI_MOUSE 165-178 1581.77 1581.84 ELEGERPLGLEQVL 
COLl_MOUSE/Melanotropin alpha 1622.73 1622.77 SYSMEHFRWGKPVa 
COLI_MOUSE 205-219 1643.74 1643.81 YGGFMTSEKSQTPLV 
COLI_MOUSE 205-219 1728.79 1728.78 (DiAc)YGGFMTSEKSQTPLV 
COLl_MOUSE~oining peptide 1940.81 1940.84 AEEEAVWGDGSPEPSPREa 
COLI_MOUSE 205-222 2046.87 2048.99 (Ac)YGGFMTSEKSQTPLVTLF 
COLI_MOUSE 217 -235 2120.89 2120.26 PLVTI.FKNAIIKNAHKKGQ 
COLl_MOUSE/Arg-CLiP 2506.21 2506.25 RPVKVVPNVAENESAEAFPLEF 
NEC2_MOUSE 94-104 1279.74 1279.63 IKMALQQEGFD 
NEC2_MOUSE 94-103 1164.58 1164.61 IKMALQQEGF 
Gonadoliberin-1 1181.39 1181.58 pQHWSYGLRPGa 
NPFF _MOUSE/Neuropeptide FF 1082.35 1082.57 FLFQPQRF 
Pr05AAS_MOUSE44~9 1611.70 1611.90 SAASAPLVETSTPLRL 
PEBP1_MOUSE 15-25 1262.50 1262.59 QEVDEPPQHAL 
PEBP1_MOUSE 26-37/Neuropeptide SF 1335.87 1335.69 RVDYAGVTVDEL 
PROC_MOUSE/Activation peptide 1656.76 1656.75 DTDLEDELEPDPRI 
SCG1_MOUSE 600-613 1663.74 1663.78 QYDGVAELDQLLHY 
SCG5_MOUSE 1517.66 1517.67 SVPHFSEEEKEAE 
SCG5_Mouse 167-176 1165.45 1165.62 LLYEKMKGGQ 
SMS/Somatostatin-14 1637.73 1637.73 AGC"KNFFWKTFTSC· 
TYB4_MOUSE 37-50 1563.91 1563.74 SKETIEQEKQAGES 
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Table 7.2 (conI) 
unknown 996.57 
unknown 994.43 
unknown 1025.56 
unknown 1030.41 
unknown 1038.24 
unknown 1051.71 
unknow 1066.37 
unknown 1066.37 
unknown 1324.56 
unknown 1329.54 
unknown 1448.88 
unknown 1670.72 
unknown 1712.75 
unknown 1717.74 
unknown 1869.77 
unknown 1586.83 
unknown 1586.69 
unknown 2152.92 
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APPENDlXA 
NEUROPEPTIDES OF THE RAT SUPRAOPTIC NUCLEUS 
Notes and Acknowledgements 
This supporting information is part of Chapter 4 and contains additional 
information including a summary of the number of pep tides characterized from known 
prohormones. We identified 86 peptides from SON punches that arc processed from 
known prohormones using our multistage extraction protocol combined with tandem 
mass spectrometry. The total number of previously Lmreported peptides is 26. Of these, 
19 peptides arc from known prohonnones and the rcst arc from other proteins. Once a 
prohormone was determined to be present by the characterization of a peptide via tandem 
MS, other Lmassigned peaks were mass matched to the known prohOlmones. In the later 
case, we considered expected prohonnone products output from the N europred prediction 
engine (http://neuroproteomics.scs.uiue.edu/neuropred.html, see Southey, B. R.; Amare, 
A.; Zimmerman, T. A.; Rodriguez-Zas, S. L.; Sweedler, J. V., NeuroPred: a tool to 
predict cleavage sites in neuropeptide precursors and provide the masses of the resulting 
peptides. Nucleic Acids Res. 2006, 34, W267-72). 
Figure A.I highlights the different protocols used to extract peptides from the 
SON. Because specific protocols allowed us to detect different peaks, our final protocol 
involved multiple stages. For example, A VP, Progonadoliberin[24-33], Somatostatin[89-
100], Protachykinin[58-68], Provasopressin[154-168], POMC[124-136], ProSAAS[42-
59]. Provasopressin[ 151-168], arc present in all extraction solutions, and 
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Provasopressin[155-168], ProSAAS[221-242], and MBP [2-11] are detected in only one 
of the three extractions. 
Figure A.2 includes the higher molecular weight range from a small group of 
MeNs. In the higher mass range we identified thymosin beta and neurophysin II. Many 
other peaks were present but due to the small amount of material present, we have not 
assigned them. 
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Table A.I Summary of total number of identified and novel peptides from known 
prohormones. Reprinted with pemlission from reference I in Chapter 4. 
Precursor 
Provasospressin 
CART 
TRH 
Proenkephalin A 
Proenkephalin B 
Protachykinin 1 
VIP 
POMC 
Somatostatin 
Secretogranin 1 
Secretogranin 2 
Secretogranin 3 
Secretogranin 5 
Cortistatin 
Somatotropin 
ProSAAS 
Neurotensin 
PACAP 
Progonadoliberin I 
ProMCH 
Interleukin-3 
Number of 
identified 
peptides 
10 
2 
1 
6 
6 
2 
2 
3 
3 
9 
3 
5 
1 
10 
2 
2 
1 
Number of new Number of new peptides peptides identified by identified by mass MSMS 
4 2 
2 
5 
2 
3 4 
4 
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Figure A.1 MALDI-TOF MS spectral comparison of different neuropeptides extraction 
protocols. (A) Pre-heated 90" C Dr water; (B) acidified acetone extract; (C) acetic acid 
extract; (D) filtered mixture of all extractions solution. Reprinted with permission from 
reference I in Chapter 4. 
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Figure A.2 Neurons isolated from SON exhibit presence of neurophysin IT. Mass spectra 
acquired from saturated DHB in water matrix. Reprinted with pennission from reference 
1 in Chapter 4. 
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APPENDlXB 
IMAGES OF THE SAMPLE PREP ARA nON OF CELL CULTURES FOR MASS 
SPECTROMETRY 
Notes and Acknowledgements 
This supporting infOlmation is p311 of Chapter 5 and contains images regarding the 
sample preparation of tissue dissection by Dr. Larry Millet and coverslip mounting on MALDI 
target. I want to acknowledge Dr. Larry Millet for his work on cell culture and for providing me 
with additional infonnation. 
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Figure B.I. Using the optic tracts (OT) as landmarks, four dissection steps were used to remove 
the tissue containing the supraoptic nucleus (SON). I) Posterior cuts (shown): bilateral incisions 
were made along the immediate posterior surface of the optic tract to a point were the tracts enter 
into the brain and are no longer visible from the ventral surface. 2) Lateral cuts (not shown): one 
cut pcr side of the brain to sevcr the optic tract where it penetrates into the brain ncar the rostral 
cerebral artery. 3) Anterior cuts (shown): these incisions were performed away from the surface 
of the optic tract, by about the same width of the optic tract, to ensure that the SON would be 
retained and not damaged in the cutting. 4) Dorsal cut (not shown): this last cut is made as close 
to the dorsal boarder of the optic tract as possible. Upon completion of these four steps, the 
excised tissue containing the SON and a portion of the optic tracts is removed. The above 
images arc paraformaldehyde-fixed sections from a single postnatal rat brain, sectioned 
horizontally by a cryostat and histochemically stained with eresyl violet to identify the Nissl 
substance. The SON appears as a darkly-stained cluster of cells adjacent to the optic tracts. 
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Figure B.2. Mounted coverslip on MALDI target. (A) Coverslip was grounded with silver paint 
to prevent charging. (B) Image window as observed with the mass spectrometer used for guiding 
laser and sample analysis. 
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